U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's Name: _____ Serial Number: _____

Date: _____ Phone: _____ Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 12-06-02
Searcher: Beverly - 4994
Terminal time: 2m
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: 2

Search Site

_____ STIC
_____ CM-1
_____ Pre-S

Type of Search

_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors

_____ IG Suite
✓ STN
✓ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
_____ Other

See results attached.

FOR OFFICIAL USE ONLY

ACCESS DB # 81763

PLEASE PRINT CLEARLY

Location (Bldg/Room#): CM1-7E15
Mail box CM1-7E18

Scientific and Technical Information Center

SEARCH REQUEST FORM

Date: 06 Dec. 02 Requester's Full Name: _____ Examiner #: S. DEVI

Art Unit: 1645 Phone (308) 9347 Serial Number: 09/486,480

Results Format Preferred (circle): (PAPER) DISK E-MAIL

MEJ

****

ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): JAMES A. SPUDICH; PETER WAGNER; STEFFEN NOCK.

Earliest Priority Date: 09.04.97

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the cited species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known.

For Sequence Searches Only* *Please include all pertinent information (parent, grandchild, divisional, or issued patent numbers) along with the appropriate serial number.*

Please ask MS. BEVERLY SHEARS to perform this search.

Please see attached claims with key words highlighted and/or Examples and synonyms provided.
Please include the following databases: Embase, Medline, Biosis, CA (Dialog 50), JAPIO, JICTEplus, Dialog 35, 65, 77, 144, 256, 266, 440, 348, 357, 113, 129, 130, 156 and 60.
Please perform an inventor's name search.

Thank you. ☺

Please return the attached claims and this search request form along with the search reports.

Devi, S.
09/486480

09/486480

```
     FILE 'REGISTRY' ENTERED AT 10:13:13 ON 06 DEC 2002
                  E ARGININE/CN 5
L1             2 S E3
                  E "POLY-ARGININE"/CN 5
                  E "POLY (L-ARGININE)"/CN 5
                  E POLYARGININE/CN 5
L2             2 S E3
                  E HEXAARGININE/CN 5
L3             1 S E3
                  E SIXARGININE/CN 5
                  E DIARGININE/CN 5
L4             5 S L1 OR L2 OR L3


                  E SILICATE/CN 5
L6             1 S E3
                  E MICA/CN 5
L7            10 S MICA ?/CN
L8            11 S L6 OR L7



L20            1 S SODIUM/CN

     FILE 'HCAPLUS' ENTERED AT 10:27:40 ON 06 DEC 2002
L1             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ARGININE/CN
L2             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  POLYARGININE/CN
L3             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HEXAARGININE/CN
L4             5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 OR L2 OR L3
L5        120519 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4 OR ?ARGININE? OR ARG
                  OR RRRRRR
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SILICATE/CN
L7            10 SEA FILE=REGISTRY ABB=ON  PLU=ON  MICA ?/CN
L8            11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 OR L7
L9            96 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5 AND (L8 OR MICA OR
                  SILICATE)
L10            6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND (TAG? OR LINK?
                  OR SPACER)



L1             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ARGININE/CN
L2             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  POLYARGININE/CN
L3             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HEXAARGININE/CN
L4             5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 OR L2 OR L3
L5        120519 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4 OR ?ARGININE? OR ARG
                  OR RRRRRR
L20            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM/CN
L23         1272 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5(S)(SPACER OR LINK?
                  OR TAG?)
L24           19 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 AND (L20 OR (SODIUM
                  OR NA)(S)SALT)
L25           15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L24 AND (MOLECULE OR
                  POLYPEPTIDE OR POLYPROTEIN OR PEPTIDE OR PROTEIN OR
                  NUCLEIC OR DNA OR DEOXYRIBONUCLEIC OR DEOXY RIBONUCLEIC
                  OR CARBOHYDRATE OR POLYSACCHARIDE OR POLY SACCHARIDE OR
                  ANTIGEN?)
```

- Key terms

Searcher : Shears 308-4994

L26 20 L10 OR L25

L26 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:935626 HCAPLUS
DOCUMENT NUMBER: 136:64121
TITLE: **Peptide** conjugates modified n- and/or c-terminally by short charged **peptide** chains
INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen Soberg; Kapusta, Daniel R.; Harlow, Kenneth William
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098324	A1	20011227	WO 2001-US19113	20010615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

DK 2000-944	A	20000616
DK 2000-1485	A	20001005
US 2000-251671P	P	20001206

OTHER SOURCE(S): MARPAT 136:64121

AB Disclosed are a variety of **peptide** conjugates represented by the following general formula R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula A1-A2-A3-A4-A5-A6 wherein A1 represents **Arg**, Lys, or His, A2 represents Tyr, Trp, or Phe, A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, **Arg** or His, A5 represents Phe, Tyr, Trp, Leu, Val or Ile, and A6 represents **Arg**, Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged **peptide** chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged **peptide** chain of from 4 to 20 amino acid residues having the D or L configuration or is missing, providing that not both of Z and Z' are missing; R1 represents H or an acyl group; R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl as defined herein; or R2 represents OH; the **peptide** conjugates of formula (I) being optionally further **linked** to a transport moiety; and salts, hydrates and solvates thereof, and C-terminally amidated or esterified derivs. thereof with suitable org. or inorg. acids, including methods or making and using such conjugates. Also

provided are antibodies that specifically bind the **peptide** conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like **peptides**.

IT **7440-23-5**, Sodium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyponatremia, treatment; **peptide** conjugates modified by short charged **peptide** chains for treatment of disorders impacted by nociceptin in relation to diuretic effects and antibodies to these **peptide** conjugates)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:252939 HCAPLUS
DOCUMENT NUMBER: 132:293190
TITLE: Composition for optimizing muscle performance during exercise
INVENTOR(S): Portman, Robert
PATENT ASSIGNEE(S): Pacifichealth Laboratories, Inc., USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6051236	A	20000418	US 1998-190885	19981112
WO 2000027408	A1	20000518	WO 1999-US26819	19991111
W: AE, AT, AU, BR, CA, CN, CU, DE, DK, ES, FI, GB, GD, ID, IL, IN, IS, JP, KR, LT, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, TR, UA, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1161249	A1	20011212	EP 1999-958932	19991111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1998-190885 A 19981112
WO 1999-US26819 W 19991111

AB A nutritional compn. comprises a dry powder for optimizing muscle performance during exercise and for enhancing muscle cell repair and recovery following the cessation of exercise. The dry nutritional compn. includes carbohydrates and proteins in a ratio in the range of 2.8 to 4.2 parts of the carbohydrates to 1.0 part of the proteins, wherein the carbohydrates are used for providing energy during exercise and the proteins are used for stimulating the release of insulin to the muscle cells during exercise and for repairing muscle cells after exercise. The dry nutritional compn. further includes glutamine for reducing muscle stress by stimulating the immune system and for stimulating muscle cell recovery after exercise; **arginine** for stimulating the release of insulin within the muscle cells in order to facilitate the transport of glucose into the muscle cells during exercise and for the synthesis of glucose into glycogen; vitamin C for use as an antioxidant for preventing free radical formation during exercise and for protecting

muscle cell integrity during exercise; and vitamin E for use as an antioxidant for preventing free radical formation during exercise and for protecting muscle cell integrity during exercise. Addnl., the dry nutritional compn. also includes one or more electrolytes for replenishing electrolytes lost during exercise and for facilitating intestinal reabsorption of fluids, and for facilitating energy dependent processes; and an herbal compd., ciwujia, for enhancing the immune system, reducing muscle stress, and decreasing heart rate during exercise.

IT **74-79-3**, L-**Arginine**, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(compn. for optimizing muscle performance during exercise)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:602790 HCAPLUS
DOCUMENT NUMBER: 131:282001
TITLE: Receptors linked to polyphosphoinositide hydrolysis stimulate Ca2+ extrusion by a phospholipase C-independent mechanism
AUTHOR(S): Broad, Lisa M.; Cannon, Toby R.; Short, Alison D.; Taylor, Colin W.
CORPORATE SOURCE: Department of Pharmacology, Cambridge, CB2 1QJ, UK
SOURCE: Biochemical Journal (1999), 342(1), 199-206
CODEN: BIJOAK; ISSN: 0264-6021
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In A7r5 cells with empty intracellular Ca2+ stores in which the cytosolic free Ca2+ concn. ([Ca2+]i) had been increased by capacitative Ca2+ entry, stimulation of receptors linked to phospholipase C (PLC), including those for Arg8-vasopressin (AVP) and platelet-derived growth factor (PDGF), caused a decrease in [Ca2+]i. This effect was further examd. in a stable variant of the A7r5 cell line in which the usual ability of hormones to stimulate non-capacitative Ca2+ entry is not expressed. In thapsigargin-treated cells, neither AVP nor PDGF affected capacitative Mn2+ or Ba2+ entry, but both stimulated the rate of Ca2+ extrusion, and their abilities to decrease [Ca2+]i were only partially inhibited by removal of extracellular Na+. These results suggest that receptors linked to PLC also stimulate plasma membrane Ca2+ pumps. Activation of **protein** kinase C by phorbol 12,13-dibutyrate (PDBu, 1 .mu.M) also caused a decrease in [Ca2+]i by accelerating Ca2+ removal from the cytosol; the effect was again only partially inhibited by removal of extracellular Na+. An inhibitor of PKC, Ro 31-8220 (10 .mu.M), abolished the ability of PDBu to decrease [Ca2+]i, without affecting the response to maximal or submaximal concns. of AVP. Similar expts. with PDGF were impracticable because Ro 31-8220, presumably by inhibiting the tyrosine kinase activity of the PDGF receptor, abolished all responses to PDGF. U 73122 (10 .mu.M), an inhibitor of PLC, completely inhibited PDGF- or AVP-evoked Ca2+ mobilization, without preventing either stimulus from causing a decrease in [Ca2+]i. We conclude that receptors coupled to PLC, whether via G-**proteins** or **protein** tyrosine kinase activity, also

share an ability to stimulate the plasma membrane Ca2+ pump via a mechanism that does not require PLC activity.

IT **7440-23-5**, Sodium, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(receptors linked to polyphosphoinositide hydrolysis stimulate calcium extrusion by a phospholipase C-independent mechanism after vasopressin and PDGF)

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:601340 HCAPLUS
DOCUMENT NUMBER: 131:298310
TITLE: Characterization of a new sodium channel mutation at arginine 1448 associated with moderate paramyotonia congenita in humans
AUTHOR(S): Bendahhou, Said; Cummins, Theodore R.; Kwiecinski, Hubert; Waxman, Stephen G.; Ptacek, Louis J.
CORPORATE SOURCE: Howard Hughes Medical Institute, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, UT, 84112, USA
SOURCE: Journal of Physiology (Cambridge, United Kingdom) (1999), 518(2), 337-344
CODEN: JPHYA7; ISSN: 0022-3751
PUBLISHER: Cambridge University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1. Paramyotonia congenita is a temp.-sensitive skeletal muscle disorder caused by missense mutations that occur in the adult skeletal muscle voltage-gated sodium channel. The authors report here the identification of a new genetic mutation in a family with the paramyotonia congenita phenotype. 2. Single-strand conformation polymorphism anal. and **DNA** sequencing showed that the defect was **linked** to a single nucleotide substitution causing an amino acid change from an **arginine** to a serine at position 1448 in the human sodium channel .alpha.-subunit. 3. Expression of the altered **protein** in human embryonic kidney (HEK) 293 cells revealed several defects in channel function: (i) the rate of fast inactivation was slower in the mutant channel compared with wild-type, (ii) steady-state fast inactivation was shifted towards hyperpolarizing potentials, (iii) the R1448S channels deactivated much more slowly, and (iv) the mutant channels recovered from the fast inactivated state more rapidly. 4. By contrast, the activation curve, steady-state slow inactivation and the rate of onset and recovery from slow inactivation were not altered by the R1448S mutation. 5. These data show that the defects obsd. in the sodium channel function could well explain the onset of the paramyotonia congenita in this family and emphasize the role of segment S4 of domain IV in sodium channel inactivation.

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(channel; sodium channel .alpha.-subunit gene SCN4A mutation at arginine 1448 assocd. with moderate paramyotonia congenita in humans affects primarily fast inactivation)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:189275 HCAPLUS
DOCUMENT NUMBER: 130:206987
TITLE: Reversible immobilization of **arginine-tagged** moieties on a **silicate** surface with application in **protein** purification
INVENTOR(S): Spudich, James A.; Nock, Steffen; Wagner, Peter
PATENT ASSIGNEE(S): Stanford University, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912036	A1	19990311	WO 1998-US18531	19980903
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9892225	A1	19990322	AU 1998-92225	19980903

PRIORITY APPLN. INFO.: US 1997-57929P P 19970904
WO 1998-US18531 W 19980903

AB This invention provides materials and methods for the site specific attachment of virtually any moiety to a layered **silicate** surface. The methods involve covalently attaching the moiety to an **arginine tag**; and contacting the **arginine tag** with the layered **silicate** (e.g., **mica**) surface. A highly specific interaction with the surfaces of layered **silicates** is mediated, at least in part, by a cation exchange with the **silicate** surface. Unlike previously described cation exchange systems, binding of the **arginine tag** is highly resistant to physiol. relevant (compatible) concns. of sodium and other ions.

IT **24937-47-1**, Poly(L-**arginine**) **25212-18-4**, Poly(L-**arginine**)
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(reversible immobilization of **arginine-tagged** moieties on a **silicate** surface with application in **protein** purifn.)

IT **7440-23-5D**, **Sodium**, **salts**, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(reversible immobilization of **arginine-tagged** moieties on a **silicate** surface with application in **protein** purifn.)

IT **74-79-3**, L-**Arginine**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(**tag**; reversible immobilization of **arginine-tagged** moieties on a **silicate** surface with application in **protein** purifn.)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:164953 HCAPLUS
DOCUMENT NUMBER: 128:304192
TITLE: Vasopressin-induced activation of **protein** kinase C in renal epithelial cells
AUTHOR(S): Ali, Nawab; Kantachuvesiri, Surasak; Smallwood, Joan I.; Macala, Lawrence J.; Isales, Carlos; Ji, Jing; Reilly, Robert; Hayslett, John P.
CORPORATE SOURCE: Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06510, USA
SOURCE: Biochimica et Biophysica Acta (1998), 1402(2), 188-196
CODEN: BBACAQ; ISSN: 0006-3002
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Recent studies indicate that the actions of **arginine** vasopressin (AVP) and other agonists that stimulate electrogenic sodium transport in renal epithelial A6 cells are **linked** to a Ca2+-mobilizing signal transduction mechanism that involves generation of inositol trisphosphate. Since diacylglycerol is the other product in this pathway, studies were performed to det. the possible role of PKC in the stimulation of sodium transport. AVP induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and PKC activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). To det. the PKC isoform(s) involved in this process, immunoblot anal. was performed using antisera that recognize both classical PKC isoforms, XPKC-I and XPCK-II, cloned from Xenopus oocytes. The transcripts of both isoforms were expressed in the A6 cell. Since **protein** recognized by antisera was translocated from cytosol to the particulate fraction after exposure to AVP, one or both isoforms were activated in the A6 cell. Further studies showed that cyclohexyladenosine and insulin, addnl. agonists of sodium transport in A6 cells, also stimulated phosphorylation of MARCKS. These results argue that Ca2+-dependent PKC is involved in the action of AVP, and that of other agonists, which stimulate sodium transport.

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transport; vasopressin-induced activation of protein kinase C in sodium transport by renal epithelial cells)

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vasopressin-induced activation of **protein** kinase C in sodium transport by renal epithelial cells)

L26 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:805968 HCAPLUS
DOCUMENT NUMBER: 128:3874
TITLE: Solid-Phase Synthesis of **Arginine**-Containing **Peptides** by Guanidine Attachment to a Sulfonyl **Linker**
AUTHOR(S): Zhong, H. Marlon; Greco, Michael N.; Maryanoff, Bruce E.
CORPORATE SOURCE: Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SOURCE: Journal of Organic Chemistry (1997), 62(26), 9326-9330
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB In the area of **mol.** diversity generation, the authors have developed a new arenesulfonyl linker for the solid-phase org. synthesis of compds. contg. guanidine groups (viz. I; P = polystyrene resin). In the cases examd. for illustration, the Arg guanidine group was attached to the novel solid support via a SO2-N bond, followed by subsequent chem. manipulation and release of the product from the resin. This new resin, I, bearing an electron-rich arenesulfonyl group, has a reasonable loading capacity of ca. 0.5 mmol/g, is stable to various reaction conditions, and is compatible with both tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) **peptide** chem. Three model arginine-contg. **peptides** were synthesized by appending amino acids onto a resin-bound arginine deriv. at either or both termini: H-Arg-Phe-OH, H-Phe-Arg-Ala-OMe, and H-Phe-Gly-Arg-Ala-OMe, obtained in isolated, purified yields of 72%, 50%, and 40%, resp. Furthermore, the authors applied resin I to the synthesis of H-Ser-Phe-Leu-Leu-Arg-Asn-NH2, an agonist hexapeptide for the thrombin receptor (16% yield).

IT **74-79-3DP**, L-**Arginine**, ether with (chloromethyl)polystyrene, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of arginino-contg. peptides by guanidine attachment to a sulfonyl

linker)

L26 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:775289 HCAPLUS
DOCUMENT NUMBER: 128:112304
TITLE: Kinetic pathway for the slow to fast transition of thrombin. Evidence of linked ligand binding at structurally distinct domains
AUTHOR(S): Lai, Ming-Tain; Di Cera, Enrico; Shafer, Jules A.
CORPORATE SOURCE: Department of Biological Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Journal of Biological Chemistry (1997), 272(48), 30275-30282
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The kinetic pathway for the Na+-induced slow .fwdarw. fast transition of thrombin was characterized. The slow form was shown to consist of two conformers in a 3:1 ratio (ES2.cntdot.ES1) at 5 .degree.C, pH 7.4, .GAMMA./20.3. ES2 binds Na+ 3 orders of magnitude faster than does ES1. The small **mol**. active site-directed inhibitor L-371,912, and the exosite I-binding ligand hirugen, like Na+, bind selectively to ES2 and induce the slow .fwdarw. fast conversion of thrombin. The slow .fwdarw. fast transition is limited by the rate of conversion of ES1 to ES2 (k.apprx.28 s-1 at 5 .degree.C). Replacement of Arg-221a or Lys-224 at the Na+-binding site with Ala appears to selectively alter the slow form and reduce the apparent affinity of the mutants for Na+ and L-371,912. This replacement, however, has little effect on the affinity for the inhibitor in the presence of satg. concns. of Na+. The kinetically linked ligand binding at the Na+-binding site, exosite I, and the active site of thrombin characterized in the present study indicates the basis for the plasticity of this important enzyme and suggests the possibility that the substrate specificity and, therefore, the procoagulant and anticoagulant activities of thrombin may be subject to allosteric regulation by as yet unidentified physiol. important effectors.

IT **74-79-3**, L-**Arginine**, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(221a, effect on thrombin slow form; kinetic pathway for sodium-induced slow to fast transition of thrombin and evidence of **linked** ligand-binding at structurally distinct domains)

IT **7440-23-5**, Sodium, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(kinetic pathway for sodium-induced slow to fast transition of thrombin and evidence of linked ligand-binding at structurally distinct domains)

L26 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:574236 HCAPLUS
DOCUMENT NUMBER: 127:274954
TITLE: Reversible, site-specific immobilization of **polyarginine-tagged** fusion proteins on **mica** surfaces
AUTHOR(S): Nock, Steffen; Spudich, James A.; Wagner, Peter
CORPORATE SOURCE: Department of Biochemistry, Beckman Center B405, Stanford University Medical Center, Stanford, CA, 94305-5307, USA
SOURCE: FEBS Letters (1997), 414(2), 233-238
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A large variety of genes is expressed as fusion proteins for the purpose of characterization and purifn. in mol. biol. We have used this strategy to append **polyarginine** peptides to achieve specific binding of the **Arg-tag** to atomically flat, neg. charged **mica** surfaces. We show that the model protein, **hexaarginine-tagged** green fluorescent protein (GFP), binds to **mica** via its **Arg-tag** based on ion exchange of naturally occurring potassium cations. Only non-specific binding was obsd. with the control protein that is free of the **Arg-tag**. This novel technol. will be widely applicable to orient functional proteins on flat surfaces.

IT **25212-18-4, Polyarginine**
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(-**tagged** fusion proteins; reversible, site-specific immobilization of **polyarginine-tagged** fusion proteins on **mica** surfaces)

L26 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:173016 HCAPLUS
DOCUMENT NUMBER: 126:195495
TITLE: Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors
AUTHOR(S): Musabayane, C. T.; Forsling, M. L.; Balment, R. J.
CORPORATE SOURCE: Dep. Physiology, Univ. Zimbabwe, Harare, Zimbabwe
SOURCE: Renal Failure (1997), 19(1), 23-32
CODEN: REFAE8; ISSN: 0886-022X
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have previously suggested that the increase in renal Na+ excretion in response to physiol. doses of **arginine** vasopressin (AVP) is not directly **linked** to the V2-mediated antidiuretic effect. In the present study we investigated the possible involvement of AVP V1 receptors in this natriuresis using a specific AVP V1 antagonist [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid), 2-O-methyltyrosine arginine vasopressin, d(CH2)5[Tyr(Me)2]AVP], infused at a rate of 15 ng/min. Male anesthetized Sprague-Dawley rats were placed on a continuous jugular infusion of 0.077M NaCl at 150 .mu.L/min. After a 3-h equilibration period, samples were collected at 20-min

intervals for 4 h for the detn. of urine flow, and Na+ and K+ excretion rates. In those animals in which the effects of AVP were studied, a 1-h control period was allowed following which AVP was infused at 0.02-0.08 pmol/min for 1 h 20 min in sep. groups of animals and then returned to the infusate alone for the last part of the expt. In other groups the AVP V1 antagonist d(CH2)5[Tyr(Me)2]AVP (15 ng/min) alone or in combination with AVP (or various dose rates) was also administered for 1 h 20 min. All dose rates of AVP produced an antidiuresis which was assocd. significantly to increased Na+ excretion rate. However, AVP administration at the medium dose rate (0.04 pmol/min) significantly decreased the amt. of urine voided by comparison with control animals (6.34 mL vs. 11.892 mL) although the urinary Na+ was elevated (967 .mu.**mol** vs. 742 .mu.**mol**). This AVP-induced increase in urinary Na+ loss was abolished in animals receiving combined AVP (0.04 pmol/min) and AVP V1 antagonist (674 .mu.**mol**) although the antidiuretic effect persisted. Urine flow and Na+ excretion rates remained unchanged in groups of animals administered AVP V1 antagonist alone. In all groups, the K+ excretion rates did not significantly differ. It is concluded that the V1 receptor mediates the natriuretic effect of AVP.

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vasopressin increases renal sodium excretion via V1 receptors)

L26 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:68738 HCAPLUS
DOCUMENT NUMBER: 126:122061
TITLE: Combined amino acid speciation in lake sediment and porewater (Aydat Lake, France)
AUTHOR(S): Alberic, P.; Sarazin, G.; Michard, G.
CORPORATE SOURCE: Lab. Geochemie Organique, Univ. Orleans, Orleans, 45100, Fr.
SOURCE: Aquatic Geochemistry (1996), 2(1), 29-49
CODEN: AQGEFP; ISSN: 1380-6165
PUBLISHER: Kluwer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dissolved and particulate fractions extd. from a lake diatom ooze were examd. for individual amino acids. The study focused on combined amino acids, the predominant form in the interstitial dissolved pool (>90%). An abundance of glycine and .beta.-alanine was obsd. in porewater samples of sediments both squeezed manually and gathered with in-situ dialysis (peeper). Sediment-press squeezing and leaching of the sediment by water gave higher total quantities and different compns. (with more aliph. and arom. protein amino acids, .alpha.-alanine being predominant). These 2 methods modify the original compn., presumably due to the formation of Fe-oxides and dissoln. of sediment org. fractions, the alteration being aggravated if squeezing is delayed. Filtration after acidification of porewaters enabled us to distinguish 2 compartments: a protein-like agglutinated fraction, and a filtrate with a high glycine and .beta.-alanine content. Further division of the filtrate by adsorption on XAD or cation-exchange resins did not reveal addnl. fractions with different individual amino acid compns. A link is suggested between the agglutinated fraction and the special compn. of the porewater extd. with sediment-press.

Dissolved org. C (DOC) and total dissolved hydrolyzable amino acids (TDHAA) (.apprx.10 mg/L and .apprx.13.mu.M, resp.) did not increase with depth, as opposed to dissolved inorg. C and volatile C. Amino acid-C accounted for <4% of DOC in porewaters. Individual amino acid compns. in the sediments were similar in all grain size fractions. Chem. extd. fractions had specific compns.: (1) org. fractions (alkali exts. and HF-insol. residues) have a similar protein amino acid compn.; (2) acid exts. have more acidic amino acids (HCl) or more glycine and non protein amino acids (HF). The similarity of amino acid compns. in the sediment HF-sol. fraction and the dissolved pool is discussed with respect to interactions between iron-**silicate** authigenic phases and porewaters.

IT **74-79-3, Arginine**, occurrence
RL: GOC (Geological or astronomical occurrence); OCCU (Occurrence)
(combined amino acid speciation in lake sediment and porewater, Aydat Lake, France)

L26 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:685420 HCAPLUS
DOCUMENT NUMBER: 123:75421
TITLE: Vasopressin-stimulated electrogenic sodium transport in A6 cells is linked to a Ca2+-mobilizing signal mechanism
AUTHOR(S): Hayslett, John P.; Macala, Lawrence J.; Smallwood, Joan I.; Kalghatgi, Leena; Gassala-Herraiz, Jose; Isales, Carlos
CORPORATE SOURCE: Dep. Internal Med., Yale Sch. Med., New Haven, CT, 06510, USA
SOURCE: Journal of Biological Chemistry (1995), 270(27), 16082-8
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Bio logy
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vasopressin is known to activate two types of cell surface receptors; V2, coupled to adenylate cyclase, and V1, linked to a Ca2+-dependent transduction system. The authors investigated whether arginine vasopressin (AVP) stimulation of electrogenic sodium transport in A6 cells, derived from Xenopus laevis, is mediated by activation of either one or both types of AVP-specific receptors. AVP caused a rapid increase in electrogenic sodium transport, reflected by the transepithelial p.d. (VT) and equiv. short circuit current (Ie) measurements. AVP also rapidly increased intracellular Ca2+ (Ca2+i) and total inositol trisphosphate. The increase in Ie. There was no evidence, however, that activation of adenylate cyclase mediated AVP-stimulated Ie. Further studies showed that although both forskolin and 8-(4-chlorophenylthio)-cAMP stimulated Ie. These results indicate that AVP-stimulated Na+ transport is mediated by a V1 receptor and a Ca2+-dependent mechanism.

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vasopressin-stimulated electrogenic sodium transport in A6 cells linkage to calcium-mobilizing signal mechanism)

L26 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:664458 HCAPLUS
DOCUMENT NUMBER: 123:51494
TITLE: Imaging ion and molecular transport at subcellular resolution by secondary ion mass spectrometry
AUTHOR(S): Chandra, Subhash; Morrison, George H.
CORPORATE SOURCE: Dep. Chem., Cornell Univ., Ithaca, NY, 14853-1301, USA
SOURCE: International Journal of Mass Spectrometry and Ion Processes (1995), 143, 161-76
CODEN: IJMPDN; ISSN: 0168-1176
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The transport of K+, Na+, and Ca2+ were imaged in individual cells with a Cameca IMS-3f ion microscope. Strict cryogenic frozen freeze-dry sample prepns. were employed. Ion redistribution artifacts in conventional chem. prepns. are discussed. Cryogenically prepd. freeze-fractured freeze-dried cultured cells allowed the three-dimensional ion microscopic imaging of elements. As smaller structures in calcium images can be resolved with the 0.5 .mu.m spatial resoln., correlative techniques are needed to confirm their identity. The potentials of reflected light microscopy, SEM and laser scanning confocal microscopy are discussed for microfeature recognition in freeze-fractured freeze-dried cells. The feasibility of using frozen freeze-dried cells for imaging **mol**. transport at subcellular resoln. was tested. Ion microscopy successfully imaged the transport of the isotopically **tagged** (13C, 15N) amino acid, L-**arginine**. The labeled amino acid was imaged at mass 28 with a Cs+ primary ion beam as the 28(13C15N)- species. After a 4 h exposure of LLC-PK1 kidney cells to 4 mM labeled arginine, the amino acid was localized throughout the cell with a preferential incorporation into the nucleus and nucleolus. An example is also shown of the ion microscopic imaging of sodium borocaptate, an exptl. therapeutic drug for brain tumors, in cryogenically prepd. frozen freeze-dried Swiss 3T3 cells.

IT **7440-23-5**, Sodium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(imaging ion and **mol**. transport at subcellular resoln. by secondary ion mass spectrometry)

L26 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:418085 HCAPLUS
DOCUMENT NUMBER: 121:18085
TITLE: Polymers as contrast media for magnetic resonance imaging
INVENTOR(S): Unger, Evan C.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9408509	A1	19940428	WO 1993-US9083	19930923
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2146986	AA	19940428	CA 1993-2146986	19930923
AU 9351387	A1	19940509	AU 1993-51387	19930923
AU 671862	B2	19960912		
EP 670695	A1	19950913	EP 1993-922369	19930923
EP 670695	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08502290	T2	19960312	JP 1993-510017	19930923
AT 210940	E	20020115	AT 1993-922369	19930923
AU 9670480	A1	19970213	AU 1996-70480	19961029
AU 687690	B2	19980226		

PRIORITY APPLN. INFO.: US 1992-960591 A 19921013
WO 1993-US9083 W 19930923

AB Novel contrast media for use in magnetic resonance imaging are described. Such contrast media are comprised of biocompatible polymers in admixt. with one or more contrast agents such as paramagnetic, superparamagnetic or proton d. contrast agents. Addnl., the polymers and contrast agent admixts. may be mixed with one or more biocompatible gases to increase the relaxivity of the resultant prepn., and/or with other components. In a preferable embodiment, the contrast medium is hypoosmotic. For example, an aq. soln. contg. PEG, water, and Gd-DTPA was prepd. and its relaxation rate was greater than the sum of the relaxation rates of the PEG soln. and the Gd-DTPA soln. alone.

IT **74-79-3, Arginine**, biological studies
RL: BIOL (Biological study)
(osmotically active agent in polymer-contg. contrast media for magnetic resonance imaging)

L26 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:19566 HCAPLUS
DOCUMENT NUMBER: 114:19566
TITLE: Changes in sodium channel gating produced by point mutations in a cytoplasmic linker
AUTHOR(S): Moorman, J. Randall; Kirsch, Glenn E.; Brown, Arthur M.; Joho, Rolf H.
CORPORATE SOURCE: Dep. Med., Univ. Texas Med. Branch, Galveston, TX, 77550, USA
SOURCE: Science (Washington, DC, United States) (1990), 250(4981), 688-91
CODEN: SCIEAS; ISSN: 0036-8075
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Voltage-gated sodium channels are transmembrane **proteins** of approx. 2000 amino acids and consist of four homologous domains (I through IV). In current topog. models, domains III and IV are linked by a highly conserved cytoplasmic sequence of amino acids. Disruptions of the III-IV linker by cleavage or antibody binding slow inactivation, the depolarization-induced closed state characteristic of sodium channels. This linker might be the pos. charged ball that is thought to cause inactivation by occluding the open channel. Therefore, groups of two or three contiguous lysines were neutralized or a glutamate was substituted for an

arginine in the III-IV **linker** of type III rat brain sodium channels. In all cases, inactivation occurred more rapidly rather than more slowly, contrary to predictions. Furthermore, activation was delayed in the arginine to glutamate mutation. Hence, the III-IV linker does not simply act as a charged blocker of the channel but instead influences all aspects of sodium channel gating.

IT **74-79-3, Arginine**, biological studies
RL: BIOL (Biological study)
(of sodium channel cytoplasmic **linker peptide**, of brain, ion channel gating in relation to)

IT **7440-23-5**, Sodium, biological studies
RL: BIOL (Biological study)
(transport of, by voltage-gated channel of brain, charge of cytoplasmic linker **peptide** effect on)

L26 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:478975 HCAPLUS
DOCUMENT NUMBER: 113:78975
TITLE: Preparation of atrial natriuretic **peptide** (ANP) analogs as natriuretics, diuretics, and vasodilators
INVENTOR(S): Johansen, Nils Langeland; Thogersen, Henning; Faarup, Peter; Lundt, Behrend Friedrich; Weis, Jan Ulrik
PATENT ASSIGNEE(S): Novo-Nordisk A/S, Den.
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 350318	A2	19900110	EP 1989-306902	19890706
EP 350318	A3	19901017		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9000561	A1	19900125	WO 1989-DK170	19890706
W: AU, DK, FI, JP, NO, US				
AU 8939775	A1	19900205	AU 1989-39775	19890706
ZA 8905137	A	19900328	ZA 1989-5137	19890706
PRIORITY APPLN. INFO.:			DK 1988-3802	19880707
			WO 1989-DK170	19890706

OTHER SOURCE(S): MARPAT 113:78975
GI



I



AB The title compds. (I; A1 = Phe, D-Phe; A2 = Asp, D-Asp, Glu, Gly; A3 = Ars, homoargine residue; A4 = Ile, Leu, Val; A5 = **Arg**, D-**Arg**, homoargine residue, Ala, amino acid with basic side chain; A6 = D-**Arg**, **Arg**, Ala, basic D- or L-amino acid; A7 = Leu, Phe, arom. amino acid; X1-X3 = **spacers** contg. neutral amino acids other than sarcosine; X4 = **spacer** contg. neutral amino acids or HN(CH2)8CO; B = bond, Q1; R1 = H, amino, acylamino; R2 = H, CO2H, CONH2; X5 = bond, SS, CONH, NHCO; m, n = 0-4), were prepd. Thus, cyclo-Phe-D-Ala-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Arg-Leu-Ser-D-Arg-Phe-NH(CH2)8CO (prepd. via solid-phase synthesis followed by carbodiimide cyclization under high diln.) had three times the vasodilating ability of ANP(5-28) in rabbit artery.

IT **7440-23-5**, Sodium, biological studies
RL: BIOL (Biological study)
(urinary excretion of, atrial natriuretic **peptide** analogs effect on)

L26 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:493627 HCAPLUS
DOCUMENT NUMBER: 109:93627
TITLE: Novel hypotensive diuretic **peptides** derived from human atrial natriuretic **peptide**
INVENTOR(S): Kambayashi, Yoshikazu; Inouye, Ken
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 266006	A2	19880504	EP 1987-202052	19871026
EP 266006	A3	19900411		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 63112598	A2	19880517	JP 1986-255312	19861027

PRIORITY APPLN. INFO.: JP 1986-255312 19861027
OTHER SOURCE(S): CASREACT 109:93627
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB An analog (I) of human .beta.-atrial natriuretic **peptide** (.beta.-hANP) (an antiparallel dimer of .alpha.-hANP with the chains **linked** by 7-23' and 7'-23 SS bonds), in which residues 1-6 and 1'-6' (Ser-Leu-**Arg**-**Arg**-Ser-Ser) are lacking, is prepd. for treatment of hypertension. I (3 .mu.g i.v.) increased the urinary Na+ excretion rate in rats from 23 (control) to 30 .mu.equiv/min; the effect persisted for about 15 min. Corresponding values for .alpha.-hANP (1 .mu.g i.v.) were 23 (control) and 41 .mu.equiv/min and 8 min, resp. I was prepd. by a soln.-phase method

in which one of the SS bonds was formed in an initial stage of synthesis and the other after completion of the **peptide** chain in the continued presence of protective groups.

IT **7440-23-5**, Sodium, biological studies
RL: BIOL (Biological study)
(of urine, atrial natriuretic **peptide** analog effect on)

L26 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:626210 HCAPLUS
DOCUMENT NUMBER: 101:226210
TITLE: Discrete non-UV-absorbing anionic and cationic spacers for isotachophoretic separations at high and low pH, respectively
AUTHOR(S): Husmann-Holloway, S.; Borriss, E.
CORPORATE SOURCE: Inst. Med. Mikrobiol., Med. Hochsch., Hannover, D-3000/61, Fed. Rep. Ger.
SOURCE: Anal. Prep. Isotachophoresis, Proc., Int. Symp. Isotachophoresis, 3rd (1984), Meeting Date 1982, 63-70. Editor(s): Holloway, Christopher J. de Gruyter: Berlin, Fed. Rep. Ger.
CODEN: 52ORAU
DOCUMENT TYPE: Conference
LANGUAGE: English

AB A catalog of 49 spacer ion listed in the order of increasing relative mobility is given for an anionic electrolyte system at high pH as well as catalog of 22 spacer ions in a cationic electrolyte system at low pH for use in isotachophoretic sepns. Tables are also given of the relative ref. unit values of the spacers. A practical application is given of the spacer catalogs for the sepn. of a mixt. of **proteins**. It is cautioned that the uncrit. use of discrete spacers, e.g., for the anal. of heterogeneous **protein** mixts., can give misleading results.

IT **7440-23-5**, uses and miscellaneous
RL: USES (Uses)
(spacers, for **protein** isotachophoresis in cationic electrolyte system at low pH)

IT **74-79-3**, properties
RL: PRP (Properties)
(**spacers**, for **protein** isotachophoresis in cationic electrolyte system at low pH)

L26 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:452665 HCAPLUS
DOCUMENT NUMBER: 97:52665
TITLE: Possible incidence of infestation by Recilia **mica**, vector of oil palm blast, on amino acid metabolism in plants
AUTHOR(S): Renard, J. L.; Quillec, G.; Ollagnier, M.
CORPORATE SOURCE: Dep. Phytopathol., Inst. Rech. Huiles Ol., Dabou, Cote d'Ivoire
SOURCE: Oleagineux (1982), 37(2), 43-8
CODEN: OLEAAF; ISSN: 0030-2082
DOCUMENT TYPE: Journal
LANGUAGE: French

AB Heavy infestations of young oil palm seedlings by Recilia not only lead to great mortality by inducing blast, but modify the plants' general metab. The N levels, lowered in the plants when insects were present, indicated that protein synthesis was disturbed. P and

S metab. were also affected, the contents being lower in infested but healthy plants than in plants not infested by Recilia. The amino acids translocation mechanism in healthy plants was blocked. For most of the amino acids analyzed, there was a marked increase, 30 times more for asparagine, and .apprx.5 to 15 times more for threonine, serine, glutamine, proline, glycine, valine, tyrosine, phenylalanine, and lysine, an almost universal phenomenon obsd. after inoculation in the case of cryptogamic affections. On the other hand, there were no increases in the levels 2 to 3 days before the symptoms became manifest; incubation is from 10 to 12 days. This indicates that blockage occurs only in the very last stages of incubation, just before the symptoms appear. The drop in asparagine, glutamine, and **arginine** levels has also been shown to be **linked** to the insects' presence alone, and not to be related to an infectious process. This study enables 2 independent phenomena to be dissocd., one doubtless resulting from the toxic action of stinging-sucking insects, which operates at an early stage, and another and later one being related to the disease itself.

IT **74-79-3**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab. of, in palm species, Recilia **mica** infestation effect on)

L26 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1954:47899 HCAPLUS
DOCUMENT NUMBER: 48:47899
ORIGINAL REFERENCE NO.: 48:8492e-h
TITLE: Circulin
INVENTOR(S): Tetrault, Philip A.
PATENT ASSIGNEE(S): Purdue Research Foundation
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2676133		19540420	US	

AB A new antibiotic circulin (I) is produced by Bacillus circulans (II). II is isolated from soil by cultivation on agar agar or in a **carbohydrate**-contg. nutrient media. I is a **polypeptide** contg. free amino groups and amide-linked N. The constituents of I are leucine, threonine, .alpha.,.gamma.-diaminobutyric acid, and an optically active isomer of pelargonic acid. The free base at pH 11 is unstable; therefore it is recovered in the form of its salts which are stable. Pure I has an activity of 6300 Escherichia coli units/mg. I-sulfate is an amorphous solid, decompn. at 226-8.degree., [.alpha.]25D is -61.6, gives a neg. Sakaguchi test indicating the absence of **arginine**, a neg. xanthoproteic reaction indicating the absence of aromatic amino acids, a neg. Knoop's test for histidine, and contains no C-S **linkages**. I-sulfate, C39H74O9N12.2 1/2 H2SO4, has a **mol**. wt. of 1200. Five of the N are present as amino N, the remainder being in amide linkage. I-HCl m. 232-6 with decompn., [.alpha.]25D is -60.1, assays 6500 units/mg. I-picrate, m. 160-8.degree. with decompn., assays 3200-3600 units/mg.

I-hilanthate m. 218-22.degree. with decompn., assays 2800 units/mg. I-reineckate assays 2400-3300 units/mg. and darkens at 185-95.degree.. I, similar to polymyxins, forms complexes with surface-active agents (i.e. dodecylbenzenesulfonic acids or **salts, salts** of sulfosuccinic acid, oleic acid esters of sulfonated aliphatic compds., **Na salts** of aryl alkyl ether sulfates, sulfonated naphthalene alkyl ethers and aliphatic ester sulfates). I is effective in inhibiting the growth of gram-neg. bacteria and is destroyed by trypsin and lipase.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, PHIC, PHIN, TOXCENTER' ENTERED AT 10:31:26 ON 06 DEC 2002)

L27 9 S L10
L28 77 S L25
L29 7 S L28 AND COVALEN?
L30 15 S L27 OR L29
L31 13 DUP REM L30 (2 DUPLICATES REMOVED)

L31 ANSWER 1 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2002-599607 [64] WPIDS
DOC. NO. CPI: C2002-169431
TITLE: Use of an erythropoietin in a pharmaceutical composition for the treatment of human diseases of central nervous system.
DERWENT CLASS: B04
INVENTOR(S): BRINES, M; CERAMI, A; CERAMI, C
PATENT ASSIGNEE(S): (BRIN-I) BRINES M; (CERA-I) CERAMI A; (CERA-I) CERAMI C; (WARR-N) WARREN INST INC KENNETH S
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002053580	A2	20020711	(200264)*	EN	118

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW

US 2002086816 A1 20020704 (200264)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002053580	A2	WO 2001-US49479	20011228
US 2002086816	A1	US 2000-753132	20001229

PRIORITY APPLN. INFO: US 2000-753132 20001229; US 2000-259245P 20001229
AN 2002-599607 [64] WPIDS
AB WO 200253580 A UPAB: 20021007
NOVELTY - A pharmaceutical composition comprises an erythropoietin.
DETAILED DESCRIPTION - A pharmaceutical composition comprises an erythropoietin selected from a component (C) (preferably

asialoerythropoietin or phenylglyoxal-erythropoietin).
(C) can be:

(i) an erythropoietin having at least no salicylic acid moieties;

(ii) an erythropoietin having at least no N-**linked** or no O-**linked carbohydrates**;

(iii) an erythropoietin having at least a reduced **carbohydrate** content by virtue of treatment of native erythropoietin with at least one glycosidase;

(iv) an erythropoietin with a **carbohydrate** portion of the erythropoietin **molecule** having at least a non-mammalian glycosylation pattern by virtue of the expression of a recombinant erythropoietin in non-mammalian cells;

(v) an erythropoietin having at least one oxidized **carbohydrates** which are also chemically reduced;

(vi) an erythropoietin having at least one modified **arginine** residue;

(vii) an erythropoietin having at least one modified lysine residues or a modification of the N-terminal amino group of the erythropoietin **molecule**;

(viii) an erythropoietin having at least a modified tyrosine residue;

(ix) an erythropoietin having at least a modified aspartic acid or a glutamic acid residue;

(x) an erythropoietin having at least a modified tryptophan residue;

(xi) an erythropoietin having at least one amino group removed;

(xii) an erythropoietin having at least an opening of at least one of the cystine **linkages** in the erythropoietin **molecule**;

(xiii) an erythropoietin having at least one substitution of at least one amino acid; or

(xiv) a truncated erythropoietin.

An INDEPENDENT CLAIM is also included for a composition for facilitating the transcytosis of a **molecule** across the endothelial cell barrier in a mammal involving administering to the mammal a composition comprising the **molecule** in association with an erythropoietin selected from (C).

ACTIVITY - Cerebroprotective; Hypotensive; Cardiant; Vasotropic; Antiinflammatory; Nootropic; Neuroprotective; Antiparkinsonian; Anti-HIV; Antialcoholic; Tranquilizer; Antidiabetic; Antiemetic; Cytostatic; Ophthalmological; Gastrointestinal-Gen.; Nephrotropic; Anticonvulsant; Antitumor; Hypertensive; Neuroleptic; Virucide; Antibacterial; Antiasthmatic; Antimanic; Hemostatic; Antisickling; Vulnerary; Antismoking; Immunosuppressive; Analgesic; Antidepressant.

Adult male rats given recombinant human erythropoietin (5000 U/kg body weight) 24 hours previously were anesthetized and prepared for coronary artery occlusion. An additional dose of erythropoietin was given at the start of the procedure and the left main coronary artery occluded for 30 minutes and then released. The same dose of erythropoietin was given daily for one week after the treatment. The animals were then studied for cardiac function and the values obtained were compared with the placebo animals. The values of the cardiac function for test/placebo animals was approx. between 120 - 140/ approx. between 100 - 120 (in the beginning); approx. equal to 60/ approx. between 40 - 60 (approx. after 60 minutes); and approx. above 60/ approx. between 40 - 60 (approx. after 120 minutes).

From the results obtained it was found that the placebo animals receiving a sham injection (saline) demonstrated a large increase in the left end diastolic pressure, indicative of a dilated, stiff heart secondary to myocardial infarction. In contradiction, animals receiving erythropoietin suffered no decrement in cardiac function, compared to sham operated controls.

MECHANISM OF ACTION - Erythropoietin receptor activity modulator.

USE - This novel composition is used for protecting, maintaining, enhancing or restoring the function or viability of erythropoietin-responsive mammalian cells such as neuronal, retinal, muscle, heart, lung, liver, kidney, small intestine, adrenal cortex, adrenal medulla, capillary endothelial, testes, ovary or endometrial cells or tissues; and their associated cells, tissues and organs, where the cells, tissues or organs are not excitable cells, tissues or organs or do not predominantly comprise excitable cells or tissues; for the treatment of cognitive dysfunction resulting from an injury caused by seizure disorders, multiple sclerosis, stroke, hypotension, cardiac arrest, ischemia, myocardial infarction, inflammation, age-related loss of cognitive function, radiation damage, cerebral palsy, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Leigh disease, AIDS dementia, memory loss, amyotrophic lateral sclerosis, alcoholism, mood disorder, anxiety disorder, attention deficit disorder, autism, Creutzfeld-Jakob disease, brain or spinal cord trauma or ischemia, heart-lung bypass, chronic heart failure, macular degeneration, diabetic neuropathy, diabetic retinopathy, glaucoma, retinal ischemia or retinal trauma (all claimed); and in a pharmaceutical composition for the treatment of human diseases of central nervous system, which have primarily neurological or psychiatric symptoms, as well as ophthalmic diseases, cardiovascular diseases, cardiopulmonary diseases, respiratory disease, kidney, urinary and reproductive diseases, gastrointestinal diseases and endocrine and metabolic abnormalities. For treating hypoxic conditions, which adversely affect excitable tissues, such as excitable tissues in the central nervous system tissue, peripheral nervous system tissue or cardiac tissue or retinal tissue including brain, heart or retina/eye; and ischemia. It is also useful for the protection of neuronal tissue pathologies, which result from reduced oxygenation of neuronal tissues, for treating any condition, which reduces the availability of oxygen to neuronal tissue resulting in stress, damage, and finally cell death including stroke, vascular occlusion, prenatal or postnatal oxygen deprivation, suffocation, choking, near drowning, carbon monoxide poisoning, smoke inhalation, trauma, surgery and radiotherapy, asphyxia, epilepsy, hypoglycemia, chronic obstructive pulmonary disease, emphysema, adult respiratory distress syndrome, hypotensive shock, septic shock, anaphylactic shock, insulin shock, sickle cell crisis, cardiac arrest, dysrhythmia, nitrogen narcosis, and neurological deficits caused by heart-lung bypass procedures.

ADVANTAGE - The compositions protect, maintain, enhance and restore the function or viability of erythropoietin-responsive mammalian cells and their associated cells, tissues and organs when administered after the onset of the disease or condition responsible for the dysfunction.

Dwg.0/15

L31 ANSWER 2 OF 13 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2002-315249 [35] WPIDS
DOC. NO. CPI: C2002-091684
TITLE: New materials consisting essentially of silica and **nucleic** acids **covalently** bonded to the silica, useful for binding **nucleic** acids and for improving the binding of **nucleic** acids to surfaces.
DERWENT CLASS: A96 B04 D16
INVENTOR(S): LYLES, M B
PATENT ASSIGNEE(S): (LYLE-I) LYLES M B
COUNTRY COUNT: 96
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002008237	A2	20020131	(200235)*	EN	9

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2001076023	A	20020205	(200236)
US 2002103350	A1	20020801	(200253)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002008237	A2	WO 2001-US23079	20010720
AU 2001076023	A	AU 2001-76023	20010720
US 2002103350	A1 Provisional	US 2000-220096P	20000721
		US 2001-910697	20010720

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001076023	A Based on	WO 200208237

PRIORITY APPLN. INFO: US 2001-910697 20010720; US 2000-220096P 20000721

AN 2002-315249 [35] WPIDS

AB WO 200208237 A UPAB: 20020603
NOVELTY - A material consisting essentially of silica and **nucleic** acids **covalently** bonded to the silica, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of binding **nucleic** acids to a surface, by providing a mixture comprising **nucleic** acids and a charged material, and contacting the mixture and a surface to produce a bound material consisting of **nucleic** acids **covalently** bonded to the surface.

USE - The silica surfaces are useful for binding **nucleic** acids and for improving the binding of **nucleic** acids to surfaces.

Dwg.0/0

L31 ANSWER 3 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2001-482889 [52] WPIDS
CROSS REFERENCE: 2001-441325 [34]
DOC. NO. CPI: C2001-144635
TITLE: Self-gelling biopolymeric liquid aqueous composition comprises pH-gelling acid soluble biopolymer e.g. optionally modified chitosan and basic water-soluble **molecule** e.g. glycerol-2-phosphate.
DERWENT CLASS: A96 B07
INVENTOR(S): CHAPUT, C; CHENITE, A; SELMANI, A; WANG, D
PATENT ASSIGNEE(S): (BIOS-N) BIO SYNTECH CANADA INC
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001036000	A1	20010525	(200152)*	EN	36

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2001013753	A	20010530	(200152)		
EP 1229940	A1	20020814	(200261)	EN	

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001036000	A1	WO 2000-CA1341	20001110
AU 2001013753	A	AU 2001-13753	20001110
EP 1229940	A1	EP 2000-975711	20001110
		WO 2000-CA1341	20001110

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001013753	A	Based on	WO 200136000
EP 1229940	A1	Based on	WO 200136000

PRIORITY APPLN. INFO: US 1999-165641P 19991115
AN 2001-482889 [52] WPIDS
CR 2001-441325 [34]
AB WO 200136000 A UPAB: 20011129
NOVELTY - Temperature controlled and pH-dependent self-gelling biopolymeric liquid aqueous composition (SBC) comprising pH-gelling acid soluble biopolymer (P1) and basic water-soluble **molecule** (M1), is new.
DETAILED DESCRIPTION - New self-gelling biopolymeric liquid aqueous composition (SBC) for producing gels comprises:
(1) 0.1-10 wt.% of a pH-gelling acid soluble biopolymer (P1);

and

(2) 0.1-10 wt.% of a water-soluble **molecule** (M1) or its residue or sequence, that is basic and having a pKa value of 6.0-8.4.

The composition has a final pH range of 5.8-7.4 and forms a stable solid and homogeneous gel with a temperature range of 10 - 70 deg. C.

USE - SBC is used as an implantable, transdermal or dermatological drug delivery system or opthalmological implant. It is useful in cells-loaded artificial matrices for engineering and culture of bio-engineered hybrid materials and tissue for surgical or laboratory testing applications. It may be used in culturing and engineering artificial articular cartilage and cartilageous tissues or organs or living artificial substitutes for ligaments, tendons, skin, bone muscles and/or metabolic organs. SBC may also be used as an injectable or implantable biomaterial which acts as support, carrier, reconstructive device or substitutes for the formation of in situ of bone-like, fibrocartilage-like or cartilage-like tissues (all claimed). SBC forms a temperature controlled pH-dependent gel.

ADVANTAGE - The composition forms a gel without the inclusion of organic solvents, monomers, ionic or **covalent** cross-**linking** that may be potentially toxic or induce a reduced biological compatibility

Dwg.0/8

L31 ANSWER 4 OF 13 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2002-107747 [15] WPIDS

DOC. NO. NON-CPI: N2002-080219

DOC. NO. CPI: C2002-033228

TITLE: Disposable absorbent article such as a sanitary napkin, tampon or diaper, with improved odor control performance and fluid absorption performance, comprises cationic polysaccharide and **silicate**.

DERWENT CLASS: A11 A96 D22 F07 P34

INVENTOR(S): CARLUCCI, G; DI CINTIO, A; PESCE, A; TORDONE, A A

PATENT ASSIGNEE(S): (PROC) PROCTER & GAMBLE CO

COUNTRY COUNT: 96

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1149596	A1	20011031	(200215)*	EN	22
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
WO 2001080915	A1	20011101	(200215)	EN	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001057205	A	20011107	(200219)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

EP 1149596	A1	EP 2000-108065	20000425
WO 2001080915	A1	WO 2001-US13160	20010424
AU 2001057205	A	AU 2001-57205	20010424

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001057205 A	Based on	WO 200180915

PRIORITY APPLN. INFO: EP 2000-108065 20000425
AN 2002-107747 [15] WPIDS
AB EP 1149596 A UPAB: 20020306
NOVELTY - A disposable absorbent article with improved odor control performance and fluid absorption performance, comprises a cationic polysaccharide and **silicate**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(1) a method of controlling odor associated with body exudates and/or body fluids, which involves contacting the body exudates and/or body fluids, with odor control system comprising cationic polysaccharide, preferably chitosan material, together with **silicate**;

(2) the use of the cross-**linked silicate** -cationic polysaccharide, namely cross-**linked silicate**-chitosan in an absorbent article suitable to be placed against or in proximity to the body of wearer, for improved odor control and/or long lasting odor control.

USE - Such as sanitary napkin, pantiliner, tampon, diaper, incontinent pad, breast pad, perspiration pad, interlabial pad, and body cleaning article (all claimed), for absorbing body fluids including instance perspiration, urine, menstrual fluids, feces, vaginal secretions and lactational fluid.

ADVANTAGE - The absorbent article has improved odor control and/or long lasting odor control and fluid handling properties. The **silicate** due to its acidic character protonates amino groups of cationic polysaccharide, which enhances its cationic properties thereby increasing odor control and/or long lasting odor control properties of polysaccharide, resulting in synergistic odor reduction towards odor associated with body fluids like menses. The increased degree of deacetylation, improves cationic character of chitosan, thereby increasing anti-microbial property, absorbing ability and gelifying ability. The addition of anionic gelling material enhances fluid absorption capacity, exhibits high gel strength during fluid absorption and improves absorption capacity under load conditions in decreased rewetting and wetting through.
Dwg.0/0

L31 ANSWER 5 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2000-572032 [53] WPIDS
DOC. NO. CPI: C2000-170509
TITLE: Non-parenteral multi-particulate formulations comprise biologically active substances bound to carrier particles for delivery across mucosal membranes.
DERWENT CLASS: A96 B04 D16
INVENTOR(S): HARDEE, G E; MEHTA, R C; TENG, C; TILLMAN, L G
PATENT ASSIGNEE(S): (ISIS-N) ISIS PHARM INC

COUNTRY COUNT: 91
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000050050	A1	20000831	(200053)*	EN	38
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000032433	A	20000914	(200063)		
EP 1156812	A1	20011128	(200201)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000050050	A1 Cont of	US 1999-256515	19990223
		WO 2000-US4662	20000223
AU 2000032433	A	AU 2000-32433	20000223
EP 1156812	A1	EP 2000-910320	20000223
		WO 2000-US4662	20000223

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000032433	A Based on	WO 200050050
EP 1156812	A1 Based on	WO 200050050

PRIORITY APPLN. INFO: US 1999-256515 19990223; WO 2000-US4662 20000223

AN 2000-572032 [53] WPIDS

AB WO 200050050 A UPAB: 20010719

NOVELTY - Non-parenteral multi-particulate formulation comprises carrier particles bound with a biologically active substance (BAS) to be delivered across a mucosal membrane and a penetration enhancer.

USE - The formulations associate with buccal, nasal, pulmonary, gastrointestinal and vaginal mucosal membranes to transport the BAS to the lymph system, blood system or epithelial tissue of the subject.

ADVANTAGE - The formulation is administered orally which is preferred by patients.

Dwg.0/1

L31 ANSWER 6 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2000-316963 [27] WPIDS
DOC. NO. CPI: C2000-095799
TITLE: Nutritional composition for optimizing muscle performance during exercise and enhancing muscle cell repair and recovery after exercise includes carbohydrates, proteins, amino acids, vitamins and ciwujia.

DERWENT CLASS: B04 B05 D13
INVENTOR(S): PORTMAN, R
PATENT ASSIGNEE(S): (PACI-N) PACIFICHEALTH LAB INC
COUNTRY COUNT: 46
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6051236	A	20000418	(200027)*		22
WO 2000027408	A1	20000518	(200032)	EN	
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: AE AT AU BR CA CN CU DE DK ES FI GB GD ID IL IN IS JP KR LT LV MX NO NZ PL PT RO RU SE SG TR UA YU ZA					
AU 2000016200	A	20000529	(200041)		
EP 1161249	A1	20011212	(200204)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 6051236	A	US 1998-190885	19981112
WO 2000027408	A1	WO 1999-US26819	19991111
AU 2000016200	A	AU 2000-16200	19991111
EP 1161249	A1	EP 1999-958932	19991111
		WO 1999-US26819	19991111

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000016200	A	Based on	WO 200027408
EP 1161249	A1	Based on	WO 200027408

PRIORITY APPLN. INFO: US 1998-190885 19981112
AN 2000-316963 [27] WPIDS
AB US 6051236 A UPAB: 20000606
NOVELTY - Nutritional composition (I) in dry powder form for optimizing muscle performance during exercise and for enhancing muscle cell repair and recovery after exercise comprises carbohydrates, proteins, glutamine, **arginine**, vitamin C, vitamin E, electrolytes, ciwujia and one or more branched-chain amino acids, the carbohydrate:protein ratio being 2.8-4.2:1.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a nutritional composition in liquid drink form, comprising (I) and water or juice;

(2) a nutritional composition in energy bar form, comprising (I) and a semi-liquid carrier comprising chocolate, oats, wheat, peanut butter, semi-dried fruits and/or grains; and

(3) a nutritional composition in jelly form, comprising (I) and a mixture of water or juice and gelatin.

ACTIVITY - Nutritional; muscular.

Ten well trained triathletes underwent two simulated duathalons, in which they first ran at 75% of their VO2max on a treadmill for 45 minutes with 1 minutes race surges every 15 minutes, followed by cycling for 30 minutes at 75% of their VO2max. After each phase, the nutritional drink or Gatorade (TM) was taken.

At the end of the cycling phase, all athletes underwent a performance bout to measure the time taken for 60000 Joules of work.

The time taken for the 60000 Joules of work to be performed was reduced by 3 minutes for those taking the nutritional drink and their heart rate during performance was reduced. Blood creatine kinase levels were reduced by 36% 24 hours after the assessment.

MECHANISM OF ACTION - Insulin stimulating.

USE - For optimizing muscle performance during exercise and for enhancing muscle cell repair and recovery after exercise.

ADVANTAGE - Unlike prior art compositions, the composition includes protein without slowing gastric emptying due to cholecystokinin release, thus improving rehydration and electrolyte distribution. Addition of antioxidant vitamins to prevent free radical generation and glutamine and ciwujia to stimulate the immune system aid rapid recovery and the ciwujia further prevents post exercise stress by lowering the heart rate. Muscular and cardiac stress during exercise is reduced, performance and endurance are extended and the composition has a pleasant taste.

Dwg.0/9

L31 ANSWER 7 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1999-394759 [33] WPIDS
DOC. NO. NON-CPI: N1999-295078
DOC. NO. CPI: C1999-115961
TITLE: Attaching moieties to a layered **silicate** surface.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): NOCK, S; SPUDICH, J A; WAGNER, P
PATENT ASSIGNEE(S): (STRD) UNIV STANFORD
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9912036	A1	19990311	(199933)*	EN	56

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AU 9892225	A	19990322	(199933)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9912036	A1	WO 1998-US18531	19980903
AU 9892225	A	AU 1998-92225	19980903

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9892225	A	Based on	WO 9912036

PRIORITY APPLN. INFO: US 1997-57929P 19970904
AN 1999-394759 [33] WPIDS

AB WO 9912036 A UPAB: 20011203
NOVELTY - A novel method of attaching a moiety to a layered **silicate** surface comprises:
(a) **covalently** attaching the moiety to an **arginine tag**; and
(b) contacting the **arginine tag** with the layered **silicate** surface.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a surface functionalized for the attachment of organic **molecules** where the functionalization is compatible with physiological **sodium salt** concentrations, the surface comprising a layered **silicate** contacted with an **arginine tag molecule**;
(2) a method of orienting a **polypeptide** on a layered **silicate** surface comprising:
(a) providing a **polypeptide covalently linked** to an **arginine tag**; and
(b) contacting the **arginine tag** with the layered **silicate** surface;
(3) a surface bearing anisotropically oriented **proteins**, the surface comprising a layered **silicate** surface contacted with **proteins**, each **protein covalently** attached to an **arginine tag**;
(4) a method of purifying a target **molecule** from a heterogeneous mixture of **molecules** comprising:
(a) providing a target **molecule** attached to an **arginine tag**; and
(b) contacting the target **molecule** with a surface of a layered **silicate** surface, whereby the target **molecule** binds to the surface;
(5) an affinity purification device comprising a vessel having a fluid inlet port and a fluid outlet port where the vessel is filled with a layered **silicate**.
USE - The methods can be used for attaching to a **silicate** surface biological **molecules**, e.g. **proteins**, an antibody, a **DNA** binding **protein**, a molecular motor, an actin filament, a microtubule, a myosin filament, an actin filament binding **protein**, a myosin filament binding **protein**, a cell surface receptor, a growth factor, a hormone or a **nucleic** acid (claimed). The methods can be used for isolation, functional studies and when using biosensors.
ADVANTAGE - The attachment of moieties to the **silicate** surface is easily reversed and yet stable to physiologically relevant concentrations of ions such as K+, Na+, Mg2+, Ca2+. For a given amount of **protein** on the surface, a higher number and/or density of reaction sites can be provided than are available using other attachment methods. In addition, because layered **silicates** (e.g. **mica**) can be easily fractured to produce atomically smooth surfaces, bound **proteins**, or other moieties, are not hidden or masked from reactive agents by surface irregularities.
Dwg.0/5

L31 ANSWER 8 OF 13 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1999-602946 [52] WPIDS
CROSS REFERENCE: 1999-612605 [53]; 2000-184751 [17]; 2000-258671

[23]

DOC. NO. CPI: C1999-175602

TITLE: New hedgehog **protein** conjugate, useful for stimulating chondrocytes, osteocytes, muscle and nerve cells.

DERWENT CLASS: A96 B04 D16

INVENTOR(S): ESSWEIN, A; LANG, K; RUEGER, P; SEYTTER, T; PAPADIMITRIOUS, A

PATENT ASSIGNEE(S): (HOFF) ROCHE DIAGNOSTICS GMBH; (CURI-N) CURIS INC

COUNTRY COUNT: 39

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 953576	A1	19991103	(199952)*	EN	25
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
NO 9902090	A	19991101	(200002)		
AU 9925009	A	19991111	(200004)		
HU 9901411	A2	19991228	(200010)		
CN 1233616	A	19991103	(200011)		
ZA 9903009	A	20000126	(200011)		39
CA 2269221	A1	19991030	(200014)	EN	
JP 2000053699	A	20000222	(200020)		18
CZ 9901478	A3	20000412	(200026)		
AU 719797	B	20000518	(200032)		
KR 99083621	A	19991125	(200055)		
BR 9903169	A	20001017	(200056)		
NZ 335385	A	20000929	(200060)		
NZ 337034	A	20010126	(200109)		
SG 80028	A1	20010417	(200128)		
MX 9903976	A1	20000601	(200133)		
US 6468978	B1	20021022	(200273)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 953576	A1	EP 1999-108032	19990423
NO 9902090	A	NO 1999-2090	19990429
AU 9925009	A	AU 1999-25009	19990429
HU 9901411	A2	HU 1999-1411	19990428
CN 1233616	A	CN 1999-106302	19990429
ZA 9903009	A	ZA 1999-3009	19990429
CA 2269221	A1	CA 1999-2269221	19990429
JP 2000053699	A	JP 1999-125005	19990430
CZ 9901478	A3	CZ 1999-1478	19990427
AU 719797	B	AU 1999-25009	19990429
KR 99083621	A	KR 1999-15503	19990429
BR 9903169	A	BR 1999-3169	19990430
NZ 335385	A	NZ 1999-335385	19990426
NZ 337034	A	NZ 1999-337034	19990803
SG 80028	A1	SG 1999-2117	19990428
MX 9903976	A1	MX 1999-3976	19990428
US 6468978	B1	US 1999-301199	19990428

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 719797	B	Previous Publ.	AU 9925009

PRIORITY APPLN. INFO: EP 1998-116733 19980903; EP 1998-107911 19980430; EP 1998-114851 19980807
AN 1999-602946 [52] WPIDS
CR 1999-612605 [53]; 2000-184751 [17]; 2000-258671 [23]
AB EP 953576 A UPAB: 20021113
NOVELTY - A hedgehog (hh) conjugate (I) comprising a **polypeptide** composed of:
(1) 10-30 hydrophobic amino acids and/or amino acids that form transmembrane helices and are positively charged;
(2) 1-4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 8-24 C atoms and which are hydrophobic; and
(3) a hydrophobic thio compound, **covalently** bound to a hh **protein** (II),
is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) production of (I); and
(2) (II) where the thiol group of the N-terminal cysteine is coupled to a thiol-protecting group or (II) is a homodimer with its N-terminal cysteines **linked** by a disulfide bridge.
MECHANISM OF ACTION - Signaling **molecule** that effects cell determination.
USE - (II) may be used to produce (I) (claimed). (I) may be administered in a composition to induce or stimulate chondrocytes, osteocytes, muscle and nerve cells.
ADVANTAGE - (I) is made hydrophobic by the presence of the hydrophobic amino acid residues. This increases the interaction of (I) with the (especially mammalian) cell membrane compared to prior art native hh **proteins** which were not modified in this way. The increased interaction with the cell membrane increases the integration of hh into the interior of the cell. This results in (I) having a 10-105 fold greater activity compared to unmodified hh, especially when used in a pharmaceutical composition. In addition, (I) does not need to be coupled to a carrier to allow slow release of (I) in a pharmaceutical composition.
Dwg.0/2

L31 ANSWER 9 OF 13 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1998:222417 BIOSIS
DOCUMENT NUMBER: PREV199800222417
TITLE: The Phe-Met-Arg-Phe-amide-activated sodium channel is a tetramer.
AUTHOR(S): Coscoy, Sylvie; Lingueglia, Eric; Lazdunski, Michel; Barbry, Pascal (1)
CORPORATE SOURCE: (1) Inst. Pharmacol. Mol. Cell., CNRS, UPR 411, 660 Route des Lucioles, Sophia Antipolis, 06560 Valbonne France
SOURCE: Journal of Biological Chemistry, (April 3, 1998) Vol. 273, No. 14, pp. 8317-8322.
ISSN: 0021-9258.
DOCUMENT TYPE: Article
LANGUAGE: English
AB The Helix aspersa Phe-Met-Arg-Phe-amide (FMRF-amide)-gated

sodium channel is formed by homomultimerization of several FMRFamide-activated Na+ channel (FaNaCh) **proteins**. FaNaCh is homologous to the subunits that compose the amiloride-sensitive epithelial sodium channel, to Caenorhabditis elegans degenerins, and to acid-sensing ionic channels. FaNaCh properties were analyzed in stably transfected human embryonic kidney cells (HEK-293). The channel was functional with an EC50 for FMRFamide of 1 muM and an IC50 (25 degreeC) for amiloride of 6.5 muM as assessed by 22Na+ uptake measurements. The channel activity was associated with the presence of a **protein** at the cell surface with an apparent molecular mass of 82 kDa. The 82-kDa form was derived from an incompletely glycosylated form of 74 kDa found in the endoplasmic reticulum. Formation of **covalent** bonds between subunits of the same complex were observed either after formation of intersubunit disulfide bonds following cell homogenization and solubilization with Triton X-100 or after use of bifunctional cross-**linkers**. This resulted in the formation of **covalent** multimers that contained up to four subunits. Hydrodynamic properties of the solubilized FaNaCh complex also indicated a maximal stoichiometry of four subunits per complex. It is likely that epithelial Na+ channels, acid-sensing ionic channels, degenerins, and the other **proteins** belonging to the same ion channel superfamily also associate within tetrameric complexes.

L31 ANSWER 10 OF 13 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1998:335554 BIOSIS
DOCUMENT NUMBER: PREV199800335554
TITLE: Reversible site-specific immobilization of poly-**arginine-tagged** fusion proteins on **mica** surfaces.
AUTHOR(S): Nock, S.; Wagner, P.; Spudich, J. A.
CORPORATE SOURCE: Dep. Biochem., Stanford Univ., Stanford, CA 94305 USA
SOURCE: Biophysical Journal, (Feb., 1998) Vol. 74, No. 2 PART 2, pp. A295.
Meeting Info.: Forty-second Annual Meeting of the Biophysical Society Kansas City, Missouri, USA February 22-26, 1998
ISSN: 0006-3495.
DOCUMENT TYPE: Conference
LANGUAGE: English

L31 ANSWER 11 OF 13 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 97459732 MEDLINE
DOCUMENT NUMBER: 97459732 PubMed ID: 9315692
TITLE: Reversible, site-specific immobilization of **polyarginine-tagged** fusion proteins on **mica** surfaces.
AUTHOR: Nock S; Spudich J A; Wagner P
CORPORATE SOURCE: Department of Biochemistry, Beckman Center B405, Stanford University Medical Center, CA 94305-5307, USA.
CONTRACT NUMBER: GM33289 (NIGMS)
SOURCE: FEBS LETTERS, (1997 Sep 8) 414 (2) 233-8.
Journal code: 0155157. ISSN: 0014-5793.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals

ENTRY MONTH: 199710
ENTRY DATE: Entered STN: 19971105
Last Updated on STN: 19971105
Entered Medline: 19971021

AB A large variety of genes is expressed as fusion proteins for the purpose of characterization and purification in molecular biology. We have used this strategy to append **polyarginine** peptides in order to achieve specific binding of the **Arg-tag** to atomically flat, negatively charged **mica** surfaces. We show that the model protein, **hexaarginine-tagged** green fluorescent protein (GFP), binds to **mica** via its **Arg-tag** based on ion exchange of naturally occurring potassium cations. Only non-specific binding was observed with the control protein that is free of the **Arg-tag**. This novel technology will be widely applicable to orient functional proteins on flat surfaces.

L31 ANSWER 12 OF 13 TOXCENTER COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:153389 TOXCENTER
COPYRIGHT: Copyright 2002 ACS
DOCUMENT NUMBER: CA12102018085H
TITLE: Polymers as contrast media for magnetic resonance imaging
AUTHOR(S): Unger, Evan C.
PATENT INFORMATION: WO 948509 A1 28 Apr 1994
SOURCE: (1994) PCT Int. Appl., 65 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1994:418085
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20020910

AB Novel contrast media for use in magnetic resonance imaging are described. Such contrast media are comprised of biocompatible polymers in admixt. with one or more contrast agents such as paramagnetic, superparamagnetic or proton d. contrast agents. Addnl., the polymers and contrast agent admixts. may be mixed with one or more biocompatible gases to increase the relaxivity of the resultant prepn., and/or with other components. In a preferable embodiment, the contrast medium is hypoosmotic. For example, an aq. soln. contg. PEG, water, and Gd-DTPA was prepd. and its relaxation rate was greater than the sum of the relaxation rates of the PEG soln. and the Gd-DTPA soln. alone.

L31 ANSWER 13 OF 13 TOXCENTER COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:114421 TOXCENTER
COPYRIGHT: Copyright 2002 ACS
DOCUMENT NUMBER: CA09707052665T
TITLE: Possible incidence of infestation by Recilia **mica**, vector of oil palm blast, on amino acid metabolism in plants
AUTHOR(S): Renard, J. L.; Quillec, G.; Ollagnier, M.
CORPORATE SOURCE: Dep. Phytopathol., Inst. Rech. Huiles Ol., Dabou, Cote d'Ivoire.
SOURCE: Oleagineux, (1982) Vol. 37, No. 2, pp. 43-8.
CODEN: OLEAAF. ISSN: 0030-2082.

COUNTRY: COTE D'IVOIRE
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1982:452665
LANGUAGE: French
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20021126

AB Heavy infestations of young oil palm seedlings by Recilia not only lead to great mortality by inducing blast, but modify the plants' general metab. The N levels, lowered in the plants when insects were present, indicated that protein synthesis was disturbed. P and S metab. were also affected, the contents being lower in infested but healthy plants than in plants not infested by Recilia. The amino acids translocation mechanism in healthy plants was blocked. For most of the amino acids analyzed, there was a marked increase, 30 times more for asparagine, and .apprx.5 to 15 times more for threonine, serine, glutamine, proline, glycine, valine, tyrosine, phenylalanine, and lysine, an almost universal phenomenon obsd. after inoculation in the case of cryptogamic affections. On the other hand, there were no increases in the levels 2 to 3 days before the symptoms became manifest; incubation is from 10 to 12 days. This indicates that blockage occurs only in the very last stages of incubation, just before the symptoms appear. The drop in asparagine, glutamine, and **arginine** levels has also been shown to be **linked** to the insects' presence alone, and not to be related to an infectious process. This study enables 2 independent phenomena to be dissocd., one doubtless resulting from the toxic action of stinging-sucking insects, which operates at an early stage, and another and later one being related to the disease itself.

(FILE 'MEDLINE' ENTERED AT 10:36:50 ON 06 DEC 2002)
L32 811 SEA FILE=MEDLINE ABB=ON PLU=ON SILICATES/CT
L33 191 SEA FILE=MEDLINE ABB=ON PLU=ON MICA/CN
L34 23803 SEA FILE=MEDLINE ABB=ON PLU=ON ARGININE/CT
L35 2 SEA FILE=MEDLINE ABB=ON PLU=ON L34 AND (L32 OR L33)

L35 ANSWER 1 OF 2 MEDLINE
AN 97459732 MEDLINE
TI Reversible, site-specific immobilization of polyarginine-tagged fusion proteins on mica surfaces.
AU Nock S; Spudich J A; Wagner P
SO FEBS LETTERS, (1997 Sep 8) 414 (2) 233-8.
Journal code: 0155157. ISSN: 0014-5793.
AB A large variety of genes is expressed as fusion proteins for the purpose of characterization and purification in molecular biology. We have used this strategy to append polyarginine peptides in order to achieve specific binding of the Arg-tag to atomically flat, negatively charged mica surfaces. We show that the model protein, hexaarginine-tagged green fluorescent protein (GFP), binds to mica via its Arg-tag based on ion exchange of naturally occurring potassium cations. Only non-specific binding was observed with the control protein that is free of the Arg-tag. This novel technology will be widely applicable to orient functional proteins on flat surfaces.

L35 ANSWER 2 OF 2 MEDLINE
AN 95111070 MEDLINE

TI Influence of surface and protein modification on immunoglobulin G adsorption observed by scanning force microscopy.
AU Droz E; Taborelli M; Descouts P; Wells T N
SO BIOPHYSICAL JOURNAL, (1994 Sep) 67 (3) 1316-23.
Journal code: 0370626. ISSN: 0006-3495.
AB Scanning force microscopy has been used successfully to produce images of individual protein molecules. However, one of the problems with this approach has been the high mobility of the proteins caused by the interaction between the sample and the scanning tip. To stabilize the proteins we have modified the adsorption properties of immunoglobulin G on graphite and mica surfaces. We have used two approaches: first, we applied glow discharge treatment to the surface to increase the hydrophilicity, favoring adhesion of hydrophilic protein molecules; second, we used the arginine modifying reagent phenylglyoxal to increase the protein hydrophobicity and thus enhance its adherence to hydrophobic surfaces. We used scanning force microscopy to show that the glow discharge treatment favors a more homogeneous distribution and stronger adherence of the protein molecules to the graphite surface. Chemical modification of the immunoglobulin caused increased aggregation of the proteins on the surface but did not improve the adherence to graphite. On mica, clusters of modified immunoglobulins were also observed and their adsorption was reduced. These results underline the importance of the surface hydrophobicity and charge in controlling the distribution of proteins on the surface.

(FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, PHIC, PHIN, TOXCENTER' ENTERED AT 10:38:02 ON 06 DEC 2002)
L36 1492 S "SPUDICH J"?/AU
L37 4322 S "WAGNER P"?/AU
L38 148 S "NOCK S"?/AU
L39 12 S L36 AND L37 AND L38
L40 23 S L36 AND (L37 OR L38)
L41 39 S L37 AND L38
L42 48 S (L40 OR L41 OR L36 OR L37 OR L38) AND L5
L43 53 S L39 OR L42
L44 21 DUP REM L43 (32 DUPLICATES REMOVED)

- Author(s)

L44 ANSWER 1 OF 21 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2002-619038 [66] WPIDS
DOC. NO. CPI: C2002-174798
TITLE: New secretion signal from the killer virus 28 toxin gene, useful for cloning genes and for secretory expression of recombinant proteins in eukaryotes.
DERWENT CLASS: B04 D16
INVENTOR(S): HEINTEL, T; SCHMITT, M; **WAGNER, P**; WOELK, U; ZAGORC, T
PATENT ASSIGNEE(S): (AVET) AVENTIS RES & TECHNOLOGIES GMBH & CO KG; (PHYL-N) PHYLOS INC
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002048187	A2	20020620	(200266)*	GE	26

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ

Total word count - document B 13886
Total word count - documents A + B 13886

9/3,AB/39 (Item 39 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00744436
BLEACH COMPOSITIONS COMPRISING OLEOYL SARCOSINATE SURFACTANTS
OLEOYLSARCOSINATTENSIDE ENTHALTENDE BLEICHMITTELZUSAMMENSETZUNGEN
COMPOSITIONS DE BLANCHIMENT COMPRENANT DES TENSIOACTIFS DE TYPE SARCOSINATE D'OLEOYLE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
POWELL, Suzanne, 8 Longborough Court S. Gosforth, Newcastle Upon Tyne NE3 1YX, (GB)
VERMOTE, Christian, Leo, Marie, Hertooie 7, B-9052 Zwijnaarde, (BE)
INGRAM, Barry, Thomas, 47 Western Way Whitley Bay, Tyne & Wear NE26 1JE, (GB)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 763096 A1 970319 (Basic)
EP 763096 B1 991215
WO 9533043 951207
APPLICATION (CC, No, Date): EP 95919235 950518; WO 95US6296 950518
PRIORITY (CC, No, Date): US 252040 940601
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-003/39; C11D-001/10
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9950	500
CLAIMS B	(German)	9950	423
CLAIMS B	(French)	9950	610
SPEC B	(English)	9950	14761

Total word count - document A 0
Total word count - document B 16294
Total word count - documents A + B 16294

9/3,AB/40 (Item 40 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00744285
COMPOSITIONS COMPRISING ETHOXYLATED/PROPOXYLATED POLYALKYLENEAMINE POLYMERS AS SOIL DISPERSING AGENTS
ZUSAMMENSETZUNGEN ENTHALTEND ETHOXYLIERTE POLYALKYLENAMINE POLYMERE ALS DISPERGIERMITTEL FUR ANSCHMUTZUNGEN
COMPOSITIONS DE DISPERSION DES SALISSURES A BASE DE POLYMERES DU TYPE POLYALKYLENEAMINE ETHOXYLEE/PROPOXYLEE

PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
WATSON, Randall, Alan, 14 Pendery Avenue, Cincinnati, OH 45215, (US)
GOSSELINK, Eugene, Paul, 3754 Susanna Drive, Cincinnati, OH 45251, (US)
ZHANG, Shulin, 7585 Lakota Springs Drive, Westchester, OH 45069, (US)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 760846 A1 970312 (Basic)
EP 760846 B1 991215
WO 9532272 951130
APPLICATION (CC, No, Date): EP 95917025 950418; WO 95US4732 950418
PRIORITY (CC, No, Date): US 248950 940525
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-003/37; C11D-003/00
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9950	479
CLAIMS B	(German)	9950	476
CLAIMS B	(French)	9950	589
SPEC B	(English)	9950	14540
Total word count - document A			0
Total word count - document B			16084
Total word count - documents A + B			16084

9/3,AB/41 (Item 41 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00733574
BLEACH COMPOSITIONS COMPRISING PROTEASE ENZYME
BLEICHMITTELZUSAMMENSETZUNGEN MIT PROTEASE
COMPOSITIONS DE BLANCHIMENT COMPRENANT UNE ENZYME PROTEASE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
GHOSH, Chanchal, Kumar, 7005 Pine Mill Drive, West Chester, OH 45069, (US)
FRANKENBACH, Gayle, Marie, 10010 Voyager Lane, Cincinnati, OH 45202, (US)
QUINN, Catherine, Michelle, 4382 Summerwind Court, Cincinnati, OH 45252, (US)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 756622 A1 970205 (Basic)
EP 756622 B1 991215
WO 9529225 951102
APPLICATION (CC, No, Date): EP 95914188 950324; WO 95US3725 950324
PRIORITY (CC, No, Date): US 232510 940422
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;

PT; SE
INTERNATIONAL PATENT CLASS: C11D-003/39; C11D-003/386
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9950	313
CLAIMS B	(German)	9950	254
CLAIMS B	(French)	9950	355
SPEC B	(English)	9950	9645
Total word count - document A			0
Total word count - document B			10567
Total word count - documents A + B			10567

9/3,AB/42 (Item 42 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00701126
LIQUID DETERGENTS WITH ORTHO-SUBSTITUTED PHENYLBORONIC ACIDS FOR INHIBITION OF PROTEOLYTIC ENZYME
FLUSSIGWASCHMITTEL MIT ORTHO-SUBSTITUIERTEN PHENYLBORSAUREN ALS PROTEASEINHIBITOR
DETERGENTS LIQUIDES A ACIDES PHENYLBORONIQUES ORTHO-SUBSTITUES POUR L'INHIBITION DE L'ENZYME PROTEOLYTIQUE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (applicant designated states: GB)
INVENTOR:
PANANDIKER, Rajan, Keshav, 6484 Oregon Pass, West Chester, OH 45069, (US)
BJORKQUIST, David, William, 36 Oliver Road, Wyoming, OH 45215, (US)
LEGAL REPRESENTATIVE:
Gibson, Tony Nicholas et al (30981), Procter & Gamble European Technical Center Temselaan 100, B-1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 726936 A1 960821 (Basic)
EP 726936 B1 990519
WO 9512655 950511
APPLICATION (CC, No, Date): EP 94932102 941028; WO 94US12407 941028
PRIORITY (CC, No, Date): US 149171 931105
DESIGNATED STATES: GB
INTERNATIONAL PATENT CLASS: C11D-003/386; C07F-005/02; C07K-005/062; C07K-005/087;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9920	584
CLAIMS B	(German)	9920	519
CLAIMS B	(French)	9920	673
SPEC B	(English)	9920	6153
Total word count - document A			0
Total word count - document B			7929
Total word count - documents A + B			7929

9/3,AB/43 (Item 43 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00697511
Biospecific emulsions.
Biospezifische Emulsionen.
Emulsions biospecifiques.
PATENT ASSIGNEE:
UNILEVER PLC, (200923), Unilever House Blackfriars, London EC4P 4BQ, (GB), (applicant designated states: GB;IE)
UNILEVER N.V., (200912), Weena 455, NL-3013 AL Rotterdam, (NL), (applicant designated states: BE;CH;DE;DK;ES;FR;GR;IT;LI;NL;PT;SE;AT)
INVENTOR:
Carson, Robert George, Unilever Research U.S., Inc., 45 River Road, Edgewater, NJ 07020, (US)
Schilling, Kurt Matthew, Unilever Research U.S., Inc., 45 River Road, Edgewater, NJ 07020, (US)
Au, Van, Unilever Research U.S., Inc., 45 River Road, Edgewater, NJ 07020, (US)
LEGAL REPRESENTATIVE:
Evans, Jacqueline Gail Victoria et al (73001), Unilever plc Patent Division Colworth House Sharnbrook, Bedford MK44 1LQ, (GB)
PATENT (CC, No, Kind, Date): EP 664111 A2 950726 (Basic)
EP 664111 A3 960821
APPLICATION (CC, No, Date): EP 94308704 941124;
PRIORITY (CC, No, Date): US 159994 931130
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-007/00; A61K-007/48; A61K-007/06;

ABSTRACT EP 664111 A3
Oil-in-water emulsions can be formed using surfactants with biospecific headgroups. Emulsion droplets adhere to surfaces of microorganisms or to various biological surface bearing appropriate adhesins, thus delivering surfactant materials directly to various surfaces. Lipophilic materials and essential oils can be targeted in this way. The emulsions may be incorporated into oral hygiene non-food compositions or compositions for topical application to skin, hair or nails.
ABSTRACT WORD COUNT: 79

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	248
SPEC A	(English)	EPAB95	7091
Total word count - document A			7339
Total word count - document B			0
Total word count - documents A + B			7339

9/3,AB/44 (Item 44 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00696706
QUINOLIZINONE TYPE COMPOUNDS

VERBINDUNGEN DES CHINOLIZINON-TYPS
COMPOSES DU TYPE DE LA QUINOLIZINONE
PATENT ASSIGNEE:
ABBOTT LABORATORIES, (225076), CHAD-0377/AP6D-2, One Abbott Park Road, Abbott Park, Illinois 60064-3500, (US), (Proprietor designated states: all)
INVENTOR:
CHU, Daniel T., 3767 Benton Street, Santa Clara, CA 95051, (US)
LI, Qun, 5245 Conifer Lane, Gurnee, IL 60031, (US)
COOPER, Curt S., 6201 Indian Trail Road, Gurnee, IL 60031, (US)
FUNG, Anthony K. L., 1145 Magnolia Avenue, Gurnee, IL 60031, (US)
LEE, Cheuk M., 504 W. Golf Road, Libertyville, IL, (US)
PLATTNER, Jacob J., 1101 New Castle, Libertyville, IL 60048, (US)
LEGAL REPRESENTATIVE:
Modiano, Guido, Dr.-Ing. et al (40786), Modiano, Josif, Pisanty & Staub, Baaderstrasse 3, 80469 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 723545 A1 960731 (Basic)
EP 723545 B1 020508
WO 9510519 950420
APPLICATION (CC, No, Date): EP 94929998 940930; WO 94US11166 940930
PRIORITY (CC, No, Date): US 137236 931014
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C07D-455/02; C07D-213/68; C07D-213/61; C07D-471/04; C07D-491/16; A61K-031/535; A61K-031/495; A61K-031/435
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200219	1334
CLAIMS B	(German)	200219	1200
CLAIMS B	(French)	200219	1700
SPEC B	(English)	200219	35279
Total word count - document A			0
Total word count - document B			39513
Total word count - documents A + B			39513

9/3,AB/45 (Item 45 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00610842
STABLE *POLYPEPTIDE"** COMPOSITION
STABILE ZUSAMMENSETZUNG VON *POLYPEPTIDEN"**
COMPOSITIONS STABLES A BASE DE *POLYPEPTIDES"**
PATENT ASSIGNEE:
COR THERAPEUTICS, INC., (1193200), 256 East Grand Avenue, Suite 80, South San Francisco, CA 94080, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
SWIFT, Robert, L., 806 Prowshead Lane, Foster City, CA 94404, (US)
DU MEE, Charles, P., 18 Coral Lane, Foster City, 94404, (US)
RANDOLPH, Anne, E., 1337 Drake Avenue, Burlingame, CA 94010, (US)
LEGAL REPRESENTATIVE:
Vossius, Volker, Dr. et al (12524), Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Holbeinstrasse 5, 81679

Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 639202 A1 950222 (Basic)
EP 639202 B1 981125
WO 9322335 931111
APPLICATION (CC, No, Date): EP 93910827 930427; WO 93US3933 930427
PRIORITY (CC, No, Date): US 876625 920430
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C07K-014/75; C07K-014/78; A61K-047/12; A61K-038/17;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9848	766
CLAIMS B	(German)	9848	808
CLAIMS B	(French)	9848	897
SPEC B	(English)	9848	18732
Total word count - document A			0
Total word count - document B			21203
Total word count - documents A + B			21203

9/3,AB/46 (Item 46 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00580903
STABILIZED ENZYMES AND DETERGENT COMPOSITIONS
STABILISIERTE ENZYME UND WASCHMITTELZUSAMMENSETZUNGEN
ENZYMES STABILISEES ET COMPOSITIONS DETERGENTES
PATENT ASSIGNEE:
NOVO NORDISK A/S, (231781), Novo Alle, 2880 Bagsvaerd, (DK), (applicant designated states: AT;BE;DE;DK;ES;FR;GB;IT;NL;SE)
INVENTOR:
VON DER OSTEN, Claus, Boulevarden 14, L66, DK-2800 Lyngby, (DK)
BRANNER, Sven, Ved Smedebakken 7A, DK-2800 Lyngby, (DK)
SVENDSEN, Allan, Bakkeleddet 28, DK-3460 Birkeroed, (DK)
HEDEGARD, Lisbeth, Classensgade 35, 5.t.h., DK-2100 Copenhagen, (DK)
ERIKSEN, Nina, Mathildevej 15, I.t.v., DK-2000 Frederiksberg, (DK)
EGMOND, Maarten, Robert, De Ness 34, NL-3461 GD Linschoten, (NL)
CASTELEIJN, Eric, Palletierburg 105, NL-2907 CG Capelle a/d Ijssel, (NL)
PATENT (CC, No, Kind, Date): EP 583339 A1 940223 (Basic)
EP 583339 B1 980708
WO 9219729 921112
APPLICATION (CC, No, Date): EP 92910232 920430; WO 92DK138 920430
PRIORITY (CC, No, Date): EP 91610036 910501
DESIGNATED STATES: AT; BE; DE; DK; ES; FR; GB; IT; NL; SE
INTERNATIONAL PATENT CLASS: C12N-009/50; C12N-015/57;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9828	368
CLAIMS B	(German)	9828	406
CLAIMS B	(French)	9828	454

SPEC B	(English)	9828	7386
Total word count - document A			0
Total word count - document B			8614
Total word count - documents A + B			8614

9/3,AB/47 (Item 47 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00533285
Detergent compositions containing stabilized enzymes
Stabilisierte Enzyme enthaltende Waschmittelzusammensetzungen
Compositions de detergents contenant des enzymes stabilises
PATENT ASSIGNEE:
UNILEVER N.V., (200916), Weena 455, NL-3013 AL Rotterdam, (NL), (applicant designated states: CH;DE;ES;FR;IT;LI;NL;SE)
UNILEVER PLC, (200929), Unilever House Blackfriars P.O. Box 68, London EC4P 4BQ, (GB), (applicant designated states: GB)
INVENTOR:
Casteleijn, Eric, Unilever Research, Vlaardingen Lab. Olivier v. Noortlaan 120, NL-3133 AT Vlaardingen, (NL)
Egmond, Maarten Robert, Unilever Research, Vlaardingen Lab. Olivier van Noortlaan 120, NL-3133 AT Vlaardingen, (NL)
Svendsen, Allen, Bakkeleddet 28, DK-3460 Birkerod, (DK)
Von Der Osten, Claus, Boulevarden 14, L66, DK-2800 Lyngby, (DK)
Hedegard, Lisbeth, Classensgade 35, 5. t.h., DK-2100 Copenhagen 0, (DK)
Eriksen, Nina, Mathidevej 15, I. t.v., DK-2000 Frederiksberg, (DK)
Branner, Sven, Ved Smedebakken 7A, DK-2800 Lyngby, (DK)
LEGAL REPRESENTATIVE:
Kan, Jacob Hendrik, Dr. et al (60421), Unilever N.V. Patent Division P.O. Box 137, NL-3130 AC Vlaardingen, (NL)
PATENT (CC, No, Kind, Date): EP 516200 A1 921202 (Basic)
EP 516200 B1 960724
APPLICATION (CC, No, Date): EP 92201150 920423;
PRIORITY (CC, No, Date): EP 91201039 910501
DESIGNATED STATES: CH; DE; ES; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: C11D-003/386; C12N-009/52; C12N-009/56;

ABSTRACT EP 516200 A1
This invention relates to enzymatic detergent compositions comprising novel stabilized proteases, in which a naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles (phi) (phi) and (psi) (psi) constitute values within the intervals (-90(degree)<(phi)<-40(degree) and -180(degree)<(psi)<180(degree)), and which position(s) are not located in regions, in which the protease is characterized by possessing a-helical or b-sheet structure.
ABSTRACT WORD COUNT: 75

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	556
CLAIMS B	(English)	EPAB96	472
CLAIMS B	(German)	EPAB96	461
CLAIMS B	(French)	EPAB96	493

SPEC A	(English)	EPABF1	7621
SPEC B	(English)	EPAB96	7393
Total word count - document A			8178
Total word count - document B			8819
Total word count - documents A + B			16997

9/3,AB/48 (Item 48 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00469768
Adsorbent and process for preparing the same
Sorbentmittel und dessen Herstellungsverfahren
Adsorbant et procede de sa preparation
PATENT ASSIGNEE:
KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA, (252805), 2-4 Nakanoshima 3-chome, Kita-ku Osaka-shi, (JP), (Proprietor designated states: all)
INVENTOR:
Tani, Nobutaka, Royal-senri 105, 11-1, Sembanishi 2-chome, Minoo-shi, Osaka-fu, (JP)
Hayashi, Tsuneo, 3-1, Nishiyama-cho, Ashiya-shi, Hyogo-ken, (JP)
LEGAL REPRESENTATIVE:
HOFFMANN - EITLE (101511), Patent- und Rechtsanwalte Arabellastrasse 4, 81925 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 464872 A1 920108 (Basic)
EP 464872 B1 000830
APPLICATION (CC, No, Date): EP 91115793 831201;
PRIORITY (CC, No, Date): JP 82212379 821202; JP 8331194 830225; JP 8368116 830418; JP 8370967 830421; JP 83187365 831005
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 225867 (EP 87100215)
EP 110409 (EP 83112042)
INTERNATIONAL PATENT CLASS: B01J-020/32; B01J-047/00; B01J-020/22

ABSTRACT EP 464872 A1
Adsorbent for removing low and/or very low density *lipoprotein"** from body fluid such as blood or plasma composed of water-insoluble porous hard gel with an exclusion limit of 10(sup 6) to 10(sup 9) daltons on which a polyanion compound and/or a sulfated compound is immobilized. The adsorbent is suitable for selective removal of VLDL and/or LDL, from blood or plasma in extracorporeal circulation treatment. (see image in original document)
ABSTRACT WORD COUNT: 71
NOTE:
Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200035	348
CLAIMS B	(German)	200035	340
CLAIMS B	(French)	200035	418
SPEC B	(English)	200035	7200
Total word count - document A			0
Total word count - document B			8306
Total word count - documents A + B			8306

9/3,AB/49 (Item 49 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00450455
LABELED *POLYPEPTIDE"** DERIVATIVES.
MARKIERTE POLYPEPTIDDERIVATE.
DERIVES DE *POLYPEPTIDE"** ETIQUETES.
PATENT ASSIGNEE:
SANDOZ LTD., (201940), Lichtstrasse 35, CH-4002 Basel, (CH), (applicant designated states: BE;CH;DK;ES;FR;GB;IT;LI;LU;NL;SE)
SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., (1297990), Brunner Strasse 59, A-1235 Vienna, (AT), (applicant designated states: AT)
SANDOZ-PATENT-GMBH, (498060), Humboldtstrasse 3, D-79539 Lorrach, (DE), (applicant designated states: DE)
INVENTOR:
ALBERT, Rainer, Rheinsprung 22/P, CH-4051 Basel, (CH)
BAUER, Wilfried, Hohle Gasse 7, CH-4431 Lampenberg, (CH)
PLESS, Janos, Kluserstrasse 24, CH-4054 Basel, (CH)
PATENT (CC, No, Kind, Date): EP 436005 A1 910710 (Basic)
EP 436005 B1 950329
WO 9101144 910207
APPLICATION (CC, No, Date): EP 90911595 900712; WO 90EP1169 900712
PRIORITY (CC, No, Date): GB 8916597 890720; GB 9004258 900226; GB 9005295 900309
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-051/08;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	4057
CLAIMS B	(German)	EPAB95	3995
CLAIMS B	(French)	EPAB95	4673
SPEC B	(English)	EPAB95	9399
Total word count - document A			0
Total word count - document B			22124
Total word count - documents A + B			22124

9/3,AB/50 (Item 50 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00326044
Novel chimeric antibodies.
Chimare Antikorper.
Anticorps chimeriques.
PATENT ASSIGNEE:
CIBA-GEIGY AG, (201300), Klybeckstrasse 141, CH-4002 Basel, (CH), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Hardman, Norman, Dr., Gstaltenrainweg 67/3, CH-4125 Riehen, (CH)
Gill, Laura Lee, Dr., Gstaltenrainweg 67, CH-4125 Riehen, (CH)
de Winter, Ronald F.J., Dr., Holly Tree Cottage,Flewton End, Milton

Ernest,Bedfordshire, (GB)
Wagner, Kathrin, Sundgauerstr. 12, CH-4055 Basle, (CH)
Heusser, Christoph, Dr., Im Bertschenacker 21, CH-4103 Bottmingen, (CH)
PATENT (CC, No, Kind, Date): EP 323806 A1 890712 (Basic)
EP 323806 B1 930317
APPLICATION (CC, No, Date): EP 88810898 881228;
PRIORITY (CC, No, Date): GB 8800077 880105; GB 8820099 880824
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/00; A61K-039/395; C12P-021/00; C12N-005/00; G01N-033/574;

ABSTRACT EP 323806 A1
The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
ABSTRACT WORD COUNT: 127

LANGUAGE (Publication,Procedural,Application): English; German; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	6488
CLAIMS B	(German)	EPBBF1	3866
CLAIMS B	(French)	EPBBF1	4255
SPEC B	(English)	EPBBF1	18016
Total word count - document A			0
Total word count - document B			32625
Total word count - documents A + B			32625

9/3,AB/51 (Item 51 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00313909
Method and therapeutic compositions for the prevention of fibrin deposition or adhesions.
Therapeutische Zusamensetzungen und Verfahren zur Verhinderung von Fibrinablagerung und Adhasionen.
Compositions therapeutiques et methode pour la prevention de depots de fibrine et d'adhesions.
PATENT ASSIGNEE:
GENENTECH, INC., (210482), 180 Point San Bruno Boulevard, South San Francisco California 94080, (US), (applicant designated states: CH;DE;FR;GB;LI)
INVENTOR:
Mohler, Marjorie A, 6571 Liggett Drive, Oakland California 94611, (US)
Nguyen, Tue H, 3636 San Benito Street, San Mateo California 94403, (US)
LEGAL REPRESENTATIVE:

Stuart, Ian Alexander et al (50491), MEWBURN ELLIS & CO. 2/3 Cursitor Street, London EC4A 1BQ, (GB)
PATENT (CC, No, Kind, Date): EP 297860 A1 890104 (Basic)
EP 297860 B1 930901
APPLICATION (CC, No, Date): EP 88305935 880630;
PRIORITY (CC, No, Date): US 68872 870701; US 125319 871125; US 210895 880624
DESIGNATED STATES: CH; DE; FR; GB; LI
INTERNATIONAL PATENT CLASS: A61K-047/06; A61K-037/54;

ABSTRACT EP 297860 A1
A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion formation comprising a sparingly soluble enzyme that is continuously released at that site for a period of time of from about three days to two weeks which may include an inert adherence enhancing vehicle.
ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	524
CLAIMS B	(German)	EPBBF1	485
CLAIMS B	(French)	EPBBF1	567
SPEC B	(English)	EPBBF1	8326
Total word count - document A			0
Total word count - document B			9902
Total word count - documents A + B			9902

9/3,AB/52 (Item 52 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00236493
Adsorbent and process for preparing the same.
Adsorbens und Verfahren zu dessen Herstellung.
Adsorbant et procede de preparation.
PATENT ASSIGNEE:
KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA, (252800), 2-4 Nakanoshima 3-chome, Kita-ku Osaka-shi Osaka-fu 530, (JP), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Tani, Nobutaka, Royal-senri 105 11-1, Sembanishi 2-chome, Minoo-shi Osaka-fu, (JP)
Hayashi, Tsuneo, 4611-107, Najio, Shioze-cho,, Nishinomiya-shi, Hyogo, (JP)
LEGAL REPRESENTATIVE:
Turk, Gille, Hrabal, Leifert (100971), Brucknerstrasse 20, D-40593 Dusseldorf, (DE)
PATENT (CC, No, Kind, Date): EP 225867 A2 870616 (Basic)
EP 225867 A3 880224
EP 225867 B1 931201
APPLICATION (CC, No, Date): EP 87100215 831201;
PRIORITY (CC, No, Date): JP 82212379 821202; JP 8331194 830225; JP 8368116 830418; JP 8370967 830421; JP 83187365 831005
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

RELATED PARENT NUMBER(S) - PN (AN):
EP 110409 (EP 831120423)
INTERNATIONAL PATENT CLASS: B01J-020/32;

ABSTRACT EP 225867 A2
Adsorbent for removing low and/or very low density *lipoprotein"** from body fluid such as blood or plasma composed of water-insoluble porous hard gel with an exclusion limit of 10(sup 6) to 10(sup 9) daltons on which a polyanion compound and/or a sulfated compound is immobilized. The adsorbent is suitable for selective removal of VLDL and/or LDL, from blood or plasma in extracorporeal circulation treatment.
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	389
CLAIMS B	(German)	EPBBF1	366
CLAIMS B	(French)	EPBBF1	474
SPEC B	(English)	EPBBF1	3798
Total word count - document A			0
Total word count - document B			5027
Total word count - documents A + B			5027

9/3,AB/53 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0241255 DBR Accession No.: 1999-11356 PATENT
Attaching moieties to a layered *silicate"** surface - used to immobilize *protein"**, particularly recombinant fusion *protein"**, for use in biosensor
AUTHOR: Spudich J A; Nock S; Wagner P
CORPORATE SOURCE: Palo Alto, CA, USA.
PATENT ASSIGNEE: Univ.Stanford 1999
PATENT NUMBER: WO 9912036 PATENT DATE: 19990311 WPI ACCESSION NO.: 1999-394759 (1933)
PRIORITY APPLIC. NO.: US 57929 APPLIC. DATE: 19970904
NATIONAL APPLIC. NO.: WO 98US18531 APPLIC. DATE: 19980903
LANGUAGE: English
ABSTRACT: A method of attaching a moiety to a layered *silicate"** surface is claimed. It involves *covalently"** attaching the moiety to an *arginine"** *tag"**, and contacting the *arginine"** *tag"** with the *silicate"** surface. Also claimed is a surface used for the attachment of organic *molecules"**, compatible with physiological *sodium"** *salt"** concentrations, and a means of orientating a *protein"** on a layered *silicate"** surface. The claims also cover a surface bearing anisotropically oriented *proteins"**, a means of purifying a target *molecule"** from a heterogenous mixture, and an affinity purification device, specifically a vessel with a fluid inlet port and outlet port, filled with a layered *silicate"** . These are used to attach a biological *molecule"** to a layered *silicate"** surface, which is used in purification of *molecules"** and in biosensors. The *arginine"** *tag"** consists of a sequence of 2-100 *arginine"** residues. The *protein"** is a *DNA"** binding *protein"**, molecular motor, actin filament, microtubule, myosin filament, actin binding *protein"**, or myosin filament binding *protein"** and may optionally

be a fusion *protein"**, produced by recombinant *DNA"** technology. (56pp)

Set	Items	Description
S10	506	AU=(SPUDICH, J? OR SPUDICH J?)
S11	3181	AU=(WAGNER, P? OR WAGNER P?)
S12	143	AU=(NOCK, S? OR NOCK S?)
S13	6	S10 AND S11 AND S12
S14	11	S10 AND (S11 OR S12)
S15	20	S11 AND S12
S16	65	(S10 OR S11 OR S12) AND S1
S17	4	(S10 OR S11 OR S12) AND S3
S18	24	(S13 OR S14 OR S15 OR S17) NOT S8
S19	17	RD (unique items)

Author(s)

>>>No matching display code(s) found in file(s): 65, 113

19/3,AB/1 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

12410531 References: 31
TITLE: Monolayers of derivatized poly(L-lysine)-grafted poly(ethylene glycol) on metal oxides as a class of biomolecular interfaces
AUTHOR(S): Ruiz-Taylor LA; Martin TL; Zaugg FG; Witte K; Indermuhle P; *Nock S"**; *Wagner P (REPRINT)"**
AUTHOR(S) E-MAIL: paul.wagner@zyomyx.com
CORPORATE SOURCE: Zyomyx Inc, 3911 Trust Way/Hayward//CA/94545 (REPRINT); Zyomyx Inc, /Hayward//CA/94545
PUBLICATION TYPE: JOURNAL
PUBLICATION: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, V98, N3 (JAN 30), P852-857
GENUINE ARTICLE#: 399JF
PUBLISHER: NATL ACAD SCIENCES, 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
ISSN: 0027-8424
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: We report on the design and characterization of a class of biomolecular interfaces based on derivatized poly(L-lysine)-grafted poly(ethylene glycol) copolymers adsorbed on negatively charged surfaces. As a model system, we synthesized biotin-derivatized poly(L-lysine)-grafted poly(ethylene glycol) copolymers, PLL-9[(PEGm)((1-x)) (PEG-biotin)(x)], where x varies from 0 to 1. Monolayers were produced on titanium dioxide substrates and characterized by x-ray photoelectron spectroscopy. The specific biorecognition properties of these biotinylated surfaces were investigated with the use of radiolabeled streptavidin alone and within complex protein mixtures. The PLL-g-PEG-biotin monolayers specifically capture streptavidin, even from a complex protein mixture, while still preventing nonspecific adsorption of other proteins. This streptavidin layer can subsequently capture biotinylated proteins. Finally, with the use of microfluidic networks and protein arraying, we demonstrate the potential of this class of biomolecular interfaces for applications based on protein patterning.

19/3,AB/2 (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

12287710 References: 20
TITLE: Proteomics: The post-genome revolution
AUTHOR(S): *Nock S (REPRINT)"**; *Wagner P"**
AUTHOR(S) E-MAIL: steffen.nock@zyomyx.com; peter.wagner@zyomyx.com
CORPORATE SOURCE: Zyomyx Inc, 3911 Trust Way/Hayward//CA/94545 (REPRINT);
Zyomyx Inc, /Hayward//CA/94545
PUBLICATION TYPE: JOURNAL
PUBLICATION: CHEMIE IN UNSERER ZEIT, 2000, V34, N6 (DEC), P348-354
GENUINE ARTICLE#: 388BV
PUBLISHER: WILEY-V C H VERLAG GMBH, PO BOX 10 11 61, D-69451 BERLIN,
GERMANY
ISSN: 0009-2851
LANGUAGE: German DOCUMENT TYPE: ARTICLE

ABSTRACT: Proteomics is an emerging field of research aimed at defining the status of every protein in a given cell. This includes the abundance, structural state and activity of each protein. Currently complex protein samples are analyzed by 2-D gel electrophoresis a method that is limited in both resolution and sensitivity. Miniaturization and integration of different technology platforms, such as microfluidics and detection, in the form of protein biochips, will advance proteomics as profoundly as DNA chips advanced genomics. Much effort is being focussed on the development of protein biochips and this article describes both conventional methods in proteomics as well as the new trends towards protein biochips.

19/3,AB/3 (Item 3 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

11319254 References: 32
TITLE: Mutational analysis of phosphorylation sites in the Dictyostelium
myosin II tail: disruption of myosin function by a single charge change
AUTHOR(S): *Nock S"**; Liang WC; Warrick HM; *Spudich JA (REPRINT)"**
AUTHOR(S) E-MAIL: jspudich@cmgm.stanford.edu
CORPORATE SOURCE: Stanford Univ, Beckman Ctr B405, /Stanford//CA/94305
(REPRINT); Stanford Univ, Beckman Ctr B405, /Stanford//CA/94305
PUBLICATION TYPE: JOURNAL
PUBLICATION: FEBS LETTERS, 2000, V466, N2-3 (JAN 28), P267-272
GENUINE ARTICLE#: 280UM
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISSN: 0014-5793
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: The dynamic assembly/disassembly of non-muscle myosin II filaments is critical for the regulation of enzymatic activities and localization, Phosphorylation of three threonines, 1823, 1833 and 2029, in the tail of Dictyostelium discoideum myosin II has been implicated in control of myosin filament assembly. By systematically replacing the three threonines to aspartates, mimicking a phosphorylated residue, we found that position 1823 is the most critical one for the regulation of myosin filament formation and in vivo function, Surprisingly, a single charge change is able to perturb filament formation and in vivo function of myosin II. (C) 2000 Federation of European Biochemical Societies.

19/3,AB/4 (Item 4 from file: 440)

09029524 References: 47
TITLE: On the role of myosin-II in cytokinesis: Division of Dictyostelium cells under adhesive and nonadhesive conditions
AUTHOR(S): Zang JH; Cavet G; Sabry JH; *Wagner P"**; Moores SL; *Spudich JA (REPRINT)"**
CORPORATE SOURCE: STANFORD UNIV,DEPT BIOCHEM/STANFORD//CA/94305 (REPRINT); STANFORD UNIV,DEPT BIOCHEM/STANFORD//CA/94305
PUBLICATION TYPE: JOURNAL
PUBLICATION: MOLECULAR BIOLOGY OF THE CELL, 1997, V8, N12 (DEC), P2617-2629
GENUINE ARTICLE#: YK930
PUBLISHER: AMER SOC CELL BIOLOGY, PUBL OFFICE, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
ISSN: 1059-1524
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: We have investigated the role of myosin in cytokinesis in Dictyostelium cells by examining cells under both adhesive and nonadhesive conditions. On an adhesive surface, both wild-type and myosin-null cells undergo the normal processes of mitotic rounding, cell elongation, polar ruffling, furrow ingression, and separation of daughter cells. When cells are denied adhesion through culturing in suspension or on a hydrophobic surface, wild-type cells undergo these same processes. However, cells lacking myosin round up and polar ruffle, but fail to elongate, furrow, or divide. These differences show that cell division can be driven by two mechanisms that we term Cytokinesis A, which requires myosin, and Cytokinesis B, which is cell adhesion dependent. We have used these approaches to examine cells expressing a myosin whose two light chain-binding sites were deleted (Delta BLCBS-myosin). Although this myosin is a slower motor than wild-type myosin and has constitutively high activity due to the abolition of regulation by light-chain phosphorylation, cells expressing Delta BLCBS-myosin were previously shown to divide in suspension (Uyeda et al., 1996). However, we suspected their behavior during cytokinesis to be different from wild-type cells given the large alteration in their myosin. Surprisingly, Delta BLCBS-myosin undergoes relatively normal spatial and temporal changes in localization during mitosis. Furthermore, the rate of furrow progression in cells expressing a Delta BLCBS-myosing is similar to that in wild-type cells.

19/3,AB/5 (Item 5 from file: 440)

08824805 References: 29
TITLE: Reversible, site-specific immobilization of *polyarginine"**-*tagged"** fusion proteins on *mica"** surfaces
AUTHOR(S): *Nock S"**; *Spudich JA"**; *Wagner P (REPRINT)"**
CORPORATE SOURCE: STANFORD UNIV,MED CTR, BECKMAN CTR B405, DEPT BIOCHEM/STANFORD//CA/94305 (REPRINT); STANFORD UNIV,MED CTR, BECKMAN CTR B405, DEPT BIOCHEM/STANFORD//CA/94305
PUBLICATION TYPE: JOURNAL
PUBLICATION: FEBS LETTERS, 1997, V414, N2 (SEP 8), P233-238
GENUINE ARTICLE#: XW759
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISSN: 0014-5793

LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: A large variety of genes is expressed as fission proteins for the purpose of characterization and purification in molecular biology, We have used this strategy to append *polyarginine"** peptides in order to achieve specific binding of the *Arg"**-*tag"** to atomically flat, negatively charged *mica"** surfaces, We show that the model protein, *hexaarginine"** -*tagged"** green fluorescent protein (GFP), binds to *mica"** via its *Arg"**-*tag"** based on ion exchange of naturally occurring potassium cations, Only non-specific binding was observed with the control protein that is free of the *Arg"**-*tag"**, This novel technology will be widely applicable to orient functional proteins on flat surfaces. (C) 1997 Federation of European Biochemical Societies.

19/3,AB/6 (Item 6 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

08684507 References: 52
TITLE: Bioreactive self-assembled monolayers on hydrogen-passivated Si(111) as a new class of atomically flat substrates for biological scanning probe microscopy
AUTHOR(S): *Wagner P (REPRINT)"**; *Nock S"**; *Spudich JA"**; Volkmuth WD; Chu S; Cicero RL; Wade CP; Linford MR; Chidsey CED
CORPORATE SOURCE: STANFORD UNIV,MED CTR, DEPT BIOCHEM/STANFORD//CA/94305 (REPRINT); STANFORD UNIV,DEPT PHYS/STANFORD//CA/94305; STANFORD UNIV,DEPT CHEM/STANFORD//CA/94305
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF STRUCTURAL BIOLOGY, 1997, V119, N2, P189-201
GENUINE ARTICLE#: XN382
PUBLISHER: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
ISSN: 1047-8477
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: This is the first report of bioreactive self-assembled monolayers, covalently bound to atomically flat silicon surfaces and capable of binding biomolecules for investigation by scanning probe microscopy and other surface-related assays and sensing devices. These monolayers are stable under a wide range of conditions and allow tailor-made functionalization for many purposes. We describe the substrate preparation and present an STM and SFM characterization, partly performed with multi-walled carbon nanotubes as tapping-mode super-tips. Furthermore, we present two strategies of introducing in situ reactive headgroup functionalities, One method entails a free radical chlorosulfonation process with subsequent sulfonamide formation. A second method employs singlet carbene-mediated hydrogen-carbon insertion of a heterobifunctional, amino-reactive trifluoromethyldiazirinyl crosslinker, We believe that this new substrate is advantageous to others, because it (i) is atomically flat over large areas and can be prepared in a few hours with standard equipment, (ii) is stable under most conditions, (iii) can be modified to adjust a certain degree of reactivity and hydrophobicity, which allows physical adsorption or covalent crosslinking of the biological specimen, (iv) builds the bridge between semiconductor microfabrication and organic/biological molecular systems, and (v) is accessible to nanopatterning and applications requiring conductive substrates. (C) 1997 Academic Press.

19/3,AB/7 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01360423
SITE-SPECIFIC, COVALENT BIOCONJUGATION OF PROTEINS
BIOCONJUGAISON COVALENTE, DE RESTRICTION, DE PROTEINES
PATENT ASSIGNEE:
Zyomyx, Inc., (2937591), 3911 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
*WAGNER, Peter"**, 2211 Village Court, Apt. 7, Belmont, CA 94002, (US)
MA, Lifu, 20209 Redwood Road, D, Castro Valley, CA 94546, (US)
*NOCK, Steffen"**, 3629 Glenwood Avenue, Redwood City, CA 94062, (US)
WILSON, David, 24702 Broadmore Avenue, Hayward, CA 94544, (US)
SYDOR, Jens, 713 Catamaran Street 2, Foster City, CA 94404, (US
PATENT (CC, No, Kind, Date):
WO 200172458 011004
APPLICATION (CC, No, Date): EP 2001926445 010327; WO 2001US9772 010327
PRIORITY (CC, No, Date): US 192640 P 000327; US 235955 P 000926
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: B23B-025/00; C07H-021/00; C07K-001/113;
C08H-001/00; C09D-189/00; G01N-033/00
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/8 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01345756
MICROFLUIDIC DEVICES AND METHODS
DISPOSITIFS MICROFLUIDIQUES ET PROCEDES ASSOCIES
PATENT ASSIGNEE:
Zyomyx, Inc., (2937591), 3911 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
JEDRZEJEWSKI, Paul, 768 Arnold Way, Menlo Park, CA 94025, (US)
*NOCK, Steffen"**, 3625 Glenwood Avenue, Redwood City, CA 94062, (US)
*WAGNER, Peter"**, 2211 Village Court, Apt. 7, Belmont, CA 94002, (US)
INDERMUHLE, Pierre, F., 610 Buckwheat Court, Apt. 1303, Hayword, CA
94544, (US)
ZAUGG, Frank, G., 2302 Carlmont Drive, 4, Belmont, CA 94002-3306, (US
PATENT (CC, No, Kind, Date):
WO 200163241 010830
APPLICATION (CC, No, Date): EP 2001916215 010223; WO 2001US5963 010223
PRIORITY (CC, No, Date): US 184381 P 000223; US 225999 P 000816
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: G01N-001/00
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/9 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01345629
CHIPS HAVING ELEVATED SAMPLE SURFACES
MICROPLAQUETTE A SURFACES D'ECHANTILLONNAGE ELEVE
PATENT ASSIGNEE:
Zyomyx, Inc., (2937591), 3911 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
INDERMUHLE, Pierre F., Apt. 1303, 610 Buckwheat Court, Hayward, CA 94544, (US)
ZAUGG, Frank G., Apt. 4, 2302 Carlmont Drive, Belmont, CA 94002-3306, (US)
*WAGNER, Peter"**, Apt. 7, 2211 Village Court, Belmont, CA 94002, (US)
*NOCK, Steffen"**, 3625 Glenwood Avenue, Redwood City, CA 94062, (US
PATENT (CC, No, Kind, Date):
WO 200162887 010830
APPLICATION (CC, No, Date): EP 2001914480 010223; WO 2001US5966 010223
PRIORITY (CC, No, Date): US 184381 P 000223; US 225999 P 000816
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12M-001/18
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/10 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01131116
ARRAYS OF PROTEINS AND METHODS OF USE THEREOF
VERFAHREN UND VERWENDUNG VON ANDORDUNGEN VON PROTEINEN
GROUPEMENTS DE PROTEINES ET PROCEDES D'UTILISATION DE CEUX-CI
PATENT ASSIGNEE:
Zyomyx, Inc., (2937590), 3912 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
*WAGNER, Peter"**, 2211 Village Court 7, Belmont, CA 94002, (US)
AULT-RICHE, Dana, 972 Cajon Way, Palo Alto, CA 94303, (US)
*NOCK, Steffen"**, 3629 Glenwood Avenue, Redwood City, CA 94062, (US)
ITIN, Christian, 315 Waverley Street 3, Menlo Park, CA 94025, (US
LEGAL REPRESENTATIVE:
Hallybone, Huw George (53031), CARPMAELS AND RANSFORD 43 Bloomsbury Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1097380 A1 010509 (Basic)
WO 0004382 000127
APPLICATION (CC, No, Date): EP 99935573 990714; WO 99US15971 990714
PRIORITY (CC, No, Date): US 115455 980714
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: G01N-033/543; G01N-033/551
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/11 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01131115
MICRODEVICES FOR SCREENING BIOMOLECULES
MIKROVORRICHTUNG ZUM SCREENING VON BIOMOLEKULEN
MICRODISPOSITIFS SERVANT A CRIBLER DES BIOMOLECULES
PATENT ASSIGNEE:
Zyomyx, Inc., (2937590), 3912 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
*WAGNER, Peter"**, 2211 Village Court 7, Belmont, CA 94002, (US)
AULT-RICHE, Dana, 972 Cajon Way, Palo Alto, CA 94303, (US)
*NOCK, Steffen"**, 3629 Glenwood Avenue, Redwood City, CA 94062, (US)
ITIN, Christian, 315 Waverley Street 3, Menlo Park, CA 94025, (US
LEGAL REPRESENTATIVE:
Hallybone, Huw George (53031), CARPMAELS AND RANSFORD 43 Bloomsbury
Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1097379 A2 010509 (Basic)
WO 0004390 000127
APPLICATION (CC, No, Date): EP 99935572 990714; WO 99US15969 990714
PRIORITY (CC, No, Date): US 115397 980714
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: G01N-033/543; C12Q-001/68
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/12 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01131114
ARRAYS OF PROTEIN-CAPTURE AGENTS AND METHODS OF USE THEREOF
VERFAHREN UND VERWENDUNG VON ANDORDUNGEN FUR PROTEINFIXIERUNGMITTEL
GROUPEMENTS D'AGENTS D'INTERCEPTION DE PROTEINE ET PROCEDES D'UTILISATION
DE CEUX-CI
PATENT ASSIGNEE:
Zyomyx, Inc., (2937590), 3912 Trust Way, Hayward, CA 94545, (US),
(Applicant designated States: all)
INVENTOR:
*WAGNER, Peter"**, 2211 Village Court 7, Belmont, CA 94002, (US)
*NOCK, Steffen"**, 3629 Glenwood Avenue, Redwood City, CA 94062, (US)
AULT-RICHE, Dana, 972 Cajon Way, Palo Alto, CA 94303, (US)
ITIN, Christian, 315 Waverley Street 3, Menlo Park, CA 94025, (US
LEGAL REPRESENTATIVE:
Hallybone, Huw George (53031), CARPMAELS AND RANSFORD 43 Bloomsbury
Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1097377 A2 010509 (Basic)
WO 0004389 000127
APPLICATION (CC, No, Date): EP 99935571 990714; WO 99US15968 990714
PRIORITY (CC, No, Date): US 115455 980714

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: G01N-033/53
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/13 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01036673
REVERSIBLE IMMOBILIZATION OF *ARGININE"**-*TAGGED"** MOIETIES ON A *SILICATE"** SURFACE
IMMOBILISATION REVERSIBLE DE FRACTIONS MARQUEES A L'*ARGININE"** SUR UNE SURFACE DE *SILICATE"**
PATENT ASSIGNEE:
STANFORD UNIVERSITY, (1153150), 857 Serra Street, Second Floor, Stanford, CA 94305-6225, (US), (Applicant designated States: all)
INVENTOR:
*SPUDICH, James, A."**, 3035 Country Club Court, Palo Alto, CA 94304, (US)
*NOCK, Steffen"**, Freiburger Strasse 3, D-76337 Waldronn 1, (DE)
*WAGNER, Peter"**, Borsigstrasse 4, D-74081 Heilbronn, (DE
PATENT (CC, No, Kind, Date): WO 9912036 990311
APPLICATION (CC, No, Date): WO 98944766 980903; WO 98US18531 980903
PRIORITY (CC, No, Date): US 57929 970904
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: G01N-033/543; G01N-033/552; G01N-033/549; C12P-021/06; C12P-021/04
LANGUAGE (Publication,Procedural,Application): English; English; English

19/3,AB/14 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0289120 DBR Accession No.: 2002-10967 PATENT
Array of protein-capture agents useful for proteomics and assaying differential gene expression at protein level, has a substrate and array of immobilization regions having many protein-capture agents on the surface - DNA chip, protein array, expression profiling and protein-A immobilization using pepsin for e.g. tumor diagnosis
AUTHOR: *WAGNER P"**; *NOCK S"**; AULT-RICHE D; ITIN C
PATENT ASSIGNEE: ZYOMYX INC 2001
PATENT NUMBER: US 6329209 PATENT DATE: 20011211 WPI ACCESSION NO.: 2002-204455 (200226)
PRIORITY APPLIC. NO.: US 353555 APPLIC. DATE: 19990714
NATIONAL APPLIC. NO.: US 353555 APPLIC. DATE: 19990714
LANGUAGE: English
ABSTRACT: DERWENT ABSTRACT: NOVELTY - An array device, comprising a substrate defining a surface, an array of space-apart immobilization regions (IR) over the surface, the IR having several protein-capture (PC) agents immobilized on the surface through immobilization groups

chemisorbed or physisorbed to the surface, and one or more border regions surrounding each IR and separating IR from one another, is new. DETAILED DESCRIPTION - An array device comprising a substrate defining a surface; an array of space-apart IRs over the surface, the IR having several protein-capture agents immobilized on the surface through immobilization groups chemisorbed or physisorbed to the surface. The immobilization groups being effective to immobilize one or more selected protein-capture agents to form protein-capture regions and the surface immobilized groups being effective to resist non-specific protein binding. It also contains one or more border regions surrounding each IR and separating the IRs from one another. Each border region comprising: (a) an ordered hydrophobic monolayer formed of alkyl chains having proximal ends which are chemisorbed or physisorbed to the surface within the IRs and opposite hydrophobic distal ends; and (b) a hydrophilic monolayer attached to the hydrophobic monolayer, comprising hydrophilic chains having a proximal end by which the hydrophilic chain is linked to an alkyl chain distal end, and an opposite hydrophilic distal end, together the hydrophobic and hydrophilic monolayers forming the border regions which are effective to resist non-specific protein binding. The protein-capture regions together form an array of protein-capture regions having surface chemisorbed or physisorbed immobilization groups resistant to non-specific binding with each protein-capture regions being separated from other protein-capture regions by one or more border regions resistant to non-specific protein binding. WIDER DISCLOSURE - Producing an array of protein-capture agents is disclosed as new. BIOTECHNOLOGY - Preferred Arrangement: Each of at least two different IRs each have immobilized different protein-capture agents. The hydrophobic polymer chains are hydrocarbon chains of 8-22 carbons and the hydrophilic polymer chains are polyethyleneglycol chains. USE - The device is useful for simultaneous detection of several proteins which are the expression products, or their fragments, of a cell or population of cells in an organism, and for various proteomics applications including assessing patterns of protein expression and modification in cells. The array of protein-capture agents is useful to compare the protein expression patterns of two cells or population of cells, to assay differential gene expression at the protein level useful in identification and validation of new potential drug targets as well as for drug screening. The array is useful for identifying a protein which is overexpressed in tumor cells, but not in normal cells. The arrays are also suitable for diagnostic applications and in diagnostic devices. The high density of the antibodies on some arrays enables a large number of different, antibody-based diagnostic tests to be formatted onto a single biochip. The protein-capture agents on the array are useful for evaluating the status of a disease condition in a tissue, such as a tumor, where the expression levels of certain proteins in the cells of the tissue is known to be indicative of a particular type of disease condition or stage of a disease condition. ADVANTAGE - The assay facilitates parallel detection and analysis of a large number of proteins in a sample. EXAMPLE - Collections of immunoglobulin (Ig)G antibodies were purchased from commercial sources. The antibodies were diluted 1:1 in binding buffer (Tris-HCl (0.1 M), NaCl (0.15 M), pH 7.5). A 2 ml minicolumn containing a gel with immobilized protein A was prepared. Less than 10 mg of immunoglobulin was applied to each 2 ml minicolumn and the column was washed with binding buffer. The bound immunoglobulins were eluted with glycine (0.1 M), NaCl (0.15 M), pH 2.8, and immediately neutralized with 1 M Tris-HCl, pH 8, to 50 mM final concentration and then dialyzed against

sodium phosphate (10 mM), NaCl (0.15 M), pH 7.2 and stored at 4 degrees C. The purified immunoglobulin were digested with immobilized pepsin to generate intact F(ab')2 fragments. Immobilized pepsin gel was washed with digestion buffer. A solution of purified IgG at 10 mg/ml was added to the immobilized pepsin gel and incubated at 37 degrees C for 2 hours. The reaction was neutralized by the addition of Tris-HCl (10 mM), pH 7.5 and centrifuged to pellet the gel. The supernatant liquid was collected and applied to an immobilized protein A column, to separate the F(ab')2 fragments from the Fc and undigested IgG. The purified F(ab')2 fragments at a concentration of 10 mg/ml were reduced at 37 degrees C for 1 hour in a buffer of sodium phosphate (10 mM), NaCl (0.15 M), 2-mercaptoethylamine (10 mM) and ethylenediamine tetraacetic acid (EDTA) (5 mM), pH 6. The Fab' fragments were separated and concentrated. The reduced Fab' fragments were diluted to 100 micro-g/ml and applied onto the bioreactive patches containing exposed aminoreactive functional groups. After an immobilization period of 30 minutes at 30 degrees C, the array was rinsed extensively with sodium phosphate (10 mM), NaCl (0.15 M) and EDTA (5 mM), pH 7. Transformed human cells were lysed, the cell debris were removed and the lysate was applied to Fab' fragment array and allowed to incubate for 2 hours at 30 degrees C. After binding, the array was washed extensively with sodium phosphate (10 mM), NaCl (0.15 M) and EDTA (5 mM), pH 7. The location and amount of bound proteins were determined by optical detection.(34 pages)

19/3,AB/15 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0277714 DBR Accession No.: 2002-01216 PATENT
Heterfunctional crosslinking reagents, protein labeling reagents, protein conjugates and their compositions, support-bound crosslinking groups, modified supports and protein arrays for site specific binding of proteins - protein array for characterizing protein interactions and diagnosis
AUTHOR: *Wagner P"**; Ma L; *Nock S"**; Wilson D; Sydor J
CORPORATE SOURCE: Hayward, CA, USA.
PATENT ASSIGNEE: Zyomyx 2001
PATENT NUMBER: WO 200172458 PATENT DATE: 20011004 WPI ACCESSION NO.: 2001-602816 (200168)
PRIORITY APPLIC. NO.: US 235955 APPLIC. DATE: 20000926
NATIONAL APPLIC. NO.: WO 2001US9772 APPLIC. DATE: 20010327
LANGUAGE: English
ABSTRACT: Hetrofunctional crosslinking reagents (I) and (II), a protein labeling reagent (III) or (IV), protein conjugates (V) and (VI), protein compositions (VII) and (VIII), support-bound crosslinking group (IX), a modified support (X) and protein arrays, are new. Also claimed are: a protein array; a method for attaching a protein to a solid support; a method for attaching a protein to heterofunctional crosslinking reagent; providing a heterofunctional crosslinker; a heterofunctional crosslinker covalently linking a protein to a compound. The reagents and compositions are of use in the characterization of protein-protein, protein-nucleic acid, protein-drug and protein-ligand interactions or in site specific binding in proteins. They are very useful for diagnostic purposes. (94pp)

19/3,AB/16 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0250773 DBR Accession No.: 2000-05263 PATENT
New arrays for analyzing components of a fluid sample, useful for drug development, functional proteomics, clinical diagnostics and biosensors - protein array produced by protein immobilization on organic thinfilm, used to detect binding protein and protein-protein interaction
AUTHOR: *Wagner P"**; Ault-Riche D; *Nock S"**; Itin C
CORPORATE SOURCE: Hayward, CA, USA.
PATENT ASSIGNEE: Zyomyx 2000
PATENT NUMBER: WO 200004382 PATENT DATE: 20000127 WPI ACCESSION NO.: 2000-171289 (2015)
PRIORITY APPLIC. NO.: US 115455 APPLIC. DATE: 19980714
NATIONAL APPLIC. NO.: WO 99US15971 APPLIC. DATE: 19990714
LANGUAGE: English
ABSTRACT: An array of proteins containing a substrate, at least one organic thinfilm on all or part of the substrate surface, and patches arranged in discrete, known regions on parts of the substrate, is claimed. The patches each contain an immobilized protein on the underlying organic thinfilm. Also claimed is a biosensor containing the array, a micromachine or diagnostic device containing the array, a means of screening a protein for the ability to interact with a component of a sample, and a means of screening proteins for the ability to bind a particular component. The claims also cover a means of detecting a protein-protein interaction, and methods of assaying in parallel for analytes in a sample. These can be used to screen for proteins that are capable of interacting with a given component, particularly using a biosensor. They can also be used in drug development, proteomics, clinical diagnostics and biosensors. The proteins immobilized on a given array are functionally related, structurally related, or belong to the same family, e.g. growth factor receptors, hormone receptors, antibodies, lectins, zinc-finger proteins, hepatitis C virus proteases, etc. (80pp)

19/3,AB/17 (Item 4 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0250754 DBR Accession No.: 2000-05244 PATENT
New arrays for assaying proteins, used for analysis of cell expression products, evaluating disease conditions, proteomics, drug screening, diagnostics and measurement of gene activity - phage display library screening
AUTHOR: *Wagner P"**; *Nock S"**; Ault-Riche D; Itin C
CORPORATE SOURCE: Hayward, CA, USA.
PATENT ASSIGNEE: Zyomyx 2000
PATENT NUMBER: WO 200004389 PATENT DATE: 20000127 WPI ACCESSION NO.: 2000-161175 (2014)
PRIORITY APPLIC. NO.: US 115455 APPLIC. DATE: 19980714
NATIONAL APPLIC. NO.: WO 99US15968 APPLIC. DATE: 19990714
LANGUAGE: English
ABSTRACT: An array of protein-capture agents (PCA), comprising a substrate, at least one organic thin film covering some or all of the surface of the substrate, and patches arranged in discrete, known regions on the portions of the substrate surface covered by organic thin film, is

claimed. Each patch comprises PCAs, capable of binding a particular expression product, or a fragment of a cell population, immobilized on the organic thin film. The array comprises different PCAs, capable of binding different expression products, or fragments, of the cell population. Also claimed are: an array of bound proteins comprising the new array and different proteins which are expession products or fragments of a cell population in an organism; a diagnostic device comprising the new array; a method for assaying in parallel for different proteins in a sample, which are expression products or fragments of a cell population in an organism; a method for evaluating a disease conditions in a tissue in an organism; a method for producing the new array involving selecting a recombinant phage display library. (89pp)

? log y

06dec02 10:58:58 User219783 Session D1892.2

DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ
NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ
UA UG US UZ VN YU ZA ZM ZW
DE 10062302 A1 20020711 (200266)
AU 2002035771 A 20020624 (200267)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002048187	A2	WO 2001-EP14588	20011212
DE 10062302	A1	DE 2000-10062302	20001214
AU 2002035771	A	AU 2002-35771	20011212

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002035771 A	Based on	WO 200248187

PRIORITY APPLN. INFO: DE 2000-10062302 20001214
AN 2002-619038 [66] WPIDS
AB WO 200248187 A UPAB: 20021014
NOVELTY - A secretion signal sequence (I) for eukaryotic expression systems that is:
(i) a 36 amino acid (aa) sequence (S1), or a variant;
(ii) 80 % homologous with (S1); or
(iii) a fragment of (S1) with 20 aa, is new.
DETAILED DESCRIPTION - A new secretion signal sequence (I) for eukaryotic expression systems is:
(i) a 36 amino acid (aa) sequence (S1), or a variant;
(ii) 80 % homologous with (S1); or
(iii) a fragment of (S1) with 20 aa.
Met-Glu-Ser-Val-Ser-Ser-Leu-Phe-Asn-Ile-Phe-Ser-Thr-Ile-Met-Val-Asn-Tyr-Lys-Ser-Leu-Val-Leu-Ala-Leu-Leu-Ser-Val-Ser-Asn-Leu-Lys-Tyr-Ala-**Arg**-Gly (S1)
INDEPENDENT CLAIMS are also included for the following:
(1) a DNA sequence (II) that encodes (I);
(2) an expression vector (EV) for eukaryotic cells comprising a promoter and a S/P secretion signal from the pptox (preprotoxin) gene of virus K28, or its functional variant with 70 % homology, positioned 3' with respect to the promoter;
(3) an expression system comprising a eukaryotic cell and EV;
(4) a fusion protein (FP) that contains the S/P secretion signal (1), or its functional variant with 80 % homology; and
(5) a DNA that encodes FP.
USE - Expression vectors containing a sequence that encodes (I) are used:
(i) for cloning genes;
(ii) for transformation of eukaryotic cells; and
(iii) for expressing proteins in eukaryotes, e.g. enzymes, receptors, transcription factors and ion channels.
ADVANTAGE - Vectors containing (I) provide efficient secretory expression of genes in eukaryotes, so represent a rapid and inexpensive way of making proteins. Particularly a fusion of (I) and a heterologous protein is secreted in higher yield than the mature toxin from which (I) is derived in naturally infected yeasts.

Dwg.0/7

L44 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:149228 HCAPLUS
DOCUMENT NUMBER: 136:275077
TITLE: Demonstration of 2:2 Stoichiometry in the Functional SRI-HtrI Signaling Complex in Halobacterium Membranes by Gene Fusion Analysis
AUTHOR(S): Chen, Xinpu; **Spudich, John L.**
CORPORATE SOURCE: Department of Microbiology and Molecular Genetics, University of Texas Medical School, Houston, TX, 77030, USA
SOURCE: Biochemistry (2002), 41(12), 3891-3896
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A fusion protein in which the C-terminus of Halobacterium salinarum sensory rhodopsin I (SRI) is connected by a flexible linker to the N-terminus of its transducer (HtrI) was constructed and expressed in H. salinarum. The fusion protein mediated attractant responses to orange light and repellent responses to UV/violet light that were comparable to those produced by the wild-type SRI-HtrI complex. Immunoblot anal. of H. salinarum membrane proteins demonstrated intact fusion protein and no detectable proteolytic cleavage products. Rapid oxidative crosslinking of a monocysteine mutant in the HtrI domain confirmed that the fusion protein exists as a homodimer in the membrane. HtrI-free SRI and HtrI-complexed SRI have been shown previously to exhibit large differences in the pH dependence of their photocycle kinetics and in the pKa of Asp76 that controls a pH-dependent spectral transition in SRI. These differences were used to assess whether only one or both SRI domains in the fusion protein were complexed properly to the HtrI homodimer. Measurement of the photochem. activity, the photocycle kinetics, and the absorption spectra at various pH values established that both SRI domains are complexed to HtrI in the fusion protein, and therefore the stoichiometry is 2:2. Closer examn. of the HtrI effect on SRI revealed that Asp76 titrn. in HtrI-free SRI fits two pKa values, with 98% and 2% of the mols. titrating with pKa's of 7 and 9, resp. The same two pKa's of Asp76 are evident in HtrI-complexed SRI, but with 13% with pKa of 7 and 87% with pKa of 9 and a similar bias toward the pKa of 9 in the fusion protein. Titrn. of the fusion protein with Ala substitution at Arg73, a residue in the photoactive site, in the SRI domain indicates that a basic residue at Arg73 is necessary for the lower pKa to be obsd. A model in which Arg73 plays a role in the HtrI effect on SRI is discussed.
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 2002:599883 HCAPLUS
DOCUMENT NUMBER: 137:321608
TITLE: Sensory rhodopsin II: functional insights from structure
AUTHOR(S): Spudich, John L.; Luecke, Hartmut
CORPORATE SOURCE: Center for Membrane Biology, Department of

Microbiology and Molecular Genetics, Department of Biochemistry and Molecular Biology, University of Texas Medical School, Houston, TX, 77030, USA
SOURCE: Current Opinion in Structural Biology (2002), 12(4), 540-546
CODEN: COSBEF; ISSN: 0959-440X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. At. resoln. structures of a sensory rhodopsin phototaxis receptor in haloarchaea (the first sensory member of the widespread microbial rhodopsin family) have yielded insights into the interaction face with its membrane-embedded transducer and into the mechanism of spectral tuning. Spectral differences between sensory rhodopsin and the light-driven proton pump bacteriorhodopsin depend largely upon the repositioning of a conserved **arginine** residue in the chromophore-binding pocket. Information derived from the structures, combined with biophys. and biochem. anal., has established a model for receptor activation and signal relay, in which light-induced helix tilting in the receptor is transmitted to the transducer by lateral transmembrane helix-helix interactions. The authors review the recent rapid progress in at.-resoln. structural analyses of the first sensory member of the widespread microbial rhodopsin family: the haloarchaeal phototaxis receptor sensory rhodopsin II.
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 4 OF 21 MEDLINE
ACCESSION NUMBER: 2002409085 IN-PROCESS
DOCUMENT NUMBER: 22153215 PubMed ID: 12163079
TITLE: Sensory rhodopsin II: functional insights from structure.
AUTHOR: **Spudich John**; Luecke Hartmut
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Department of Microbiology and Molecular Genetics, and Center for Membrane Biology, University of Texas Medical School, 77030, Houston, Texas, USA.
SOURCE: CURRENT OPINION IN STRUCTURAL BIOLOGY, (2002 Aug) 12 (4) 540.
Journal code: 9107784. ISSN: 0959-440X.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20020807
Last Updated on STN: 20020807
AB Atomic resolution structures of a sensory rhodopsin phototaxis receptor in haloarchaea (the first sensory member of the widespread microbial rhodopsin family) have yielded insights into the interaction face with its membrane-embedded transducer and into the mechanism of spectral tuning. Spectral differences between sensory rhodopsin and the light-driven proton pump bacteriorhodopsin depend largely upon the repositioning of a conserved arginine residue in the chromophore-binding pocket. Information derived from the structures, combined with biophysical and biochemical analysis,

has established a model for receptor activation and signal relay, in which light-induced helix tilting in the receptor is transmitted to the transducer by lateral transmembrane helix-helix interactions.

L44 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
ACCESSION NUMBER: 2002:584854 HCAPLUS
DOCUMENT NUMBER: 137:292236
TITLE: Attenuation of the exercise-induced increase in skeletal muscle Flt-1 mRNA by nitric oxide synthase inhibition
AUTHOR(S): Gavin, T. P.; **Wagner, P. D.**
CORPORATE SOURCE: Department of Medicine, University of California San Diego, La Jolla, CA, USA
SOURCE: Acta Physiologica Scandinavica (2002), 175(3), 201-209
CODEN: APSCAX; ISSN: 0001-6772
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The vascular endothelial growth factor (VEGF) receptor [fms-like-tyrosine kinase (Flt-1) and fetal liver kinase-1 (Flk-1)] response to acute exercise was investigated. In female Wistar rats, VEGF receptor mRNA response to a single acute exercise bout was examd. using semi-quant. Northern blot from the left gastrocnemius muscle at rest and post-exercise at 0, 1, 2, 4, 8, 16, 24, and 48 h. Exercise altered both Flt-1 and Flk-1 mRNA, with significant increases in Flt-1 mRNA at 1 and 24 h. However, post-hoc anal. was unable to discern the time point where a significant increase in Flk-1 mRNA occurred. To investigate the regulation of Flt-1 mRNA by exercise, the authors examd. if nitric oxide synthase (NOS) inhibition alters the Flt-1 mRNA response. Eight groups [condition: rest or exercise; drug: saline, 30 mg kg-1 N.omega.-nitro-L-**arginine** Me ester (L-NAME), 300 mg kg-1 L-NAME or 300 mg kg-1 D-NAME] were used to det. the effect of NOS inhibition on Flt-1 mRNA response to exercise. L-NAME, a known NOS inhibitor, attenuated the exercise-induced increase in Flt-1 mRNA by .apprx.50%. These findings suggest that: (1) exercise alters Flt-1 and Flk-1 gene expression; and (2) NO is important in the regulation of the Flt-1 gene response to exercise.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:613891 HCAPLUS
TITLE: Theoretical study on spectral tuning in bacteriorhodopsin and sensory rhodopsin II
AUTHOR(S): Ren, Lei; Martin, Charles H.; Wise, Kevin; Gillespie, Nathan; Luecke, Hartmut; Lanyi, Janos K.; **Spudich, John L.**; Birge, Robert R.
CORPORATE SOURCE: Department of Chemistry, Syracuse University, Syracuse, NY, 13244, USA
SOURCE: Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002), BIOL-119. American Chemical Society: Washington, D. C.
CODEN: 69CZPZ
DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Quantum mech. and mol. mech. calcns. of bacteriorhodopsin (bR) and sensory rhodopsin II (SRII) have been carried out to det. the difference of opsin shifts between these two proteins. SRII is unique among the archaeal rhodopsins in having an absorption max. near 500 nm, roughly 70 nm blue shifted from the other pigments, such as bR. The mol. origins responsible for both photophys. properties are examd. here with ref. to the 2.4.ANG. crystal structure of sensory rhodopsin II (NpSRII) from Natronobacterium pharaonis. We use semiempirical MO theory (MOZYME) to optimize the chromophore within the chromophore binding site, and MNDO-PSDCI MO theory to calc. the spectroscopic properties. Through a comparison of corresponding calcns. on the 1.55.ANG. crystal structure of bacteriorhodopsin (BR), we identify the principal mol. mechanisms, and residues, responsible for the spectral blue shift in NpSRII. We conclude that the major source of the blue shift is assocd. with significantly different positions of **Arg**-72 (**Arg**-82 in BR) in the two proteins.

L44 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 3

ACCESSION NUMBER: 2001:730615 HCAPLUS
DOCUMENT NUMBER: 135:285362
TITLE: Site-specific, covalent bioconjugation of proteins
INVENTOR(S): **Wagner, Peter**; Ma, Lifu; **Nock, Steffen**; Wilson, David; Sydor, Jens
PATENT ASSIGNEE(S): Zyomyx, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072458	A1	20011004	WO 2001-US9772	20010327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002013003	A1	20020131	US 2001-820210	20010327

PRIORITY APPLN. INFO.: US 2000-192640P P 20000327
US 2000-235955P P 20000926

AB Heterofunctional crosslinking groups are provided having the formula X-L1-W(L2-Y)(L3-Z) (I) wherein W is a covalent core component; L1, L2 and L3 are independently linking groups; X is a non-covalent or reversibly covalent protein tag binder; Y is an activatable covalent linking group; and Z is a protected or unprotected covalent crosslinking group. The heterofunctional crosslinking reagent is useful for covalently linking a protein to a compd., a biol. compd.,

or a substrate within one or more specific regions of the protein.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
ACCESSION NUMBER: 2001:781553 HCAPLUS
DOCUMENT NUMBER: 136:33605
TITLE: Molecular Mechanism of Spectral Tuning in Sensory Rhodopsin II
AUTHOR(S): Ren, Lei; Martin, Charles H.; Wise, Kevin J.; Gillespie, Nathan B.; Luecke, Hartmut; Lanyi, Janos K.; **Spudich, John L.**; Birge, Robert R.
CORPORATE SOURCE: Departments of Chemistry and of Molecular and Cell Biology, University of Connecticut, Storrs, CT, 06269, USA
SOURCE: Biochemistry (2001), 40(46), 13906-13914
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Sensory rhodopsin II (SRII) is unique among the archaeal rhodopsins in having an absorption max. near 500 nm, blue shifted roughly 70 nm from the other pigments. In addn., SRII displays vibronic structure in the .lambda.max absorption band, whereas the other pigments display fully broadened band maxima. The mol. origins responsible for both photophys. properties are examd. here with ref. to the 2.4 .ANG. crystal structure of sensory rhodopsin II (NpSRII) from Natronobacterium pharaonis. We use semiempirical MO theory (MOZYME) to optimize the chromophore within the chromophore binding site, and MNDO-PSDCI MO theory to calc. the spectroscopic properties. The entire first shell of the chromophore binding site is included in the MNDO-PSDCI SCF calcn., and full single and double CI is included for the chromophore .pi.-system. Through a comparison of corresponding calcns. on the 1.55 .ANG. crystal structure of bacteriorhodopsin (bR), we identify the principal mol. mechanisms, and residues, responsible for the spectral blue shift in NpSRII. We conclude that the major source of the blue shift is assocd. with the significantly different positions of **Arg**-72 (**Arg**-82 in bR) in the two proteins. In NpSRII, this side chain has moved away from the chromophore Schiff base nitrogen and closer to the .beta.-ionylidene ring. This shift in position transfers this pos. charged residue from a region of chromophore destabilization in bR to a region of chromophore stabilization in NpSRII, and is responsible for roughly half of the blue shift. Other important contributors include Asp-201, Thr-204, Tyr-174, Trp-76, and W402, the water mol. hydrogen bonded to the Schiff base proton. The W402 contribution, however, is a secondary effect that can be traced to the transposition of **Arg**-72. Indeed, secondary interactions among the residues contribute significantly to the properties of the binding site. We attribute the increased vibronic structure in NpSRII to the loss of **Arg**-72 dynamic inhomogeneity, and an increase in the intensity of the second excited 1Ag*- -like state, which now appears as a sep. feature within the .lambda.max band profile. The strongly allowed 1Bu*+-like state and the higher-energy 1Ag*- -like state are highly mixed in NpSRII, and the latter state borrows intensity from the

former to achieve an observable oscillator strength.
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 5
ACCESSION NUMBER: 2001:643922 HCAPLUS
DOCUMENT NUMBER: 135:284760
TITLE: Crystal structure of sensory rhodopsin II at 2.4 angstroms: insights into color tuning and transducer interaction
AUTHOR(S): Luecke, Hartmut; Schobert, Brigitte; Lanyi, Janos K.; Spudich, Elena N.; **Spudich, John L.**
CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, 92697, USA
SOURCE: Science (Washington, DC, United States) (2001), 293(5534), 1499-1503
CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We report an at.-resoln. structure for a sensory member of the microbial rhodopsin family, the phototaxis receptor sensory rhodopsin II (NpSRII), which mediates blue-light avoidance by the haloarchaeon Natronobacterium pharaonis. The 2.4 angstrom structure reveals features responsible for the 70- to 80-nm blue shift of its absorption max. relative to those of haloarchaeal transport rhodopsins, as well as structural differences due to its sensory, as opposed to transport, function. Multiple factors appear to account for the spectral tuning difference with respect to bacteriorhodopsin: (i) repositioning of the guanidinium group of **arginine** 72, a residue that interacts with the counterion to the retinylidene protonated Schiff base; (ii) rearrangement of the protein near the retinal ring; and (iii) changes in tilt and slant of the retinal polyene chain. Inspection of the surface topog. reveals an exposed polar residue, tyrosine 199, not present in bacteriorhodopsin, in the middle of the membrane bilayer. We propose that this residue interacts with the adjacent helixes of the cognate NpSRII transducer NpHtrII.
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
ACCESSION NUMBER: 2000:299780 HCAPLUS
DOCUMENT NUMBER: 133:69375
TITLE: Nitric oxide synthase inhibition attenuates the skeletal muscle VEGF mRNA response to exercise
AUTHOR(S): Gavin, Timothy P.; Spector, David A.; Wagner, Harrieth; Breen, Ellen C.; **Wagner, Peter D.**
CORPORATE SOURCE: Department of Medicine, University of California, La Jolla, CA, 92093-0623, USA
SOURCE: Journal of Applied Physiology (2000), 88(4), 1192-1198

CODEN: JAPHEV; ISSN: 8750-7587
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor-.beta.1 (TGF-.beta.1) mRNA increase in rat skeletal muscle in response to a single acute exercise bout. Nitric oxide (NO) is released locally by muscle vascular endothelium and muscle fibers during exercise, contributes to the blood flow response to exercise, and regulates mitochondrial respiration. We hypothesized that a redn. in NO prodn., via NO synthase inhibition, would demonstrate a link between NO and the VEGF, bFGF, and TGF-.beta.1 gene responses to exercise. To investigate this hypothesis, 9-wk-old female Wistar rats were divided into eight treatment groups (n = 6 each): (1) saline + rest, (2) saline + exercise, (3) 30 mg/kg N.omega.-nitro-L-**arginine** Me ester (L-NAME, a known NOS inhibitor) + rest, (4) 30 mg/kg L-NAME + exercise, (5) 300 mg/kg L-NAME + rest, (6) 300 mg/kg L-NAME + exercise, (7) 300 mg/kg N.omega.-nitro-D-**arginine** Me ester (D-NAME, inactive enantiomer of L-NAME) + rest, and (8) 300 mg/kg D-NAME + exercise. Exercise consisted of 1 h of running at 20 m/min on a 10.degree. incline. VEGF, TGF-.beta.1, and bFGF mRNA from left gastrocnemius were analyzed by quant. Northern blot. Submaximal exercise for 1 h increased VEGF mRNA 4.2-fold and TGF-.beta.1 mRNA 1.5-fold in untreated rats but did not increase bFGF mRNA. The exercise-induced increase in VEGF mRNA was attenuated .apprx.50% by 30 and 300 mg/kg L-NAME; the TGF-.beta.1 mRNA increase was unaffected by 300 mg/kg L-NAME. In addn., 300 mg/kg D-NAME had no effect on the exercise-induced increase in VEGF mRNA. Administration of 300 mg/kg L-NAME had no effect on bFGF mRNA. These findings suggest that NO is important in the regulation of the VEGF gene response to exercise through increases in VEGF transcription or by increases in the VEGF mRNA half-life.
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 7
ACCESSION NUMBER: 1999:189275 HCAPLUS
DOCUMENT NUMBER: 130:206987
TITLE: Reversible immobilization of **arginine** -tagged moieties on a silicate surface with application in protein purification
INVENTOR(S): **Spudich, James A.; Nock, Steffen; Wagner, Peter**
PATENT ASSIGNEE(S): Stanford University, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912036	A1	19990311	WO 1998-US18531	19980903

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9892225 A1 19990322 AU 1998-92225 19980903
PRIORITY APPLN. INFO.: US 1997-57929P P 19970904
WO 1998-US18531 W 19980903

AB This invention provides materials and methods for the site specific attachment of virtually any moiety to a layered silicate surface. The methods involve covalently attaching the moiety to an **arginine** tag; and contacting the **arginine** tag with the layered silicate (e.g., mica) surface. A highly specific interaction with the surfaces of layered silicates is mediated, at least in part, by a cation exchange with the silicate surface. Unlike previously described cation exchange systems, binding of the **arginine** tag is highly resistant to physiol. relevant (compatible) concns. of sodium and other ions.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 8
ACCESSION NUMBER: 1998:436767 HCAPLUS
DOCUMENT NUMBER: 129:133518
TITLE: Conditional loss-of-myosin-II-function mutants reveal a position in the tail that is critical for filament nucleation
AUTHOR(S): Moores, Sheri L.; **Spudich, James A.**
CORPORATE SOURCE: Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, 94305, USA
SOURCE: Molecular Cell (1998), 1(7), 1043-1050
CODEN: MOCEFL; ISSN: 1097-2765
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Myosin-II must be assembled into filaments to perform its cellular functions. Two conditional loss-of-myosin-II-function mutants were recovered from a previous genetic screen with defects that were mapped to the coiled-coil tail region of Dictyostelium myosin-II. Strikingly, both tail mutations affected the same **arginine** residue at position 1880. A single amino acid substitution, R1880P, disrupted both the dimerization and tetramerization steps of filament nucleation. Even a single charge reversal at this position, R1880D, was sufficient to inhibit filament assembly, while other single charge reversals in the region of antiparallel contact suppressed these filament assembly mutants. The considerable impact of small electrostatic forces on nucleation suggests that these steps are delicately balanced and easily reversible.

L44 ANSWER 13 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1998:335554 BIOSIS
DOCUMENT NUMBER: PREV199800335554
TITLE: Reversible site-specific immobilization of poly-**arginin**o-tagged fusion proteins on mica

surfaces.
AUTHOR(S): **Nock, S.; Wagner, P.; Spudich, J. A.**
CORPORATE SOURCE: Dep. Biochem., Stanford Univ., Stanford, CA 94305 USA
SOURCE: Biophysical Journal, (Feb., 1998) Vol. 74, No. 2 PART 2, pp. A295.
Meeting Info.: Forty-second Annual Meeting of the Biophysical Society Kansas City, Missouri, USA February 22-26, 1998
ISSN: 0006-3495.
DOCUMENT TYPE: Conference
LANGUAGE: English

L44 ANSWER 14 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1998:335553 BIOSIS
DOCUMENT NUMBER: PREV199800335553
TITLE: New strategies in site-specific immobilization of proteins on micro- and nanostructured surfaces.
AUTHOR(S): **Wagner, P. (1); Nock, S. (1);** Heidecker, M. (1); Shih, W. (1); Ulman, N.; **Spudich, J. A. (1)**
CORPORATE SOURCE: (1) Dep. Biochem., Stanford Univ., Stanford, CA 94305 USA
SOURCE: Biophysical Journal, (Feb., 1998) Vol. 74, No. 2 PART 2, pp. A295.
Meeting Info.: Forty-second Annual Meeting of the Biophysical Society Kansas City, Missouri, USA February 22-26, 1998
ISSN: 0006-3495.
DOCUMENT TYPE: Conference
LANGUAGE: English

L44 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 9
ACCESSION NUMBER: 1997:574236 HCAPLUS
DOCUMENT NUMBER: 127:274954
TITLE: Reversible, site-specific immobilization of **polyarginine**-tagged fusion proteins on mica surfaces
AUTHOR(S): **Nock, Steffen; Spudich, James A.; Wagner, Peter**
CORPORATE SOURCE: Department of Biochemistry, Beckman Center B405, Stanford University Medical Center, Stanford, CA, 94305-5307, USA
SOURCE: FEBS Letters (1997), 414(2), 233-238
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A large variety of genes is expressed as fusion proteins for the purpose of characterization and purifn. in mol. biol. We have used this strategy to append **polyarginine** peptides to achieve specific binding of the **Arg**-tag to atomically flat, neg. charged mica surfaces. We show that the model protein, **hexaarginine**-tagged green fluorescent protein (GFP), binds to mica via its **Arg**-tag based on ion exchange of naturally occurring potassium cations. Only non-specific binding was obsd. with the control protein that is free of the Arg-tag. This novel technol. will be widely applicable to orient functional

proteins on flat surfaces.

L44 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 10
ACCESSION NUMBER: 1997:564116 HCAPLUS
DOCUMENT NUMBER: 127:217193
TITLE: Bioreactive self-assembled monolayers on hydrogen-passivated Si(111) as a new class of atomically flat substrates for biological scanning probe microscopy
AUTHOR(S): **Wagner, Peter; Nock, Steffen ; Spudich, James A.**; Volkmuth, Wayne D.; Chu, Steve; Cicero, Ronald L.; Wade, Christopher P.; Linford, Matthew R.; Chidsey, Christopher E. D.
CORPORATE SOURCE: Department of Biochemistry, Stanford University Medical Center, Stanford, CA, 94305-5307, USA
SOURCE: Journal of Structural Biology (1997), 119(2), 189-201
CODEN: JSBIEM; ISSN: 1047-8477
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This is the first report of bioreactive self-assembled monolayers, covalently bound to atomically flat silicon surfaces and capable of binding biomols. for investigation by scanning probe microscopy and other surface-related assays and sensing devices. These monolayers are stable under a wide range of conditions and allow tailor-made functionalization for many purposes. We describe the substrate prepn. and present an STM and SFM characterization, partly performed with multiwalled carbon nanotubes as tapping-mode supertips. Furthermore, we present two strategies of introducing in situ reactive headgroup functionalities. One method entails a free radical chlorosulfonation process with subsequent sulfonamide formation. A second method employs singlet carbene-mediated hydrogen-carbon insertion of a heterobifunctional, amino-reactive trifluoromethyldiazirinyl crosslinker. We believe that this new substrate is advantageous to others, because it (i) is atomically flat over large areas and can be prepd. in a few hours with std. equipment, (ii) is stable under most conditions, (iii) can be modified to adjust a certain degree of reactivity and hydrophobicity, which allows phys. adsorption or covalent crosslinking of the biol. specimen, (i.v.) builds the bridge between semiconductor microfabrication and org./biol. mol. systems, and (v) is accessible to nanopatterning and applications requiring conductive substrates.

L44 ANSWER 17 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1997:90661 BIOSIS
DOCUMENT NUMBER: PREV199799389864
TITLE: RGD and other recognition sequences for integrins.
AUTHOR(S): Ruosalhti, Erkki
CORPORATE SOURCE: La Jolla Cancer Res. Cent., Burnham Inst., 10901 North Torrey Pines Rd., La Jolla, CA 92037 USA
SOURCE: **Spudich, J. A. [Editor]**. Annual Review of Cell and Developmental Biology, (1996) Vol. 12, pp. 697-715. Annual Review of Cell and Developmental Biology.
Publisher: Annual Reviews Inc. P.O. Box 10139, 4139

El Camino Way, Palo Alto, California 94306, USA.
ISSN: 1081-0706. ISBN: 0-8243-3112-5.
DOCUMENT TYPE: Book; General Review
LANGUAGE: English

L44 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 11
ACCESSION NUMBER: 1996:393104 HCAPLUS
DOCUMENT NUMBER: 125:51873
TITLE: Protonatable residues at the cytoplasmic end of transmembrane helix-2 in the signal transducer HtrI control photochemistry and function of sensory rhodopsin I
AUTHOR(S): Jung, Kwang-Hwan; **Spudich, John L.**
CORPORATE SOURCE: Dep. Microbiol. Mol. Genet., Univ. Texas Med. Sch. Health Sci. Cent., Houston, TX, 77030, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1996), 93(13), 6557-6561
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Neutral residue replacements were made of 21 acidic and basic residues within the N-terminal half of the Halobacterium salinarium signal transducer HtrI [the halobacterial transducer for sensory rhodopsin I (SRI)] by site-specific mutagenesis. The replacements are all within the region of HtrI that we previously concluded from deletion anal. to contain sites of interaction with the phototaxis receptor SRI. Immunoblotting shows plasmid expression of the htrI-sopI operon contg. the mutations produces SRI and mutant HtrI in cells at near wild-type levels. Six of the HtrI mutations perturb photochem. kinetics of SRI and one reverses the phototaxis response. Substitution with neutral amino acids of Asp-86, Glu-87, and Glu-108 accelerate, and a **Arg**-70, **Arg**-84, and **Arg**-99 retard, the SRI photocycle. Opposite effects on photocycle rate cancel in double mutants contg. one replaced acidic and one replaced basic residue. Laser flash spectroscopy shows the kinetic perturbations are due to alteration of the rate of reprotonation of the retinylidene Schiff base. All of these mutations permit normal attractant and repellent signaling. The substitution of Glu-56 with the isosteric glutamine converts the normally attractant effect of orange light to a repellent signal in vivo at neutral pH (inverted signaling). Low pH corrects the inversion due to Glu-56 .fwdarw. Gln and the apparent pK of the inversion is increased when **arginine** is substituted at position 56. The results indicate that the cytoplasmic end of transmembrane helix-2 and the initial part of the cytoplasmic domain contain interaction sites with SRI. To explain these and previous results, we propose a model in which (i) the HtrI region identified here forms part of an electrostatic bonding network that extends through the SRI protein and includes its photoactive site; (ii) alteration of this network by photoisomerization-induced Schiff base deprotonation and reprotonation shifts HtrI between attractant and repellent conformations; and (iii) HtrI mutations and extracellular pH alter the equil. ratios of these conformations.

L44 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1997:146409 BIOSIS

DOCUMENT NUMBER: PREV199799445612
TITLE: Infrared spectroscopy of photo-active yellow protein: Characterization of a signaling state.
AUTHOR(S): Hoff, W. D. (1); Xie, A.; Kroon, A.; **Spudich, J. L. (1)**; Chance, M.; Hellingwerf, K. J.
CORPORATE SOURCE: (1) Dep. Microbiol. Mol. Genet., Univ. Texas, Houston, TX USA
SOURCE: Progress in Biophysics and Molecular Biology, (1996) Vol. 65, No. SUPPL. 1, pp. 180.
Meeting Info.: XIIth International Biophysics Congress Amsterdam, Netherlands August 11-16, 1996
ISSN: 0079-6107.
DOCUMENT TYPE: Conference; Abstract
LANGUAGE: English

L44 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 12
ACCESSION NUMBER: 1995:510448 HCAPLUS
DOCUMENT NUMBER: 122:285007
TITLE: Residue replacements of buried aspartyl and related residues in sensory rhodopsin I: D201N produces inverted phototaxis signals
AUTHOR(S): Olson, Karl D.; Zhang, Xue-Nong; **Spudich, John L.**
CORPORATE SOURCE: Dep. of Microbiology, Univ. of Texas Medical Sch., Houston, TX, 77030, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1995), 92(8), 3185-9
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Residue replacements were made at five positions (**Arg**-73, Asp-76, Tyr-87, Asp-106, and Asp-201) in the Halobacterium salinarium phototaxis receptor sensory rhodopsin I (SR-I) by site-specific mutagenesis. The sites were chosen for their correspondence in position to residues of functional importance in the homologous light-driven proton pump bacteriorhodopsin found in the same organism. This work identifies a residue in SR-I shown to be of vital importance to its attractant signaling function: Asp-201. The effect of the substitution with the isosteric asparagine is to convert the normally attractant signal of orange light stimulation to a repellent signal. In contrast, similar neutral substitution of the four other ionizable residues near the photoactive site allows essentially normal attractant and repellent phototaxis signaling. Wild-type two-photon repellent signaling by the receptor is intact in the Asp-201 mutant, genetically sepg. the wild-type attractant and repellent signal generation processes. A possible explanation and implications of the inverted signaling are discussed. Results of neutral residue substitution for Asp-76 confirm our previous evidence that proton transfer reactions involving this residue are not important to phototaxis but that Asp-76 functions as the Schiff base proton acceptor in proton translocation by transducer-free SR-I.

L44 ANSWER 21 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1995:240673 BIOSIS
DOCUMENT NUMBER: PREV199598254973

09/486480

TITLE:	The role of endothelium-derived relaxing factor (EDRF) in the whole body and hindlimb vascular responses during hypoxic hypoxia.
AUTHOR(S):	King, C. E. (1); Curtis, S. E.; Winn, M. J.; Mewburn, J. D. (1); Cain, S. M.; Chapler, C. K.
CORPORATE SOURCE:	(1) Dep. Physiol., Queen's Univ., Kingston, ON K7L 3N6 Canada
SOURCE:	Hogan, M. C. [Editor]; Mathieu-Costello, O. [Editor]; Poole, D. C. [Editor]; **Wagner, P. D. [Editor]** . Advances in Experimental Medicine and Biology, (1994) Vol. 361, pp. 285-293. Advances in Experimental Medicine and Biology; Oxygen transport to tissue XVI. Publisher: Plenum Press 233 Spring Street, New York, New York, USA. Meeting Info.: 21st Annual Meeting of the International Society on Oxygen Transport to Tissue San Diego, California, USA August 14-18, 1993 ISSN: 0065-2598. ISBN: 0-306-44827-0.
DOCUMENT TYPE:	Book; Conference
LANGUAGE:	English

FILE 'HOME' ENTERED AT 10:41:49 ON 06 DEC 2002

Searcher : Shears 308-4994

Devi, S.
09/486480

06dec02 10:50:51 User219783 Session D1892.1

```
SYSTEM:OS  - DIALOG OneSearch
  File  35:Dissertation Abs Online  1861-2002/Nov
        (c) 2002 ProQuest Info&Learning
  File  65:Inside Conferences  1993-2002/Dec W1
        (c) 2002 BLDSC all rts. reserv.
  File 144:Pascal  1973-2002/Dec W1
        (c) 2002 INIST/CNRS
  File 266:FEDRIP  2002/Oct
        Comp & dist by NTIS, Intl Copyright All Rights Res
  File 440:Current Contents Search(R)  1990-2002/Dec 05
        (c) 2002 Inst for Sci Info
*File 440: Daily alerts are now available.
  File 348:EUROPEAN PATENTS  1978-2002/Nov W04
        (c) 2002 European Patent Office
  File 357:Derwent Biotech Res.  _1982-2002/Dec W2
        (c) 2002 Thomson Derwent & ISI
*File 357: File is now current.  See HELP NEWS 357.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
  File 113:European R&D Database  1997
        (c)1997 Reed-Elsevier(UK)Ltd All rts reserv
*File 113: This file is closed (no updates)
```

- key terms

Set	Items	Description
Set	Items	Description
S1	111477	ARGININE OR ARG OR POLYARGININE OR HEXAARGININE OR DIARGININE OR SIXARGININE OR RRRRRR
S2	798	S1 AND (MICA? ? OR SILICATE? ?)
S3	366	S2 AND (TAGGING OR TAG? ? OR TAGGED OR SPACER? ? OR LINK?)
S5	185	S3 AND ((NA OR SODIUM)(5N)SALT? ?)
S6	173	S5 AND (MOLECULE? ? OR POLYPEPTIDE? ? OR POLYPROTEIN? ? OR PROTEIN? ? OR PEPTIDE? ? OR NUCLEIC OR DNA OR DEOXYRIBONUCLEIC OR DEOXY(W)RIBONUCLEIC OR CARBOHYDRATE? ? OR POLYSACCHARIDE? ? OR POLY(W)SACCHARIDE? ? OR ANTIGEN?)
S8	53	S6 AND COVALEN?
S9	53	RD (unique items)

```
>>>No matching display code(s) found in file(s): 65, 113

 9/3,AB/1     (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2002 European Patent Office. All rts. reserv.

01424231
Shaped detergent compositions
Geformte Waschmittel
Compositions detergentes formees
PATENT ASSIGNEE:
  THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza,
    Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
  Lant, Neil Joseph, 15 Manor Walk, Benton, Newcastle upon Tyne TE7 7XX,
    (GB)
  Salager, Serge Eric, Lennekmarelaan 38/28, 1932 Woluwe St. Etienne, (BE)
  Eshuis, Johan Hans, Frankrijklei 16 - B-8, 2000 Antwerpen, (BE)
```

Pena-Romero, Angelina, Museumlaan 71, 3080 Tervuren, (BE)
LEGAL REPRESENTATIVE:
Alexander, Sean Matthew et al (98191), N.V. Procter & Gamble Services Company S.A. Temselaan 100, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1201745 A1 020502 (Basic)
APPLICATION (CC, No, Date): EP 2001870013 010119;
PRIORITY (CC, No, Date): EP 2000870254 001031
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/04; C11D-017/02; C11D-017/00

ABSTRACT EP 1201745 A1
The present invention relates to a shaped detergent composition comprising:
(a) a surfactant; and
(b) at least one bead comprising benefit agent wherein the bead floats in deionised water at 20(degree)C.
In the compositions of the present invention the bead(s) comprising the benefit agent survive well in the wash liquor and, therefore, it is easier to control the release of the active. In addition, the present shaped compositions can be effectively dosed via the dispensing drawer of standard washing machines
ABSTRACT WORD COUNT: 83
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200218	256
SPEC A	(English)	200218	22596
Total word count - document A			22852
Total word count - document B			0
Total word count - documents A + B			22852

9/3,AB/2 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01422990
Detergent compositions
Waschmittelzusammensetzungen
Compositions detergentes
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Lant, Neil Joseph, 15 Manor Walk, Benton, Newcastle upon Tyne NE7 7XX, (GB)
Eshuis, Johan Hans, Frankrijklei 116-B-8, 2000 Antwerpen, (BE)
Salager, Serge Eric, Lennekemarelaan 38/28, 1932 Woluwe St. Etienne, (BE)
Pena-Romero, Angelina (NMN), Museumlaan 71, 3080 Tervuren, (BE)
LEGAL REPRESENTATIVE:
Mather, Peter Geoffrey et al (80815), NV Procter & Gamble Services SA, 100 Temselaan, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1201743 A1 020502 (Basic)

APPLICATION (CC, No, Date): EP 2000870254 001031;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/00

ABSTRACT EP 1201743 A1
The present invention relates to a shaped detergent composition comprising:
(a) a surfactant; and
(b) at least one particle comprising benefit agent wherein the particle floats in deionised water at 20(degree)C.
In the compositions of the present invention the particle(s) comprising the benefit agent survive well in the wash liquor and, therefore, it is easier to control the release of the active. In addition, the present shaped compositions can be effectively dosed via the dispensing drawer of standard washing machines
ABSTRACT WORD COUNT: 83
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200218	277
SPEC A	(English)	200218	20470
Total word count - document A			20747
Total word count - document B			0
Total word count - documents A + B			20747

9/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01422989
Detergent compositions
Waschmittelzusammensetzungen
Compositions lessivielles
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Lant, Neil Joseph, 15 Manor Walk, Benton, Newcastle upon Tyne NE7 7XX, (GB)
Salager, Serge Eric, Lennekemarelaan 38/28, 1932 Woluwe St. Etienne, (BE)
Eshuis, Johan Hans, Frankrijklei 116-B-8, 2000 Antwerpen, (BE)
Pena-Romero, Angelina (NMN), Museumlaan 71, 3080 Tervuren, (BE)
LEGAL REPRESENTATIVE:
Mather, Peter Geoffrey et al (80815), NV Procter & Gamble Services SA, 100 Temselaan, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1201742 A1 020502 (Basic)
APPLICATION (CC, No, Date): EP 2000870253 001031;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/00

ABSTRACT EP 1201742 A1

The present invention relates to a shaped detergent composition comprising surfactant and cationic fabric softener, characterised in that the composition disintegrates within 5 minutes of been placed in deionised water at 20(degree)C and that after disintegration, the average particle size of the composition is less than 5mm, preferably less than 3mm.

The compositions of the present invention can be effectively dosed via the dispensing drawer of standard washing machines and can deliver two or more actives to the wash liquor, even if such actives are incompatible with each other.

ABSTRACT WORD COUNT: 90

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200218	275
SPEC A	(English)	200218	21115
Total word count - document A			21390
Total word count - document B			0
Total word count - documents A + B			21390

9/3,AB/4 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01422988
Detergent compositions
Waschmittelzusammensetzungen
Compositions detergentes
PATENT ASSIGNEE:
The Procter & Gamble Company, (200171), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Lant, Neil Joseph, 15 Manor Walk, Benton, Newcastle upon Tyne NE7 7XX, (GB)
Salager, Serge Eric, Lennekemarelaan 38/28, 1932 Woluwe St. Etienne, (BE)
Eshuis, Johan Hans, Frankrijklei 116-B-8, 2000 Antwerpen, (BE)
Pena-Romero, Angelina (NMN), Museumlaan 71, 3080 Tervuren, (BE)
LEGAL REPRESENTATIVE:
Mather, Peter Geoffrey et al (80815), NV Procter & Gamble Services SA, 100 Temselaan, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1201741 A1 020502 (Basic)
APPLICATION (CC, No, Date): EP 2000870252 001031;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/00

ABSTRACT EP 1201741 A1

The present invention relates to a shaped detergent composition, said composition comprising:

(a) a surfactant; and

(b) a plurality of discrete particles comprising benefit agent, said particles having an average particle size of at least 1.2mm, preferably from 1.5mm to 10mm, more preferably from 2.0mm to 5mm, even more preferably from 2.3mm to 4mm.

The compositions of the present invention can be effectively dosed via the dispensing drawer of standard washing machines without being caught up in the mechanism of the machine.
ABSTRACT WORD COUNT: 85

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200218	281
SPEC A	(English)	200218	21006
Total word count - document A			21287
Total word count - document B			0
Total word count - documents A + B			21287

9/3,AB/5 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01413327
ALPHA-ISOMALTOSYLGLUCOSACCHARIDE SYNTHASE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF
Alpha-Isomaltosylglukosaccharidsynthase, Verfahren zu deren Herstellung und Verwendung
SYNTHASE D'ALPHA-ISOMALTOSYLGLUCOSACCHARIDE, PROCEDE DE PREPARATION ET UTILISATION ASSOCIES
PATENT ASSIGNEE:
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, (792445), 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP), (Applicant designated States: all)
INVENTOR:
KUBOTA,M, K.K.Hayashibara Seibutsu Kagaku Kenkyujo, 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP)
TSUSAKI,K K.K.Hayashibara Seibutsu Kagaku Kenkyujo, 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP)
HIGASHIYAMA, K.K.Hayashib.Seibutsu Kagaku Kenkyujo, 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP)
FUKUDA,S K.K.Hayashibara Seitbutsu Kagaku Kenkyujo, 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP)
MIYAKE,T, K.K.Hayashibara Seibutsu Kagaku Kenkyujo, 2-3, Shimoishii 1-chome, Okayama-shi, Okayama 700-0907, (JP)
LEGAL REPRESENTATIVE:
Daniels, Jeffrey Nicholas et al (69921), Page White & Farrer 54 Doughty Street, London WC1N 2LS, (GB)
PATENT (CC, No, Kind, Date): EP 1229112 A1 020807 (Basic)
WO 200210361 020207
APPLICATION (CC, No, Date): EP 2001958377 010725; WO 2001JP6412 010725
PRIORITY (CC, No, Date): JP 2000233364 000801; JP 2000234937 000802
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12N-009/24; C12P-019/00; C07H-003/06; A23L-001/30; A61K-047/26; A61K-007/00; A61K-007/50; A61K-007/16; A61K-007/48

ABSTRACT EP 1229112 A1
The object of the present invention is to provide an (alpha)-isomaltosylglucosaccharide-forming enzyme, process of the same,

cyclotetrasaccharide, and saccharide composition comprising the saccharide which are obtainable by using the enzyme; and is solved by establishing an (alpha)-isomaltosylglucosaccharide-forming enzyme which forms a saccharide, having a glucose polymerization degree of at least three and having both the (alpha)-1,6 glucosidic *linkage"** as a *linkage"** at the non-reducing end and the (alpha)-1,4 glucosidic *linkage"** other than the *linkage"** at the non-reducing end, by catalyzing the (alpha)-glucosyl-transfer from a saccharide having a glucose polymerization degree of at least two and having the (alpha)-1,4 glucosidic *linkage"** as a *linkage"** at the non-reducing end without substantially increasing the reducing power; (alpha)-isomaltosyl-transferring method using the enzyme; method for forming (alpha)-isomaltosylglucosaccharide; process for producing a cyclotetrasaccharide having the structure of cyclo(-->6)-(alpha)-D-glucopyranosyl-(1-->3)-(alpha)-D-glucopyranosyl-(1->6)-(alpha)-D-glucopyranosyl-(1-->3)-(alpha)-D-glucopyranosyl-(1-->) using both the (alpha)-isomaltosylglucosaccharide-forming enzyme and the (alpha)-isomaltosyl-transferring enzyme; and the uses of the saccharides obtainable therewith.

ABSTRACT WORD COUNT: 150

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; Japanese

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200232	2482
SPEC A	(English)	200232	33780
Total word count - document A			36262
Total word count - document B			0
Total word count - documents A + B			36262

9/3,AB/6 (Item 6 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

01400150

Detergent tablet

Waschmitteltablette

Tablette detergente

PATENT ASSIGNEE:

The Procter & Gamble Company, (200171), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)

INVENTOR:

Speed, Lynda Anne, 34 Oakfield Road, Gosforth, Newcastle upon Tyne NE3 4HS, (GB)

Painter, Jeffrey Donald, 11662 Enyart Road, Loveland, Ohio 45140, (US)

LEGAL REPRESENTATIVE:

Brooks, Maxim Courtney et al (46131), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)

PATENT (CC, No, Kind, Date): EP 1184450 A2 020306 (Basic)

APPLICATION (CC, No, Date): EP 2001127422 981124;

PRIORITY (CC, No, Date): US 66903 P 971126

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE

RELATED PARENT NUMBER(S) - PN (AN):

EP 960188 (EP 98961773)

INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-001/62; C11D-003/39; C11D-003/386

ABSTRACT EP 1184450 A2

According to the present invention there is provided a detergent tablet comprising a compressed portion and a non compressed portion wherein the compressed portion comprises a mould and dissolves at a faster rate than the non-compressed portion on a weight by weight basis, measured using the SOTAX dissolution test method described herein and the non-compressed portion is at least partially retained with the mould.

ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200210	611
SPEC A	(English)	200210	22790
Total word count - document A			23401
Total word count - document B			0
Total word count - documents A + B			23401

9/3,AB/7 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01376477
Laundry additive sachet
Waschezusatzbeutel
Sachet d'additif de lessive

PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)

INVENTOR:
Porta, Antonella (NMN), Via Madonna di Ponza snc, Formia, (IT)
van der Heijden, Mark Pieter Adrie, Via Titta Scarpetta 1, 00153 Roma, (IT)

LEGAL REPRESENTATIVE:
Engisch, Gautier et al (75192), BVBA Procter & Gamble Europe SPRL, Temselaan 100, 1853 Strombeek-Bever, (BE)

PATENT (CC, No, Kind, Date): EP 1170356 A1 020109 (Basic)
APPLICATION (CC, No, Date): EP 2000870155 000706;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/04; C11D-003/37; C11D-003/12; D06F-039/02

ABSTRACT EP 1170356 A1

The present invention relates to a laundry additive sachet. The sachet comprises a cavity in which is found a dye absorbing agent and a dirt binding agent. The sachet provides a system of scavenging fugitive dyes or pigments and dirt from laundry wash water.

ABSTRACT WORD COUNT: 45

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count

CLAIMS A	(English)	200202	492
SPEC A	(English)	200202	14048
Total word count - document A			14540
Total word count - document B			0
Total word count - documents A + B			14540

9/3,AB/8 (Item 8 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01364831
Detergent tablet
Waschmitteltablette
Tablette detergente
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Rowland, Barry, 84 Queen Alexandra Road, Sunderland SR2 9HW, (GB)
McGregor, Alasdair Duncan, Route du Moulin Roget 43, 1237 Avully, (CH)
Addison, Michael Crombie, 47 Clousden Grange, Forest Hall Newcastle upon Tyne NE12 0YX, (GB)
Speed, Lynda Anne, 34 Oakfield Road, Gosforth, Newcastle upon Tyne NE3 4HS, (GB)
LEGAL REPRESENTATIVE:
Brooks, Maxim Courtney et al (46131), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 1162258 A2 011212 (Basic)
APPLICATION (CC, No, Date): EP 2001203388 980803;
PRIORITY (CC, No, Date): GB 9716351 970802
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 960187 (EP 98938306)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/22; C11D-003/37; C11D-003/386; C11D-003/39

ABSTRACT EP 1162258 A2
The present invention provides a detergent tablet comprising:
a) a compressed portion comprising active detergent components;
b) a non compressed, non-encapsulating portion comprising active detergent components. Detergent components which are sensitive to compression can be incorporated into tablets and greater control of washing processes can be achieved.
ABSTRACT WORD COUNT: 50

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200150	833
SPEC A	(English)	200150	21476
Total word count - document A			22309
Total word count - document B			0
Total word count - documents A + B			22309

9/3,AB/9 (Item 9 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

01364160
A process of treating fabrics with a detergent tablet comprising an ion exchange resin
Verfahren zur Behandlung von Gewebe mit einem Waschmittelformkorper enthaltend ein Ionenaustauscherharz
Procede de traitement de tissu avec une tablette detergente comprenant une resine echangeuse d'ions
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Esposito, Andrea (NMN), V. Cardinal Caprara 34, 00167 Rome, (IT)
Del Duca, Valerio (NMN), Via Portuense 391, 00149 Rome, (IT)
Zanzazzi, Silvia (NMN), Via M. Boneparte Valentini 45, 06123 Perugia, (IT)
LEGAL REPRESENTATIVE:
Morelle, Evelyne Charlotte Isabelle et al (89811), BVBA Procter & Gamble Europe Sprl, Temselaan 100, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1162257 A1 011212 (Basic)
APPLICATION (CC, No, Date): EP 2000870123 000609;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/37

ABSTRACT EP 1162257 A1
A process of treating fabrics which comprises the steps of forming an aqueous bath comprising water, a conventional laundry detergent and a laundry detergent additive tablet and subsequently contacting said fabrics with said aqueous bath, wherein said laundry detergent additive tablet comprises an ion exchange resin. A disintegration benefit is provided to the tablet used in the process according to the present invnetion.
ABSTRACT WORD COUNT: 64

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200150	344
SPEC A	(English)	200150	14924
Total word count - document A			15268
Total word count - document B			0
Total word count - documents A + B			15268

9/3,AB/10 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01346033
Odour control system comprising a cationic *polysaccharide"** and an odour controlling agent
Geruchskontrollsystem mit kationischen *Polysacchariden"** und einem Stoff zur Geruchsverminderung
Systeme de controle des odeurs contenant un *polysaccharide"** cationique

et un agent de neutralisation d'odeurs
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Di Cintio, Achille, Via Marconi, 177, 65126 Pescara, (IT)
Pesce, Antonella, Via L'Aquila 21, 65120 Pescara, (IT)
Carlucci, Giovanni, Via A. Fieramosca 118, 66100 Chieti, (IT)
Gagliardini, Alessandro, Via Castelbellino, 14, 60035 Jesi (Ancona), (IT)
LEGAL REPRESENTATIVE:
Kremer, Veronique Marie Josephine et al (87352), Procter & Gamble European Service GmbH Sulzbacher Strasse 40, 65824 Schwalbach am Taunus, (DE)
PATENT (CC, No, Kind, Date): EP 1149595 A1 011031 (Basic)
APPLICATION (CC, No, Date): EP 2000108064 000425;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61L-015/28; A61L-015/46; A61L-028/00

ABSTRACT EP 1149595 A1
The present invention relates to articles suitable for controlling odours, especially odours associated with bodily fluids, which comprise a cationic *polysaccharide"**, preferably chitosan material, together with an odour controlling agent, preferably an odour absorbent agent and/or a chelating agent. This combination provides synergistic reduced odour control towards malodours associated with bodily fluids like menses.
ABSTRACT WORD COUNT: 55

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200144	611
SPEC A	(English)	200144	13858
Total word count - document A			14469
Total word count - document B			0
Total word count - documents A + B			14469

9/3,AB/11 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01329530
Detergent tablet
Waschmitteltablette
Tablette detergente
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Rowland, Barry, 84 Queen Alexandra Road, Sunderland SR2 9HW, (GB)
McGregor, Alasdair Duncan, 27 Shaftesbury Grove, Heaton, Newcastle upon Tyne NE6 5FA, (GB)
Addison, Michael Crombie, 47 Clousden Grange, Forest Hall, Newcastle upon Tyne NE12 0YX, (GB)
Speed, Lynda Anne, 34 Oakfield Road, Gosforth, Newcastle upon Tyne NE3 4HS, (GB)

LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 1134281 A1 010919 (Basic)
APPLICATION (CC, No, Date): EP 2001112070 980803;
PRIORITY (CC, No, Date): GB 9716351 970802
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 960187 (EP 98938306)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/386; C11D-003/08

ABSTRACT EP 1134281 A1
The present invention provides a detergent tablet comprising:
a) a compressed portion comprising active detergent components;
b) a non compressed, non-encapsulating portion comprising active detergent components. Detergent components which are sensitive to compression can be incorporated into tablets and greater control of washing processes can be achieved.
ABSTRACT WORD COUNT: 50

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200138	669
SPEC A	(English)	200138	21697
Total word count - document A			22366
Total word count - document B			0
Total word count - documents A + B			22366

9/3,AB/12 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01316725
Laundry additive sachet
Waschezusatzbeutel
Sachet avec additives pour le linge
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Del Duca, Valerio, Via Portuense 391, 00149 Rome, (IT)
Albanesi, Mario, Via dei Monti di San Paolo 16, 00126 Rome, (IT)
Isoldi, Gina, Via Giulio Bonasoni 61, 00133 Rome, (IT)
LEGAL REPRESENTATIVE:
Morelle, Evelyne Charlotte Isabelle et al (89811), BVBA Procter & Gamble Europe Sprl, Temselaan 100, 1853 Strombeek-Bever, (BE)
PATENT (CC, No, Kind, Date): EP 1126070 A1 010822 (Basic)
APPLICATION (CC, No, Date): EP 2000870124 000609;
PRIORITY (CC, No, Date): EP 2000870023 000217
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: D06F-039/02

ABSTRACT EP 1126070 A1

The present invention relates to laundry additive sachets. The sachets comprise at least two compartments and may comprise further compartments. At least one of the compartments comprises a liquid laundry additive composition.
ABSTRACT WORD COUNT: 34

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200134	296
SPEC A	(English)	200134	17023
Total word count - document A			17319
Total word count - document B			0
Total word count - documents A + B			17319

9/3,AB/13 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01300202
Detergent compositions
Waschmittel
Compositions detergentes
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Addison, Michael Crombie, 47 Clousden Grange, Forest Hall, Newcastle upon Tyne NE12 0YX, (GB)
LEGAL REPRESENTATIVE:
Brooks, Maxim Courtney et al (46131), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 1113071 A2 010704 (Basic)
APPLICATION (CC, No, Date): EP 2001104522 980401;
PRIORITY (CC, No, Date): GB 9725461 971203
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 922756 (EP 98105906)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/00; C11D-003/36; C11D-003/10

ABSTRACT EP 1113071 A2
According to the present invention there is provided a washing detergent in the form of a tablet comprising one or more detergent compositions and wherein at least one detergent composition dissolves in a dishwashing machine in less than 3 minutes.
ABSTRACT WORD COUNT: 41

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200127	385
SPEC A	(English)	200127	21847
Total word count - document A			22232
Total word count - document B			0
Total word count - documents A + B			22232

9/3,AB/14 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01297990
4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
4-Oxo-2-Ureido-1,4,5,6-Tetrahydropyrimidinderivate als Antibakterielle und Antiprotozoen Mittel
Derives de 4-oxo-2-ureido-1,4,5,6-tetrahydropyrimidine utiles comme agents antibacteriens et antiprotozoaires
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Linde II, Robert Gerald, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
Hayward, Matthew Merrill, Pfizer Global Res. & Dev, Eastern Point Road, Groton, Connecticut 06340, (US)
Kaneko, Takushi, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
LEGAL REPRESENTATIVE:
Wood, David John et al (37882), PFIZER LIMITED, European Patents Department, Ramsgate Road,, Sandwich, Kent CT13 9NJ, (GB)
PATENT (CC, No, Kind, Date): EP 1113008 A1 010704 (Basic)
APPLICATION (CC, No, Date): EP 2000311164 001214;
PRIORITY (CC, No, Date): US 173433 P 991229
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C07D-239/22; C07D-403/06; C07D-403/12; A61P-031/04; A61P-033/02

ABSTRACT EP 1113008 A1
The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein Z, R1), R9), and R10) are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating bacterial and protozoal infections in mammals by administering the above compounds.
ABSTRACT WORD COUNT: 57

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200127	1286
SPEC A	(English)	200127	6965
Total word count - document A			8251
Total word count - document B			0
Total word count - documents A + B			8251

9/3,AB/15 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01289147
Polynucleotide encoding *autoantigens"** associated with endometriosis
Endometriose-assoziierte-*Autoantigene"** kodierendes Polynukleotid
Polynucleotide codant pour des auto-*antigenes"** associes a l'endometriose
PATENT ASSIGNEE:
DIAGNOSTIC PRODUCTS CORPORATION, (728210), 5700 West 96th Street, Los Angeles California 90045, (US), (Applicant designated States: all)
INVENTOR:
El Shami, A. Said, 11016 Red Barn Road, Camarillo, California 93032, (US)
Menon, Surendra Nath, 4052 Jackson Avenue, Culver City, California 90232, (US)
French, Cynthia K., 14 Virgil Court, Irvine, California 92612, (US)
LEGAL REPRESENTATIVE:
Campbell, Patrick John Henry et al (80141), J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ, (GB)
PATENT (CC, No, Kind, Date): EP 1106690 A2 010613 (Basic)
EP 1106690 A3 010725
APPLICATION (CC, No, Date): EP 2000310408 001123;
PRIORITY (CC, No, Date): US 447399 991123
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12N-015/12; C07K-014/47; C12Q-001/68; C12N-005/10; C07K-016/18; G01N-033/53; G01N-033/557; C07K-019/00; A61K-038/17

ABSTRACT EP 1106690 A3
This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, *polypeptides"** associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and *polypeptide"**.
ABSTRACT WORD COUNT: 38
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200124	2421
SPEC A	(English)	200124	20110
Total word count - document A			22531
Total word count - document B			0
Total word count - documents A + B			22531

9/3,AB/16 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01288052
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:

Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Christopher James, 1 Percy Gardens, Tynemouth, North Shields, Tyne & Wear NE30 4HG, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 1104805 A2 010606 (Basic)
EP 1104805 A3 010613
APPLICATION (CC, No, Date): EP 2001104424 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911268 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 979865 (EP 99305386)
INTERNATIONAL PATENT CLASS: C11D-017/00

ABSTRACT EP 1104805 A3
1. A multi-phase detergent tablet for use in a washing machine, the tablet comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a compressed body adhesively contained within said mould, wherein the tablet composition comprises one or more detergent actives which is predominantly concentrated in the second phase, and wherein the second phase additionally comprises a binder. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 94

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200123	317
SPEC A	(English)	200123	20090
Total word count - document A			20407
Total word count - document B			0
Total word count - documents A + B			20407

9/3,AB/17 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01286342
Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzundungshemmendes Mittel
Composes de sulfamoylheteroaryl-pyrazole comme analgesiques et agents anti-inflammatoires
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Ando, Kazuo, Pfizer Pharmaceuticals Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393, (JP)

Kawamura, Kiyoshi, Pfizer Pharmaceuticals Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393, (JP)
LEGAL REPRESENTATIVE:
Atkinson, Jonathan David Mark et al (83483), Urquhart-Dykes & Lord Tower
House Merrion Way, Leeds LS2 8PA, (GB)
PATENT (CC, No, Kind, Date): EP 1104760 A1 010606 (Basic)
APPLICATION (CC, No, Date): EP 2000310441 001124;
PRIORITY (CC, No, Date): US 168889 P 991203
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C07D-405/14; C07D-413/14; C07D-417/14;
A61K-031/4439; A61P-029/00

ABSTRACT EP 1104760 A1
This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein A and R' are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2) is NH2)); R3) and R4) are each hydrogen, halo, (C1))-C4)))alkyl optionally substituted with halo and the like; and X1) to X4) are each hydrogen, halo, hydroxy, (C1))-C4)))alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
ABSTRACT WORD COUNT: 97

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200123	5180
SPEC A	(English)	200123	27571
Total word count - document A			32751
Total word count - document B			0
Total word count - documents A + B			32751

9/3,AB/18 (Item 18 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01286335
Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents
Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzun dungshemmendes Mittel
Composes heteroarylphenylpyrazoles comme agents analgesiques et anti-inflammatoires
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Ando, Kazuo, Pfizer Global Research & Development, 2, Aza-5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393, (JP)
Kawamura, K., Pfizer Global Research & Development, 2, Aza-5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393, (JP)
Kato, Tomoki, Pfizer Global Research & Development, 2, Aza-5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393, (JP)
Minich, Martha Lou, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)

Lundy, Kristin Marie, Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
Cheng, Hengmiao, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
Li, Jin., Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, (US)
Bronk, Brian Scott, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
Sakya, Subas Man, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, (US)
LEGAL REPRESENTATIVE:
Motion, Keith Robert et al (91141), Pfizer Limited Patents Department Ramsgate Road, Sandwich, Kent CT13 9NJ, (GB)
PATENT (CC, No, Kind, Date): EP 1104759 A1 010606 (Basic)
APPLICATION (CC, No, Date): EP 2000310356 001122;
PRIORITY (CC, No, Date): US 168890 P 991203
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C07D-405/14; C07D-417/14; C07D 413/14; C07D-409/14; C07D-401/14; A61K-031/506; A61P-029/00

ABSTRACT EP 1104759 A1
This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein A and R1) are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2) is (C1))-C4)))alkyl optionally substituted with halo, amino or an alkyl amino; R3) and R4) are each hydrogen, halo, (C1))-C4)))alkyl optionally substituted with halo and the like; and X1) to X4) are each hydrogen, halo, hydroxy, (C1))-C4)))alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
ABSTRACT WORD COUNT: 106

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200123	4890
SPEC A	(English)	200123	20021
Total word count - document A			24911
Total word count - document B			0
Total word count - documents A + B			24911

9/3,AB/19 (Item 19 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01285957
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)

Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington,
Northumberland NE23 9FS, (GB)
Binder, Christopher James, 1 Percy Gardens, Tynemouth, North Shields,
Tyne & Wear NE30 4HG, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House
7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 1103597 A2 010530 (Basic)
EP 1103597 A3 010606
APPLICATION (CC, No, Date): EP 2001104427 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911218 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 976819 (EP 99305384)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/386

ABSTRACT EP 1103597 A3
A multi-phase detergent tablet comprising:
a) a first phase in the form of a shaped body having at least one
mould therein; and
b) a second phase in the form of a compressed body adhesively
contained within said mould, and wherein the second phase comprises an
enzyme. The multi-phase tablets provide improved dissolution and cleaning
characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 66

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200122	460
SPEC A	(English)	200122	20081
Total word count - document A			20541
Total word count - document B			0
Total word count - documents A + B			20541

9/3,AB/20 (Item 20 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01285956
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza,
Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington,
Northumberland NE23 9FS, (GB)
Binder, Christopher James, 1 Percy Gardens, Tynemouth, North Shields,
Tyne & Wear NE30 4HG, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House
7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 1103596 A2 010530 (Basic)

EP 1103596 A3 010613
APPLICATION (CC, No, Date): EP 2001104426 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911217 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 979864 (EP 99305385)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/39

ABSTRACT EP 1103596 A3
A multi-phase detergent tablet for use in a washing machine, the tablet comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a particulate solid compressed within said mould. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200122	643
SPEC A	(English)	200122	20088
Total word count - document A			20731
Total word count - document B			0
Total word count - documents A + B			20731

9/3,AB/21 (Item 21 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01285955
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Applicant designated States: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Christopher James, 1 Percy Gardens, Tynemouth, North Shields, Tyne & Wear NE30 4HG, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 1103595 A2 010530 (Basic)
EP 1103595 A3 010613
APPLICATION (CC, No, Date): EP 2001104425 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911264 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 979866 (EP 99305387)

INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/22

ABSTRACT EP 1103595 A3
A multi-phase detergent tablet comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a compressed body adhesively contained within said mould, wherein the tablet composition comprises one or more detergent actives which is predominantly concentrated in the second phase, and wherein the second phase additionally comprises a disrupting agent. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 86

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200122	537
SPEC A	(English)	200122	20084
Total word count - document A			20621
Total word count - document B			0
Total word count - documents A + B			20621

9/3,AB/22 (Item 22 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01119837
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Christopher James, 116 St. Georges Terrace, Jesmond, Newcastle upon Tyne NE2 2DP, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 979866 A1 000216 (Basic)
EP 979866 B1 020227
APPLICATION (CC, No, Date): EP 99305387 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911264 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1103595 (EP 2001104425)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/22

ABSTRACT EP 979866 A1
A multi-phase detergent tablet comprising:

a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a compressed body adhesively contained within said mould, wherein the tablet composition comprises one or more detergent actives which is predominantly concentrated in the second phase, and wherein the second phase additionally comprises a disrupting agent. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 86

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200007	531
CLAIMS B	(English)	200209	973
CLAIMS B	(German)	200209	949
CLAIMS B	(French)	200209	1139
SPEC A	(English)	200007	20076
SPEC B	(English)	200209	19289
Total word count - document A			20611
Total word count - document B			22350
Total word count - documents A + B			42961

9/3,AB/23 (Item 23 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01119836
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200179), 301 East Sixth Street, Cincinnati Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Christopher James, 116 St. Georges Terrace, Jesmond, Newcastle upon Tyne NE2 2DP, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 979865 A1 000216 (Basic)
EP 979865 B1 020410
APPLICATION (CC, No, Date): EP 99305386 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911268 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1104805 (EP 2001104424)
INTERNATIONAL PATENT CLASS: C11D-017/00

ABSTRACT EP 979865 A1
1. A multi-phase detergent tablet for use in a washing machine, the

tablet comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a compressed body adhesively contained within said mould, wherein the tablet composition comprises one or more detergent actives which is predominantly concentrated in the second phase, and wherein the second phase additionally comprises a binder. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 94

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200007	311
CLAIMS B	(English)	200215	988
CLAIMS B	(German)	200215	948
CLAIMS B	(French)	200215	1149
SPEC A	(English)	200007	20078
SPEC B	(English)	200215	19299
Total word count - document A			20393
Total word count - document B			22384
Total word count - documents A + B			42777

9/3,AB/24 (Item 24 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01119835
Process for preparing detergent tablets
Verfahren zur Herstellung von Waschmitteltabletten
Procede de preparation des comprimes detergents
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Christopher James, 116 St. Georges Terrace, Jesmond, Newcastle upon Tyne NE2 2DP, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 979864 A1 000216 (Basic)
EP 979864 B1 020102
APPLICATION (CC, No, Date): EP 99305385 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911217 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1103596 (EP 2001104426)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/39

ABSTRACT EP 979864 A1
A multi-phase detergent tablet for use in a washing machine, the tablet

comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and
b) a second phase in the form of a particulate solid compressed within said mould. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200007	634
CLAIMS B	(English)	200201	437
CLAIMS B	(German)	200201	399
CLAIMS B	(French)	200201	515
SPEC A	(English)	200007	20072
SPEC B	(English)	200201	19145
Total word count - document A			20710
Total word count - document B			20496
Total word count - documents A + B			41206

9/3,AB/25 (Item 25 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01115556
Detergent tablet
Waschmitteltablette
Comprime detergent
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
Ricci, Patrizio, 105 Rassel, 1780 Wemmel, (BE)
Bennie, Brenda Frances, 34A Delamere Crescent, Cramlington, Northumberland NE23 9FS, (GB)
Binder, Cristopher James, 116 St. Georges Terrace, Jesmond, Newcastle upon Tyne NE2 2DP, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 976819 A1 000202 (Basic)
EP 976819 B1 020130
APPLICATION (CC, No, Date): EP 99305384 990707;
PRIORITY (CC, No, Date): GB 9815525 980717; GB 9911218 990517
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1103597 (EP 2001104427)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/386

ABSTRACT EP 976819 A1
A multi-phase detergent tablet comprising:
a) a first phase in the form of a shaped body having at least one mould therein; and

b) a second phase in the form of a compressed body adhesively contained within said mould, and wherein the second phase comprises an enzyme. The multi-phase tablets provide improved dissolution and cleaning characteristics together with excellent tablet integrity and strength.
ABSTRACT WORD COUNT: 66

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200005	453
CLAIMS B	(English)	200205	770
CLAIMS B	(German)	200205	724
CLAIMS B	(French)	200205	867
SPEC A	(English)	200005	20081
SPEC B	(English)	200205	19025
Total word count - document A			20538
Total word count - document B			21386
Total word count - documents A + B			41924

9/3,AB/26 (Item 26 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01057904
DISHWASHING METHOD
GESCHIRRSPULVERFAHREN
PROCEDE POUR LAVER LA VAISSELLE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
SPEED, Lynda, Anne, 21 Mayfield Road, Gosforth, Newcastle upon Tyne NE3 4HE, (GB)
PAINTER, Jeffrey, Donald, 11652 Enyart Road, Loveland, OH 45140, (US)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 960188 A1 991201 (Basic)
EP 960188 B1 020605
WO 9927067 990603
APPLICATION (CC, No, Date): EP 98961773 981124; WO 98US25074 981124
PRIORITY (CC, No, Date): US 66903 P 971126
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1184450 (EP 2001127422)
INTERNATIONAL PATENT CLASS: C11D-017/00
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200223	700
CLAIMS B	(German)	200223	673
CLAIMS B	(French)	200223	833
SPEC B	(English)	200223	21725
Total word count - document A			0

Total word count - document B 23931
Total word count - documents A + B 23931

9/3,AB/27 (Item 27 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01042466
Detergent composition
Detergenzusammensetzung
Composition detergente
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
Addison, Michael Crombie, 47 Clousden Grange, Forest Hall, Newcastle upon Tyne, NE12 0YX, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 922756 A1 990616 (Basic)
EP 922756 B1 010919
APPLICATION (CC, No, Date): EP 98105906 980401;
PRIORITY (CC, No, Date): GB 9725461 971203
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1113071 (EP 2001104522)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/00; C11D-003/36; C11D-003/20; C11D-003/10

ABSTRACT EP 922756 A1
According to the present invention there is provided a washing detergent in the form of a tablet comprising one or more detergent compositions and wherein at least one detergent composition dissolves in a dishwashing machine in less than 3 minutes.
ABSTRACT WORD COUNT: 41

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	199924	371
CLAIMS B	(English)	200138	377
CLAIMS B	(German)	200138	352
CLAIMS B	(French)	200138	462
SPEC A	(English)	199924	21828
SPEC B	(English)	200138	20224

Total word count - document A 22203
Total word count - document B 21415
Total word count - documents A + B 43618

9/3,AB/28 (Item 28 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01027637

DISHWASHING METHOD
VERFAHREN ZUM SPULEN VON GESCHIRR
PROCEDE POUR LAVER LA VAISSELLE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
ROWLAND, Barry, 84 Queen Alexandra Road, Sunderland SR2 9HW, (GB)
MCGREGOR, Alasdair, Duncan, 27 Shaftesbury Grove,Heaton, Newcastle upon Tyne NE6 5FA, (GB)
ADDISON, Michael, Crombie, 47 Clousden Grange,Forest Hall, Newcastle upon Tyne NE12 0YX, (GB)
SPEED, Lynda, Anne, 21 Mayfield Road,Gosforth, Newcastle upon Tyne NE3 4HE, (GB)
LEGAL REPRESENTATIVE:
Samuels, Lucy Alice et al (87111), Gill Jennings & Every Broadgate House 7 Eldon Street, London EC2M 7LH, (GB)
PATENT (CC, No, Kind, Date): EP 960187 A1 991201 (Basic)
EP 960187 B1 021023
WO 99006522 990211
APPLICATION (CC, No, Date): EP 98938306 980803; WO 98US16144 980803
PRIORITY (CC, No, Date): GB 9716351 970802
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1134281 (EP 2001112070)
EP 1162258 (EP 2001203388)
INTERNATIONAL PATENT CLASS: C11D-017/00; C11D-003/386; C11D-003/08
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200243	619
CLAIMS B	(German)	200243	599
CLAIMS B	(French)	200243	747
SPEC B	(English)	200243	20168
Total word count - document A			0
Total word count - document B			22133
Total word count - documents A + B			22133

9/3,AB/29 (Item 29 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01008038
*PEPTIDES"** PROMOTING THE ACTIVATION OF LATENT TGF--g(b) AND METHOD FOR SCREENING TGF--g(b) ACTIVITY REGULATORS
*PEPTIDE"** , DIE DIE AKTIVIERUNG VON LATENTEM TGF-BETA UNTERSTUTZEN, UND EIN VERFAHREN ZUR INDENTIFIKATION VON REGULATOREN DER TGF-BETA-AKTIVITAT.
*PEPTIDES"** FAVORISANT L'ACTIVATION DE TGF--g(b) LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF--g(b)
PATENT ASSIGNEE:
KYOWA HAKKO KOGYO CO., LTD., (229067), 6-1, Ohtemachi 1-chome, Chiyoda-ku, Tokyo 100-8185, (JP), (applicant designated states: AT;BE;CH;CY;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:
YAMASAKI, Motoo, 3-9-13, Naka-machi Machida-shi, Tokyo 194-0021, (JP)
SHIBATA, Kenji, 1-630-9, Atago Tama-shi, Tokyo 206-0041, (JP)
SATO, Yasufumi, 2-12-4, Kunimigaoka Aoba-ku, Sendai-shi Miyagi 989-3201, (JP)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100314), Siebertstrasse 4, 81675 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 922710 A1 990616 (Basic)
WO 9851704 981119
APPLICATION (CC, No, Date): EP 98919563 980512; WO 98JP2089 980512
PRIORITY (CC, No, Date): JP 12068397 970512
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C07K-014/495; A61K-038/17; G01N-033/566;

ABSTRACT EP 922710 A1
Provided are *peptides"** having an activity to promote the release of active TGF-(beta) from latent TGF-(beta) or an activity to promote the binding of latent TGF-(beta) to a cell membrane which are represented by general formula (1): (wherein R1) represents hydrogen, or substituted or unsubstituted alkanoyl, etc.; R2) represents hydroxy, or substituted or unsubstituted alkoxy or amino; and A represents an amino acid sequence which is selected from partial sequences of a TGF-(beta) precursor sequence); methods of screening compounds to be used for the treatment or prevention of TGF-(beta) -related diseases which comprise evaluating the above activities; and compounds obtainable by such methods and pharmaceutically acceptable salts thereof.
Said compounds and *peptides"** are useful for the treatment or prevention of diseases such as cancer, diabetic retinopathy, atherosclerosis, etc.
ABSTRACT WORD COUNT: 129

LANGUAGE (Publication,Procedural,Application): English; English; Japanese
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9924	753
SPEC A	(English)	9924	14049
Total word count - document A			14802
Total word count - document B			0
Total word count - documents A + B			14802

9/3,AB/30 (Item 30 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00999326
Thermal preactivation of gaseous precursor filled compositions
Thermische Voraktivierung von Zusammensetzungen mit einer Fullung bestehend aus gasformigen Vorlaufer
Preactivation thermique de compositions remplies d'un precurseur geaseux
PATENT ASSIGNEE:
IMARX PHARMACEUTICAL CORP., (2069730), 1635 East 18th Street, Tucson, AZ 85749, (US), (applicant designated states:
AT;BE;CH;CY;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
Unger, Evan C., 13365 East Camino, La Cebadilla, Tucson, Arizona 85749, (US)

LEGAL REPRESENTATIVE:
James, Anthony Christopher W.P. et al (78471), Carpmaels & Ransford 43 Bloomsbury Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 901793 A1 990317 (Basic)
APPLICATION (CC, No, Date): EP 98307421 980914;
PRIORITY (CC, No, Date): US 929847 970915
DESIGNATED STATES: DE; ES; FR; GB; IT
INTERNATIONAL PATENT CLASS: A61K-049/00; A61K-041/00;
ABSTRACT EP 901793 A1

The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

ABSTRACT WORD COUNT: 84

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9911	1390
SPEC A	(English)	9911	51117
Total word count - document A			52507
Total word count - document B			0
Total word count - documents A + B			52507

9/3,AB/31 (Item 31 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00951213
DETERGENT COMPOSITIONS
WASCHMITTELZUSAMMENSETZUNGEN
COMPOSITIONS DETERGENTES
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
HALL, Robin, Gibson, 27 Blackfriars Court,Stowell Street, Newcastle upon Tyne NE1 4XB, (GB)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 934379 A1 990811 (Basic)
EP 934379 B1 020227
WO 9817758 980430
APPLICATION (CC, No, Date): EP 97910779 971002; WO 97US17855 971002
PRIORITY (CC, No, Date): GB 9621799 961018; GB 9621791 961018; GB 9705841 970320
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-001/645
NOTE:
No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200209	537
CLAIMS B	(German)	200209	459
CLAIMS B	(French)	200209	623
SPEC B	(English)	200209	13426

Total word count - document A 0
Total word count - document B 15045
Total word count - documents A + B 15045

9/3,AB/32 (Item 32 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00951211
DETERGENT COMPOSITIONS COMPRISING A MIXTURE OF QUATERNARY AMMONIUM CATIONIC SURFACTANT AND ALKYL SULFATE ANIONIC SURFACTANT
WASCHMITTEL ENTHALTEND EINE MISCHUNG AUS EINEM QUATERNAREN AMMONIUMTENSID SOWIE EINEM ALKYLSULFAT
COMPOSITIONS DETERGENTES COMPRENANT UN MELANGE D'UN TENSIOACTIF CATIONIQUE QUATERNAIRE ET D'UN TENSIOACTIF ANIONIQUE D'ALKYLE SULFATE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
HALL, Robin Gibson, 27 Blackfriars Court, Stowell Street, Newcastle upon Tyne NE1 4XB, (GB)
MOSS, Michael Alan John, 13 Painshawfield Road, Stocksfield, Northumberland NE43 7DZ, (GB)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 970169 A1 000112 (Basic)
EP 970169 B1 020911
WO 98017759 980430
APPLICATION (CC, No, Date): EP 97910765 971002; WO 97US17783 971002
PRIORITY (CC, No, Date): GB 9621799 961018; GB 9621791 961018; GB 9705802 970320
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-001/65; C11D-001/12; C11D-001/62; C11D-001/94; C11D-001/14
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200237	718
CLAIMS B	(German)	200237	622
CLAIMS B	(French)	200237	797
SPEC B	(English)	200237	12875

Total word count - document A 0
Total word count - document B 15012
Total word count - documents A + B 15012

9/3,AB/33 (Item 33 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00923312
Human telomerase catalytic subunit
Katalytische Untereinheit der menschlichen Telomerase
Sous-unite catalytique de la telomerase humaine
PATENT ASSIGNEE:
Geron Corporation, (1733111), 230 Constitution Drive, Menlo Park, CA 94025, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
University Technology Corporation, (2274850), Suite 250, 3101 Iris Avenue , Boulder, CO 80301, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
Cech, Thomas R., 1545 Rockmount Circle, Boulder Colorado 80303, (US)
Lingner, Joachim, Pl. Croix-Blanche 25, 1066 Epalinges, (CH)
Nakamura, Toru, 4940 Thunderbird Circle, 204, Boulder Colorado 80303, (US)
Chapman, Karen B., 71 Cloud View Road, Sausalito California 94965, (US)
Morin, Cregg B., 3407 Janice Way, Palo Alto California 94303, (US)
Harley, Calvin, 1730 University Avenue, Palo Alto California 94301, (US)
Andrews, William H., 6102 Park Avenue, Richmond California 94085, (US)
LEGAL REPRESENTATIVE:
Bizley, Richard Edward et al (28352), Hepworth, Lawrence, Bryer & Bizley Merlin House Falconry Court Baker's Lane, Epping Essex CM16 5DQ, (GB)
PATENT (CC, No, Kind, Date): EP 841396 A1 980513 (Basic)
APPLICATION (CC, No, Date): EP 97307757 971001;
PRIORITY (CC, No, Date): US 724643 961001; US 844419 970418; US 846017 970425; US 851843 970506; US 854050 970509; US 911312 970814; US 912951 970814; US 915503 970814
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/54

ABSTRACT EP 841396 A1
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
ABSTRACT WORD COUNT: 64

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9820	968
SPEC A	(English)	9820	83027
Total word count - document A			83995
Total word count - document B			0
Total word count - documents A + B			83995

9/3,AB/34 (Item 34 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00803679
Method of processing camera speed silver chloride photographic elements using peroxide bleaching solutions
Verfahren zur Verarbeitung kamerataUchlicher, photographischer Silberchloridelemente, worin Peroxidbleichlosungen verwendet werden
Procede de traitement de produits photographiques au chlorure d'argent dont la sensibilite est convenable pour l'utilisation dans une camera, lequel procede uti
PATENT ASSIGNEE:
EASTMAN KODAK COMPANY, (201212), 343 State Street, Rochester, New York 14650, (US), (applicant designated states: CH;DE;FR;GB;IT;LI;NL)
INVENTOR:
Have, Shirleyanne Elizabeth, c/o Eastman Kodak Co., Patent Legal Staff, 343 State Street, Rochester, New York 14650-2201, (US)
Szajewski, Richard Peter, c/o Eastman Kodak Co., Patent Legal Staff, 343 State Street, Rochester, New York 14650-2201, (US)
Buchanan, John Michael, c/o Eastman Kodak Co., Patent Legal Staff, 343 State Street, Rochester, New York 14650-2201, (US)
LEGAL REPRESENTATIVE:
Nunney, Ronald Frederick Adolphe et al (34411), Kodak Limited Patent Department Headstone Drive, Harrow Middlesex HA1 4TY, (GB)
PATENT (CC, No, Kind, Date): EP 747764 A1 961211 (Basic)
APPLICATION (CC, No, Date): EP 96107998 960520;
PRIORITY (CC, No, Date): US 452239 950526
DESIGNATED STATES: CH; DE; FR; GB; IT; LI; NL
INTERNATIONAL PATENT CLASS: G03C-007/42;

ABSTRACT EP 747764 A1
Camera speed color photographic elements are effectively bleached using a peroxide bleaching solution containing critical amounts of peroxide and chloride ion. These elements have predominantly chloride silver halide emulsions that contain less than 2% iodide ion, and are substantially free of a bleaching rate retarding amount of a development inhibitor having a free valence that binds to silver. No vesiculation in the processed element is observed after bleaching.
ABSTRACT WORD COUNT: 84

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	372
SPEC A	(English)	EPAB96	8672
Total word count - document A			9044
Total word count - document B			0
Total word count - documents A + B			9044

9/3,AB/35 (Item 35 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00793263
Stabilised peroxide bleaching solutions and their use for processing of photographic elements
Stabilisierte Peroxid-Bleichlosungen und deren Verwendung zur Verarbeitung von photographischen Elementen

Solutions de blanchiment a base de peroxyde stabilisees et leur utilisation pour le traitement d'elements photographiques

PATENT ASSIGNEE:
EASTMAN KODAK COMPANY, (201214), 343 State Street, Rochester, New York 14650-2201, (US), (applicant designated states: DE;FR;GB)
INVENTOR:
Haye, Shirleyanne Elizabeth, c/o Eastman Kodak Co., 343 State Street, Rochester, New York 14650-2201, (US)
Reyes, Mayra Beatriz, c/o Eastman Kodak Co., 343 State Street, Rochester, New York 14650-2201, (US)
LEGAL REPRESENTATIVE:
Nunney, Ronald Frederick Adolphe et al (34411), Kodak Limited Patent Department Headstone Drive, Harrow Middlesex HA1 4TY, (GB)

PATENT (CC, No, Kind, Date): EP 738919 A2 961023 (Basic)
EP 738919 A3 970115
EP 738919 B1 981230
APPLICATION (CC, No, Date): EP 96200947 960415;
PRIORITY (CC, No, Date): US 422468 950417; US 423257 950417
DESIGNATED STATES: DE; FR; GB
INTERNATIONAL PATENT CLASS: G03C-007/42; G03C-007/30;

ABSTRACT EP 738919 A2

Color photographic elements are bleached after exposure and development by using a hydrogen peroxide bleaching solution. This solution comprises a hydrogen peroxide bleaching agent, chloride ions in an amount of at least 0.35 mol/l, a first acidic compound which is an organic phosphonic acid or a salt thereof, and a second acidic compound which is either a 2-pyridinecarboxylic acid or 2,6-pyridinedicarboxylic acid (or a salt thereof), or a polyaminocarboxylic acid having one or more secondary amines at a pH of 8 to 11 (or a salt thereof). The bleaching solution is stabilized by the presence of the two acidic compounds. (see image in original document)

ABSTRACT WORD COUNT: 124

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9853	977
CLAIMS B	(German)	9853	950
CLAIMS B	(French)	9853	1097
SPEC B	(English)	9853	4698
Total word count - document A			0
Total word count - document B			7722
Total word count - documents A + B			7722

9/3,AB/36 (Item 36 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00746551

BUILT DETERGENT COMPOSITIONS COMPRISING OLEOYL SARCOSINATE
WASCHMITTELZUSAMMENSETZUNGEN MIT BUILDER ENTHALTEND OLEOYLSARCOSINATE
COMPOSITIONS DE DETERGENTS POUR GROSSES LESSIVES CONTENANT UN SARCOSINATE D'OLEOYLE

PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)

INVENTOR:
MURCH, Bruce, Prentiss, 7846 Glenbrook Court, Cincinnati, OH 45224, (US)
SWIFT, Ronald, Allen, II, 121 Towne Commons Way 14, Cincinnati, OH 45215, (US)
YOU, Jing-Feng, 5460 Fawnview Court, West Chester, OH 45069, (US)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 763087 A1 970319 (Basic)
EP 763087 B1 000126
WO 9533029 951207
APPLICATION (CC, No, Date): EP 95921506 950530; WO 95US6821 950530
PRIORITY (CC, No, Date): US 251982 940601
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-001/10; C11D-003/12; C11D-003/08
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200004	271
CLAIMS B	(German)	200004	211
CLAIMS B	(French)	200004	283
SPEC B	(English)	200004	12135
Total word count - document A			0
Total word count - document B			12900
Total word count - documents A + B			12900

9/3,AB/37 (Item 37 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00746524
DETERGENT COMPOSITIONS WITH OLEOYL SARCOSINATE AND POLYMERIC DISPERSING AGENT
WASCHMITTELZUSAMMENSETZUNGEN MIT OLEOYLSARCOSINATE UND POLYMERES DISPERGIERMITTEL
COMPOSITIONS DETERGENTES A BASE DE SARCOSINATE D'ACIDE OLEIQUE ET DE POLYMERE DISPERSANT
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
WILLMAN, Kenneth, William, 5603 Williamsburg Way, Fairfield, OH 45014, (US)
VANDERMEER, James, Michael, 5725 Genevieve Place, Fairfield, OH 45014, (US)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 763086 A1 970319 (Basic)
EP 763086 B1 991208
WO 9533028 951207
APPLICATION (CC, No, Date): EP 95921466 950530; WO 95US6755 950530
PRIORITY (CC, No, Date): US 252126 940601
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;

PT; SE
INTERNATIONAL PATENT CLASS: C11D-001/10; C11D-003/37
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9949	312
CLAIMS B	(German)	9949	247
CLAIMS B	(French)	9949	351
SPEC B	(English)	9949	10837
Total word count - document A			0
Total word count - document B			11747
Total word count - documents A + B			11747

9/3,AB/38 (Item 38 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00746312
HIGH ACTIVE DETERGENT COMPOSITION CONTAINING OLEOYL SARCOSINATES FOR IMPROVED SOLUBILITY
HOCHLEISTUNGSWASCHMITTEL ENTHALTEND OLEOYLSARCOSINATE FUR VERBESSERTE LOSLICHHEIT
COMPOSITION DE DETERGENT HAUTEMENT ACTIVE RENFERMANT DES SARCOSINATES D'OLEOYLE DESTINES A AMELIORER LA SOLUBILITE
PATENT ASSIGNEE:
THE PROCTER & GAMBLE COMPANY, (200173), One Procter & Gamble Plaza, Cincinnati, Ohio 45202, (US), (Proprietor designated states: all)
INVENTOR:
SWIFT, Ronald, Allen, II, 121 Towne Commons Way 14, Cincinnati, OH 45215, (US)
ADAMS, Theodore, James, Jr., 4806 Chalet Drive, Cincinnati, OH 45217, (US)
WILLMAN, Kenneth, William, 5603 Williamsburg Way, Fairfield, OH 45014, (US)
LEGAL REPRESENTATIVE:
Peet, Jillian Wendy et al (73352), Procter & Gamble Technical Centres Limited, Whitley Road, Longbenton, Newcastle upon Tyne NE12 9TS, (GB)
PATENT (CC, No, Kind, Date): EP 763090 A1 970319 (Basic)
EP 763090 B1 000119
WO 9533032 951207
APPLICATION (CC, No, Date): EP 95920683 950530; WO 95US6820 950530
PRIORITY (CC, No, Date): US 252294 940601
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C11D-001/37; C11D-017/00
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200003	286
CLAIMS B	(German)	200003	227
CLAIMS B	(French)	200003	303
SPEC B	(English)	200003	13070
Total word count - document A			0

```
     FILE 'REGISTRY' ENTERED AT 14:29:42 ON 06 DEC 2002
L1         1787 S MGSSHHHHHHSSGLVPRGS | RRRRRR/SQSP

     FILE 'HCAPLUS' ENTERED AT 14:32:20 ON 06 DEC 2002
L2          110 S L1 AND (TAG? OR LINK? OR SPACER)
L3            5 S L2 AND IMMOBIL?

     FILE 'REGISTRY' ENTERED AT 14:34:25 ON 06 DEC 2002
                E SILICATE/CN 5
L4              1 S E3
                E MICA/CN 5
L5             10 S MICA ?/CN
L6             11 S L4 OR L5

     FILE 'HCAPLUS' ENTERED AT 14:35:19 ON 06 DEC 2002
L7              0 S L2 AND (L6 OR SILICATE OR MICA)
L8              0 S L1 AND (L6 OR SILICATE OR MICA)

L3   ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2002:778096  HCAPLUS
DOCUMENT NUMBER:          137:289890
TITLE:                    DART conjugates of proteins and nucleic acids
                          for use as analytical and therapeutic tools
INVENTOR(S):              Roberts, Radclyffe L.; De Figueiredo, Paul
PATENT ASSIGNEE(S):       University of Washington, USA
SOURCE:                   PCT Int. Appl., 205 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002079393      A2   20021010       WO 2002-US10566  20020402
     WO 2002079393      C2   20021114
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
             NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
             SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRIORITY APPLN. INFO.:                  US 2001-281133P  P  20010402
                                        US 2001-281342P  P  20010403
AB   The present invention provides Dynamic Action Ref. Tools, or DARTs,
     and methods of making and using DARTs.  DARTs are conjugates of
     three moieties: a DART includes a Mol. Shaft covalently
     linked to a Linkage Polypeptide that is covalently
     linked to a Mol. Point. that can be used to detect a protein
     or nucleic acid analyte and that signal detection by a function of
     either the protein or the nucleic acid component of the conjugate.
     One of the components may be an affinity group such as an antigen or
     antibody, a second component is a nucleic acid that may be a probe
```

sequence or a nucleic acid enzyme or a **linker** between two proteins. The oligonucleotide may contain functional elements or protein or enzyme recognition sites. The third component may be a second protein such as a reporter enzyme. The combination of protein and nucleic acid specificities and activities allows DARTs to be used in a wide range of applications. DARTs can be used, for example, for the isolation and anal. of nucleic acids, polypeptides, and the like, for regulating biol. activities and investigating inter-mol. interactions, and the like. DARTs, and DART libraries, can be formed and manipulated in vivo or in vitro. DARTs can be purified, and portions of DARTs can be exchanged with portions of other DARTs.

IT **467518-50-9**
RL: PRP (Properties)
(unclaimed protein sequence; dART conjugates of proteins and nucleic acids for use as anal. and therapeutic tools)

L3 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:785522 HCAPLUS
DOCUMENT NUMBER: 136:82220
TITLE: Mechanisms Leading to an Oriented **Immobilization** of Recombinant Proteins Derived from the P24 Capsid of HIV-1 onto Copolymers
AUTHOR(S): Allard, Laure; Cheynet, Valerie; Oriol, Guy; Veron, Laurent; Merlier, Francoise; Scremin, Gerald; Mandrand, Bernard; Delair, Thierry; Mallet, Francois
CORPORATE SOURCE: UnitH Mixte UMR 2142, CNRS-bioMHrieux, ENS-Lyon, Lyon, 69364, Fr.
SOURCE: Bioconjugate Chemistry (2001), 12(6), 972-979
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To investigate the mechanism leading to an oriented **immobilization** of recombinant proteins onto synthetic copolymers, five genetically modified HIV-1 p24 capsid proteins (RH24, RH24A4K2, RH24R6, RH24R4K2, and RH24K6) were tested for their efficiency to covalently bind to maleic anhydride-alt-Me vinyl ether (MAMVE) and N-vinyl pyrrolidone-alt-maleic anhydride (NVPMA) copolymers. These proteins contain, at their C-termini, **tags** differing in cationic and/or reactive amino acids d. We demonstrated that an increase of the charge and amine d. in the **tag** enhances the coupling yield, the most efficient **tag** being a six-lysine one. The reactivity of the proteins depends directly on the reactivity of the **tag**, and this led us to conclude that the **tag** was the site where the covalent grafting with the polymer occurred. Thus, design of such **tags** provides a new efficient and versatile method allowing oriented **immobilization** of recombinant proteins onto copolymers.

IT **385845-78-3**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(amino acid sequence; oriented immobilization of recombinant HIV-1 capsid protein p24 analogs onto copolymers)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:425348 HCAPLUS
DOCUMENT NUMBER: 127:30125
TITLE: Integrated nucleic acid hybridization devices using **immobilized** probes and management of surface electrostatic properties and charges
INVENTOR(S): Hogan, Michael; Powdrill, Thomas; Iverson, Bonnie; Akiyama, Nobuko; Xiao, Du; Mallik, Arnab
PATENT ASSIGNEE(S): Baylor College of Medicine, USA; Genometrix; Hogan, Michael; Powdrill, Thomas; Iverson, Bonnie; Akiyama, Nobuko; Xiao, Du; Mallik, Arnab
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9718226	A1	19970522	WO 1996-US18212	19961114
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2235762	AA	19970522	CA 1996-2235762	19961114
AU 9676122	A1	19970605	AU 1996-76122	19961114
EP 910570	A1	19990428	EP 1996-938841	19961114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001508281	T2	20010626	JP 1997-519045	19961114

PRIORITY APPLN. INFO.: US 1995-6696P P 19951114
WO 1996-US18212 W 19961114

AB A hybridization device that has oligonucleotide probes **immobilized** on a solid substrate that has a support surface with a neutral or neg. electrostatic field and a hybridization surface. The hybridization surface is prepd. by attachment of a suitable **spacer** and surface charge-modifying groups to the support surface. Oligonucleotide probes are attached to the **spacer** by a covalent bond or a slowly reversible non-covalent bond. By maintaining a neutral or pos. surface charge, the loss of sensitivity arising from a neg. charged surface that is repellent to the sugar phosphate backbone of the nucleic acid is minimized. The oligonucleotide probe is **linked** to the hybridization surface of the solid substrate at a distance of no more than 100 angstroms. The device can be used to detect single base changes in a target nucleic acid sequence.

IT 68822-53-7, Salmine A 1
RL: DEV (Device component use); MOA (Modifier or additive use); USES

(Uses)
(hybridization surfaces coated with; integrated nucleic acid hybridization devices using **immobilized** probes and management of surface electrostatic properties and charges)

L3 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:36999 HCAPLUS
DOCUMENT NUMBER: 116:36999
TITLE: **Immobilized** fusion proteins as biocatalysts: preparation and use
INVENTOR(S): Rudolph, Rainer; Kopetzki, Erhard; Fischer, Stephan; Grossmann, Adelbert; Hoell-Neugebauer, Baerbel
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Germany
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4001508	A1	19910725	DE 1990-4001508	19900119
CA 2047235	AA	19910720	CA 1991-2047235	19910118
WO 9110910	A2	19910725	WO 1991-EP86	19910118
WO 9110910	A3	19911003		
W: AU, CA, FI, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9170724	A1	19910805	AU 1991-70724	19910118
AU 633686	B2	19930204		
EP 464184	A1	19920108	EP 1991-903190	19910118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04503610	T2	19920702	JP 1991-503068	19910118
ZA 9100374	A	19920930	ZA 1991-374	19910118
NO 9103673	A	19910918	NO 1991-3673	19910918

PRIORITY APPLN. INFO.: DE 1990-4001508 19900119
DE 1990-4002636 19900130
WO 1991-EP86 19910118

AB Biocatalysts are prepd. by expressing chimeric genes for enzymes fused to binding peptides in host cells, isolating and binding the fusion proteins to a carrier having affinity for the binding peptide, and using the **immobilized** biocatalyst for prepn. of a desired product from a substrate. A plasmid encoding .alpha.-glucosidase fused to the hexapeptide Arg6 was prepd. and the chimeric gene expressed in Escherichia coli. The fusion protein was isolated from the cells and **immobilized** on Fraktogel EMD SO3--650. The resulting biocatalyst was used to prep. glucose from maltose.

IT **137881-52-8D**, fusion products with glucosidase
RL: USES (Uses)
(manuf. with Escherichia coli of, **immobilization** on polymer of, maltose manuf. in relation to)

L3 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:468035 HCAPLUS
DOCUMENT NUMBER: 115:68035
TITLE: Hydrophobic attachment site for adhesion

peptides

INVENTOR(S): Pierschbacher, Michael D.; Honsik, Cyril J.; Dreisbach, Lisa B.
PATENT ASSIGNEE(S): La Jolla Cancer Research Foundation, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9011297	A1	19901004	WO 1990-US1486	19900320
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 5120829	A	19920609	US 1989-326168	19890320
CA 2046631	AA	19900921	CA 1990-2046631	19900320
EP 464140	A1	19920108	EP 1990-905829	19900320
EP 464140	B1	19940727		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04506511	T2	19921112	JP 1990-505512	19900320
JP 2723669	B2	19980309		
ES 2057553	T3	19941016	ES 1990-905829	19900320
US 5587456	A	19961224	US 1992-932929	19920820
US 5591822	A	19970107	US 1995-435317	19950505
US 5760176	A	19980602	US 1996-729980	19961010

PRIORITY APPLN. INFO.:
US 1989-326168 19890320
WO 1990-US1486 19900320
US 1991-787318 19911030
US 1992-932929 19920820
US 1995-435317 19950505

OTHER SOURCE(S): MARPAT 115:68035
AB A method is provided for attaching adhesion peptides contg. a RGD sequence to a solid surface through a hydrophobic domain; the peptides are also provided. The hydrophobic domain contains either hydrophobic amino acids or fatty acids. Addnl., **spacers** (e.g. amino acids) between the hydrophobic and biol. active domains can improve the presentation of the biol. active site. The peptides of the invention can be used to detect the presence of a ligand complementary to the biol. active site. The peptides can also be attached to e.g. prostheses, dental implants, or tissue culture app. Thus XG(R)GDSPASSKL6NH2 (X = NH2, acetyl, amino acid, etc.) promoted significant attachment of MG-63 osteosarcoma cells in polystyrene microtiter plates at peptide concns. of 10-0-3 .mu.g/well. The peptide XG(R)GDSPASSKL4NH2 (X as above) promoted marginal cell attachment only at the highest concn. (100 pg/well). Cell attachment studies using peptides contg. phenylalanine and myristic acid domains are also described.

IT **135251-36-4**
RL: PRP (Properties)
(cell attendant with adhesion peptide sequence of, hydrophobic domain for **immobilization** in relation to)

E1 THROUGH E5 ASSIGNED

FILE 'REGISTRY' ENTERED AT 14:36:32 ON 06 DEC 2002
L9 5 SEA FILE=REGISTRY ABB=ON PLU=ON (135251-36-4/BI OR

137881-52-8/BI OR 385845-78-3/BI OR 467518-50-9/BI OR
68822-53-7/BI)

L10 5 L9 AND L1

L10 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN **467518-50-9** REGISTRY
CN L-Phenylalanine, L-methionylglycyl-L-seryl-L-seryl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-seryl-L-serylglycyl-L-leucyl-L-valyl-L-prolyl-L-arginylglycyl-L-seryl-L-histidyl-L-methionyl-L-alanyl-L-seryl-L-methionyl-L-threonylglycylglycyl-L-glutaminyl-L-glutaminyl-L-methionylglycyl-L-arginylglycyl-L-seryl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 36: PN: WO02079393 SEQID: 33 unclaimed protein
CI MAN
SQL 36

SEQ 1 MGSSHHHHHH SSGLVPRGSH MASMTGGQQM GRGSEF
========== =========
HITS AT: 1-19

REFERENCE 1: 137:289890

L10 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN **385845-78-3** REGISTRY
CN Capsid protein p24 (human immunodeficiency virus-1 synthetic isoform RH24R6) (9CI) (CA INDEX NAME)
CI MAN
SQL 252

SEQ 1 MRGSHHHHHH GSVDESMVQN IQGQMVHQAI SPRTLNAWVK VVEEKAFSPE
51 VIPMFSALSE GATPQDLNTM LNTVGGHQAA MQMLKETINE EAAEWDRVHP
101 VHAGPIAPGQ MREPRGSDIA GTTSTLQEQI GWMTNNPPIP VGEIYKRWII
151 LGLNKIVRMY SPTSILDIRQ GPKEPFRDYV DRFYKTLRAE QASQEVKNWM
201 TETLLVQNAN PDCKTILKAL GPAATLEEMM TACQGVGGPG RRRRRRSVDE
======
251 SL
HITS AT: 241-246

REFERENCE 1: 136:82220

L10 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN **137881-52-8** REGISTRY
CN L-Arginine, N2-[N2-[N2-[N2-[N2-(N2-glycyl-L-arginyl)-L-arginyl]-L-arginyl]-L-arginyl]-L-arginyl]- (9CI) (CA INDEX NAME)
SQL 7

SEQ 1 GRRRRRR
======
HITS AT: 2-7

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 116:36999

L10 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 135251-36-4 REGISTRY

CN L-Leucine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginylglycyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 13

SEQ 1 RRRRRRGLLL LLL
======
HITS AT: 1-6

REFERENCE 1: 115:68035

L10 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN **68822-53-7** REGISTRY
CN Salmine A I (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thynnin Y 2 (tunny), 6-L-serine-7-L-serine-16-L-proline-17-de-L-tyrosine-19-L-valine-21-L-arginine-22-de-L-alanine-23-de-L-alanine-29-glycine-30-glycine-
OTHER NAMES:
CN L-Arginine, L-prolyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-seryl-L-arginyl-L-prolyl-L-valyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-valyl-L-seryl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginylglycylglycyl-L-arginyl-L-arginyl-L-arginyl-
CI MAN
SQL 31

SEQ 1 PRRRRSSSRP VRRRRPRVSR RRRRRGGRRR R
= =====
HITS AT: 20-25

REFERENCE 1: 127:30125

REFERENCE 2: 124:169076

REFERENCE 3: 121:134781

REFERENCE 4: 114:181117
REFERENCE 5: 111:3150

REFERENCE 6: 107:111653

REFERENCE 7: 104:221091

REFERENCE 8: 102:74651

REFERENCE 9: 96:176415

REFERENCE 10: 96:64730

FILE 'HOME' ENTERED AT 14:37:19 ON 06 DEC 2002